Scientific Report 2012/2013

Scientific Report 2012 ›2013 Results and Perspectives

2

Scientific Report 2012 ›2013 Results and Perspectives

Contents

6

Humanitas Research Hospital

16 International scientific cooperation 18 The importance of evaluation 22

esults and perspectives for Humanitas Research: R transferring laboratory discoveries to patients

26 Cooperation networks 28 Clinical-scientific activities

I mmunity and inflammation

33 Research on immunology.

Does “miR� stand for microRegulation?

interview with alberto mantovani highlights

34 pietro invernizzi

Epatology translational research:

the role of microRNAs as biomarkers

35 massimo locati icroRNAs: new tiny players with a M huge impact on immunity

37 paola allavena

new anti-tumour drug A of marine origin

38 Gerry Scotti supports

30 Translational research

4

4 research projects Fondazione Humanitas per la Ricerca

Oncology

even in hard times

interview with armando santoro

i nterview with maurizio fornari

interview with gianluigi condorelli

highlights

highlights

highlights

ew perspectives in lymphoma therapy N with new agents

57 michela matteoli

In search of answers from synapses

ovel molecular mechanism N of heart failure

63 patrizia presbitero

63 maurizio gasparini

dvances in surgical treatment of A hepatocellular carcinoma

How technology can treat heart failure

65 elisa di pasquale

46 paolo zucali

61 daniele catalucci

Translational research in cardiovascular disease

The Liver Unit for the translational research on hepatocellular carcinoma

45 guido torzilli

Cardiovascular

against cancer

44 lorenza rimassa

59 A total dedication to heart

43 ercole brusamolino

Neuroscience

53 An extraordinary year

41 New allies in the fight

he multidisciplinary fight against T mesothelioma

I nduced pluripotent stem cells as a tool for in vitro models of human heart diseases and therapeutic discoveries

47 marco alloisio

alignant pleural mesothelioma: M a challenging surgery

48 lorenzo bello

ultidisciplinary approach in the M treatment of CNS tumours

49 marta scorsetti

he role of radiotherapy in brain T tumours

50 luca castagna

hat’s new in allogenic stem cell W transplantation

51 andrea lania

variety of approaches for the wide A spectrum of neuroendocrine tumours

67 Board of Directors 68 Departments and teams 68 Clinical Area 74 Scientific Research and Laboratories 76 Papers published 2012 76 Preclinical Research 85 Translational research 93 Clinical research

5

6

Humanitas Research Hospital

7

Humanitas Research Hospital

A close integration between health care, research and training to offer our patients the world’s best affordable care: this is the mission at Humanitas. This ambitious aim sees hundreds of professionals – i.e. physicians, researchers, nurses, technicians, and other staff – at the frontline every day.

“In our work, the patient has always been placed at the center as a person, as a whole human being with his/her own complexity, which goes far beyond one single pathology, or a combination of pathologies. Only an approach which considers the person as a whole allows to respond appropriately to modern health care needs – says Ivan Colombo, Vice President of Humanitas. Healthcare, supported by the best specialist skills and integrated with multidisciplinary training, must be constantly supported by continuous research activity. In order to meet these objectives, Humanitas changed its clinical organization, and created specialized centers for cancer (Humanitas Cancer Center), cardiovascular, neurological and orthopaedic diseases.

The constant and considerable investments in state-of-the-art technologies for diagnosis, treatment and research allowed researchers to carry out scientific work that has been recognised worldwide, as appears in the latest SCImago rankings.

8

An integrated general hospital with a high specialization Emergency Center Humanitas is an Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS, an accreditation in the Italian system as an institution devoted to excellence in clinical care and research). In other words, a multi-specialty and highly integrated general hospital with 747 beds (of which 75 are in the medical, surgical, and oncological day-hospital and 28 in the intensive care unit, while 130 beds are reserved to cardio-ortho-neuromotor rehabilitation in a separate building), 25 operating theatres, 5 angiographic rooms, and 190 outpatients clinics.

Humanitas is accredited by the Italian National Health Service. Its diagnostic and therapeutic activities meet people’s requirements at a local, national, and international level with over 140,000 patients from all Italian Regions and from abroad are taken care of each year.

Moreover, it is equipped with a high specialization Emergency Center, attended by over 55,000 patients every year.

9

Humanitas Research Hospital

Within Humanitas operates the Humanitas Cancer Center, a specialist center for cancer research and cure. Specialist rooms, and therapeutic paths geared around the patients’ needs combine with state-of-the-art technology and personalized therapies, with a 360-degree assistance. Multidisciplinary cooperation is fundamental, not only at an oncological level, but also between all the specialists who may intervene in the cure process.

Humanitas Cancer Center hosts highly specialized experts in oncology. The Polyclinic is able to cater for all the patients’ needs – be they cardiologic, rehabilitative or emergencyrelated – and is organized so as to guarantee support to relatives and continuous care – even after dismissal – through homehospitalization and cooperation with local hospices. In addition, special attention is given to people who were healed from cancer,

whose number is increasing nowadays, and who may need to follow a specific path which is both medical- and assistance-related – as well as psychological – thanks to specifically designed medical rooms and pathways.

At Humanitas, research – which is fundamental for the improvement of the cure quality and results – encompasses all the areas of the curing process: prevention, screening, development of new drugs and support therapies, laparoscopic and robotic surgery, radiotherapy. All this without leaving out pre-clinical research and focusing on the mechanisms where oncologic diseases originate.

A specific website – www.cancercenter.it – presents the activities of the Centre, clinical trials, the initiatives for screening and prevention, and patient support services, as well as the latest news from the Oncology world.

Köln, Germany

Andreas Engert Köln University Clinic Dublin, Ireland

John Crown St. Vincent University Hospital Boston, Usa

Eric Van Cutsen

Harvard Medical School and Dana-Farber Cancer Institute

University Hospital Gasthuisberg

Silvia Formenti Antonella Surbone New York University School of Medicine

10

Humanitas Cancer Center Advisory Board Members

Ruprecht Karl University and Salem-Hospital

Leuven, Belgium

Kenneth C. Anderson

New York, Usa

Heidelberg, Germany

Markus Büchler

milano, Italy

Alberto Costa European School of Oncology

Humanitas Cancer Center’s figures

200 health professionals (physicians, surgeons, psychologists, physicists, and biologists) 200 nursing professionals 200 clinical and basic researchers 30,000 patients per year, 40% from Regions other than Lombardy 300 clinical trials and projects aimed at developing new therapeutical options in the last 3 years

The Center

30,000 sqm 300 beds 80 outpatient clinics 10 operating theatres 1 Translational Research Center with a Biobank, Molecular Biology and Clinical Pharmacology labs

Last generation technology equipment for diagnosis and treatment

5 linear accelerators for Radiotherapy, included the innovative TrueBeam and TrueBeam STx accelerators 2 PET-CT and a cyclotron for radiopharmaceutical production 4 CTs 5 NMRs, included a 3 Tesla NMR and an open-bore NMR 1 Da Vinci Surgical System

Tokyo, Japan

Masatoshi Makuuchi Tokyo University

11

Humanitas Research Hospital

Quality and International accreditation For Humanitas a strict link between efficient management and high quality clinical activity is mandatory. Consistently, Humanitas was the first polyclinic in Italy, and among the few in Europe, to have been polyclinic certified by the Joint Commission International. This acknowledgement of excellence has been confirmed and renewed four times since 2002 and has required the compliance with over 1,300 standards.

On the patients’ side Humanitas cooperates with Fondazione Humanitas and Fondazione Ariel to provide support to patients and their families.

In particular, Fondazione Humanitas supports patients with chronic diseases and their families by means of dedicated programs and properly trained nursing volunteers, while Fondazione Ariel supports children affected by cerebral palsy and their families through orientation activities, psychological and social support and assistance.

Our effort to combine therapy and research with training is also evident in our efforts to integrate different skills within a single system, so as to meet patients’ needs in a more complex world. This is the reason why we experience and promote the coexistence of institutions with specific and apparently very different missions under the same roof, i.e.

Humanitas and Humanitas Cancer Center as far as assistance is concerned, but also Humanitas and Ariel Foundations for care and support, and the Università di Milano – which offers an international degree course –, as well as the Consiglio Nazionale delle Ricerche and Fondazione Humanitas per la Ricerca in the research sector.

12

Technology and Innovation Humanitas is a research hospital with a strong tendency for an interdisciplinary, integrated approach and high specialization. From cardiac surgery to orthopaedics, from oncosurgery to neurosurgery, the most advanced standards at an international level are offered, as well as up to date technologies.

Among these, radiotherapy, with last generation nuclear accelerators – which include TrueBeam, the first and the only one in Italy and the innovative TrueBeam STx – operating at high speed and allowing for an extremely fast and precise treatment.

Humanitas is also equipped with a robotic surgical system to treat cardiac arrhythmias, a 3 Tesla nuclear magnetic resonance, an open-bore NMR, and a PET-CT. Moreover, it has acquired with an innovative ESO system, the first and only in Italy, that enables an accurate assessment of vertebral column and lower limbs in weight-bearing standing position and reduces the radiation dose considerably. It offers surgeons and orthopaedics a big amount of relevant clinical information to manage each case appropriately and with minimal invasivity.

Humanitas also stands out because of the role of robotic surgery, which represents the new frontier in minimally invasive surgery.

13

Humanitas Research Hospital

A latest generation excimer laser, unique in the world due to the integration of multiple and sophisticated technologies and the dedicated softwares, has been developed with the cooperation of the team of Humanitas’ Ophtalmology Center.

It can correct vision defects (myopia, astigmatism, hypermetropia) and represents the cutting edge of this new high specialty Humanitas’ center, set in the heart of the Polyclinic: 23 professionals, 797 sqm, an expert team able to assist each day more than 200 patients from Italy and from abroad.

14

15

foto Emanuela Gambazza

Humanitas Research Hospital

International scientific cooperation The challenge of integrating health care, research and training is played on international grounds: “this means being confronted with the best international institutions at all levels (i.e. assistance, research and training) in order to attract and train the best minds, from Italy or from abroad, who are going to be physicians and researchers of the future” – explains Alberto Mantovani, Scientific Director of Humanitas.

There is a closed link between therapy quality, research and training. Generally speaking, patients are expected to be treated better where research is performed and centers of clinical excellence are thus also dedicated to training and research. Offering patients the best assistance means attracting the most talented researchers from all over the world and providing young physicians an international training. This is the best way to get in touch with most advanced progress, to keep up-to-date and develop critical thinking.

This is why we have been strongly committed with the Università di Milano (in fact some University courses take place at Humanitas) in order to create the International Medical School, an international degree course in Medicine in English. It has been active for three years and it is a great opportunity for Italian students who are stimulated by colleagues from all over the world to open their minds to different views and to broaden their own perspective”.

The teaching approach of the International Medical School is completely new to Italy. The different subjects are integrated with multidisciplinary cooperation. This reduces the constraints of the traditional teacher-student approach and allows the students’ active involvement through ‘active learning’ approaches like problem-based learning, which promotes cooperation and team work, as well as critical thinking. The whole process takes place under a tutor’s guidance and supervision. The tutor is one of the fundamental roles of this international course, especially during the years at the clinic: the introduction of a tutor every two students allow to plan and simulate bedside clinical activities more carefully, and to organise work in small groups. The aim of this is to enable progressive operational au16

tonomy. The international character of this degree

“MIMed”, International Medical School “MIMed” was designed to integrate academic training, experience in hospital, and research laboratory environments. Adopting an innovative approach, at least in traditional Italian teaching, but in line with the most advanced international academic standards, the study course combines lectures held in English with original teaching methods where students play an active role and are largely responsible for their own learning.

Interactions with teachers, a broad spectrum of experience in the field, a solid clinical tutoring system, small study groups, problem-based learning and problem-solving are the main features of the learning process.

The hospital as a teaching site Humanitas is a teaching center of the Università degli Studi di Milano. Specifically, it hosts the courses of the University School of Medicine, the International Medical School (www.mimed. it), the courses in Biotechnology and Nursing Schools.

Humanitas Lectures include a series of top level scientific meetings organised in partnership with the Università degli Studi di Milano. These lectures focus on the development and evolution of the biomedical research at the service of human health.

Among the speakers, the Nobel Prize awardees Prof. Rolf Zinkernagel and Prof. Françoise Barré-Sinoussi are worth mentioning.

17

Humanitas Research Hospital

course however, is not only limited to the teaching approach. In fact, the educational model and the use of the English language allowed to attract a number of foreign students on one hand, and to start International cooperation on the other, so as to promote exchanges with European and American Universities. A key characteristic of this degree course is to provide students with the opportunity to come into contact with prestigious research environments abroad, and to choose to work there if they intend to. For this reason, we started a cooperation with the NBME (National Board of Medical Examiners), the organization which deals with medical professional certification in the USA, so that students are able to meet the strict criteria required to be admitted to specialization schools in the USA.

“The International background represents a commitment and a constant challenge towards top-level training – continues professor Mantovani – including the environment of research, where we are actively involved in International PhD courses: the Open University one in the UK, as well as the PhD in Pathology at the Università di Milano”.

The importance of evaluation Research represents the main arena where the standing of Humanitas is to be assessed. Mantovani explains: “We have had positive results so far. Scientists from all over the world are hosted in our laboratories (see map).

The year 2012, as was the case for the two previous years, saw our scientific productivity increase constantly in quality, so that levels remained very high, as indicated by the bibliometric indexes: over 2,200 Impact Factor points in 2012 (ranking among the first IRCCS institutions in scientific output), with a consistent focus on the immunodegenerative area, where we are recognized as an IRCCS. We are convinced that this is a crucial field for contemporary medicine, in that it has a strong impact on different clinical areas, ranging from cancer to cardiovascular diseases, inflammatory and autoimmune diseases.

The ranking results obtained by the end of 2012 from SCImago, the organization which analyses the publications from over 3,000 research centers worldwide, showed that Humanitas is one of the 105 medical institutions out of 595 in total that obtained the Green Label of Research Impact in 2012: this means that the impact of its publications is more than twice the average. Thus, in the SCImago ranking of health research institutions, based

18

on research quality, Humanitas ranks in the top 20% worldwide. It is certainly a great

germany UK

canada

Hungary

france usa

colombia

romania switzerland

spain cuba

poland

Taiwan india

Brazil

Geographical distribution of foreign researchers at Humanitas, from January 1st 2011 to February 28th 2012 Italian researchers who returned after an experience abroad Total 11

19

Humanitas Research Hospital

achievement for us, and represents a further stimulus for improvement. This is mainly true for patients, but also for our students and young researchers.

Humanitas firmly believes in evaluation. “This – Ivan Colombo says – led Humanitas to be the first polyclinic to be accredited by the Joint Commission International and to be endowed with an Advisory Board for basic research whose chairman is the Nobel Prize awardee Prof.

Rolf Zinkernagel. The international Advisory Board includes physicians and researchers from the most important clinical and research Cancer Centers in the world, with which we share clinical and research activities of the Humanitas Cancer Center”.

The regularly planned site visit of the Advisory Board, at the end of 2012, ended with overall praise for research activities at Humanitas. This shows that our efforts have been recognised, and stimulates us to improve further.

“Progress and growth during the last 3 years has been outstanding. (…)

The recruitment of translational researchers and physician scientists has been particularly successful and should be further expanded. (…)

The overall increase in scientific productivity is particular impressive. (…)

Progress in education has been outstanding. (…) The establishment of the International Medical School and the M.D., Ph.D. program is viewed as a major strength of the HRI, which positions the Institute as a leader in the training of the next generation of physician scientists in Europe. (…)

The ranking of Humanitas is also very impressive (…): is now top 10% in Italy and Western Europe worldwide (SCImago ranking)”.

Site visit Advisory Board, December 2012

20

Exc. (%)

Humanitas excellence worldwide

45

Cold Spring harbor lab (USA) INSTITUTE FOR SYSTEM BIOLOGY (USA) HOWARD HUGHES (USA) J. CRAIG VENTER (USA) SANGER INSTITUTE (UK)

40 35 30 25

DIANA-FARBER CANCER INSTITUTE (USA) SLOAN KETTERING (USA)

MAYO CLINIC (USA)

ICH

20 15 10 5 0 50 55 60 65 70 75 80 85 90 95

Q1 (%)

SCImago Research Group publishes a yearly report which evaluates institutions around the world with meaningful scientific output.

SIR World Reports 2012 is the most comprehensive ranking of Worldwide Research Institutions, including 3,290 institutions from 106 countries that together are responsible for more than 80% of worldwide scientific output during the term 2006-10.

The evaluation is based on several indicators among which it has to be mentioned: • the Normalized Impact (NI, in %) which shows the relationship between an institution’s average scientific impact and the world average set to a score of 1.

Humanitas, with a NI score of 2.1 is cited 110% above world average; • the Excellence Rate (Exc, in %) which indicates the amount of an institution’s scientific output that is included into the set of the 10% of the most cited papers in their respective scientific fields.

It is a measure of high quality output of research institutions.

23.8% of Humanitas’ scientific output is included in that first decade.

Moreover, Humanitas is one of the 105 health institutions (out of 595 in the world) which obtained in 2012 the Green Label of Research Impact, the highest grade among the levels of NI.

NI

Exc

in Italy

top 10%

top 10%

in Western Europe

top 20% top 10%

in the world

top 20% top 20% 21

Humanitas Research Hospital

Results and perspectives for Humanitas Research: transferring laboratory discoveries to patients “We obtained important results which including laboratory discoveries and high quality clinical studies which analyze and validate diagnostic and therapeutic procedures – professor Mantovani continues –. Thanks to the use of genomics techniques in different areas at the

patient’s service, it has been possible to identify potential targets in areas of diagnostic and therapeutic intervention for autoimmune diseases and to validate targeted therapies which – in the case of tumours – are guided by molecular characteristics. One of the challenges of the years to come is to turn advancements made in genomics and post-genomics into diagnostic and therapeutic innovation at the patient’s service. Another challenge is to focus on gender medicine, which deals with gender-related problems and differences, with particular reference to the female sex. The results we have obtained so far tell us that we are on the right track using bi-directional cooperation between research, benchside and bedside. In other words, we must transfer laboratory data to patients and let patients drive our lab efforts”.

In the last years, the introduction and development of increasingly sophisticated research technologies – both basic and clinical – have allowed the time span between scientific discovery and practical application to be reduced, for instance with daily practice in wards. “It has become fundamental to guarantee that lab results are transferred to patients rapidly.

This is in fact the main aim of research which is referred to as translational, which is based on close integration between bench and bedside. This is why it is fundamental to guarantee training for professionals who are competent scientific researchers and work in close contact with patients at the same time: MDs and researchers (PhDs) who work both in the hospital and lab, combine the strict rigour of research with the ongoing relationship with patients who benefit from the most advanced research outcomes and discoveries. This is why the challenge ahead of us is to provide targeted training for MDs and researchers (MD/PhD), as is the case internationally.

We are firm believers in this ‘bridging’ between the lab and the bedside, a basic tenet of translational research and sup-

22

port it constantly.

Translational research Humanitas’ scientific and research activity has always been characterised by an enormous potential for transferring findings from benchside to bedside, implying a close integration and exchange of data between laboratory and hospital wards, crucial to promptly transfer the results of its research into everyday clinical practice.

Research and Teaching Center At the University Research and Teaching Center, which is fully integrated with the Hospital counterpart, over 200 researchers have been working with cutting-edge technology, such as the recently acquired two-photon microscope. The group operates in close collaboration with the hospital (over 550 physicians on the identification of inflammation mechanisms at the outset of the processes ) to facilitate the direct application of the most recent advances in health care, through a systematic and ongoing process of innovation.

Scientists and researchers from 16 countries spanning 4 continents carry out research in immunology and are involved in studies on high impact noncommunicable diseases, e.g. cancer, myocardial infarction, stroke, and autoimmune diseases.

23

24

GREECE

italy

switzerland

EUROSTARS austria

czech rep.

UK belgium netherlands NORway denmark sweden germany

usa

germany

germany

netherlands

The network of the EU-sponsored research projects

ireland spain france

italy

LeDucq Foundation

france

italy

switzerland

france

usa

Humanitas Research Hospital

BeTheCure (IMI)

Fondazione Humanitas per la Ricerca is involved in supporting clinical and basic studies on pathophysiology of immunological defense mechanisms and of risk factors for several diseases, among which chronic inflammatory, cancer, cardiovascular, and neurological diseases.

The research activity of Fondazione Humanitas is monitored by an Advisory Board whose chairman is the Nobel Prize awardee Prof. Rolf Zinkernagel.

The Advisory Board of Fondazione Humanitas per la Ricerca:

germany

Lorenzo Moretta, MD Research Director Giannina Gaslini Pediatric Institute Professor of General Pathology University of Genova - Genova, Italy

italy

france

italy

WHIM-Thernet (E Rare JTC)

switzerland

brazil

italy

switzerland

TIMER

france

ireland

ADITEC

Napoleone Ferrara, MD/PhD Genentech Inc. South San Francisco, USA

austria

usa

UK belgium netherlands norway denmark sweden germany

Charles Dinarello, MD Professor of Medicine Division of Infectious Diseases University of Colorado Health Sciences Center Denver, Colorado, USA

Gรถran K. Hansson, MD/PhD Karolinska University Hospital Stockholm, Sweden

UK

Fabio Cominelli, MD/PhD University Hospital Dept. of Medicine-Gastroenterology Cleveland, Ohio, USA

Pietro De Camilli, MD Eugene Higgins Professor of Cell Biology and of Neurobiology Director, Yale Program in Cellular Neuroscience and Neurodegeneration and Repair New Haven, Connecticut, USA

Ireland

Rolf Zinkernagel, MD/PhD (President) University of Zurich and University Hospital of Zurich Institute of Experimental Immunology Zurich, Switzerland

25

Humanitas Research Hospital

Cooperation networks Scientific research grows naturally in an international dimension (which is boundless by nature), and progresses in the cure of patients. This is why it is fundamental that Humanitas takes part to global cooperation networks. As Ivan Colombo explains, “The intensity and proactive character of international relationships at Humanitas is illustrated by the ability to be part (or promoters, or leaders) of highly competitive European projects. Projects that are supported by the European Union represent only a small portion of our international dimension.

We are currently working on projects with the United States and with Far East countries, in particular with Singapore. Moreover, we have established structured collaborations with international centers into the wordlwide research scenery, for instance with Brazil�.

Collaboration at an international level is fundamental even in clinical practice. In recent years, the collaboration with national and international top-ranking hospitals and the constant effort to implement the most advanced technologies has led to outstanding results in the treatment of neoplastic, gastrointestinal, cardiovascular, neurological and immunological diseases.

Concerning our mission against cancer, many clinical research trials designed for the application and testing of new drugs, rely on scientific collaboration with important centers both in the US and Europe: New York, Boston, Tampa, Stanford, Amsterdam, Dublin, Marseille.

ireland UK

sweden

denmark

belgium

Countries involved in international cooperation networks

netherlands germany austria

usa

26

portugal

switzerland

france

croatia

japan

Castellanza Humanitas Mater Domini

Bergamo Humanitas Gavazzeni

www.materdomini.it

www.humanitasgavazzeni.it

Research Fondazione Humanitas per la Ricerca www.humanitasricerca.org

Torino Clinica Cellini www.clinicacellini.it

Take care Fondazione Humanitas www.fondazionehumanitas.it Fondazione Ariel www.fondazioneariel.it

Rozzano Istituto Clinico Humanitas www.humanitas.it

Catania Humanitas Centro Catanese di Oncologia www.humanitascatania.it

The Humanitas Group in Italy Humanitas Research Hospital is the flagship of the Humanitas Group, an Italian hospital network distinguished by its quality, research, high specialization, common medical culture and emphasis on the humanization of care.

27

Humanitas Research Hospital

Clinical-scientific activities Clinical activities Outpatients 2009

Inpatients

1,246,415

2010

1,635,391

2011

1,742,004

0

500

1000

50,423

2010

49,720

2011

50,211 36,472

2012*

2,226,459

2012*

2009

1500 2000 2500 thousands of patients

0

10

20

30

40 50 60 thousands of patients

*data not comparable: since 2012 day-hospital Cancer Center admissions have been included in outpatients’ activities

Humanitas’ people Total people 2009

1811

2010

1880

2011

1939

2012

1963 0

500

1000

1500

2000

Research activities Published papers 2009

2009

289

2010

125

250

375

1875

2012

416 0

1727

2011

363

2012

1587

2010

349

2011

28

Raw impact factor*

500

2253 0

500

1000

1500

2000

2500

* The raw IF is the sum of the IF of each journal that publishes the paper with at least one name of an Humanitas physician.

Staff 352

18% 50%

32%

Physicians and researchers 629

Nurses, technicians, biologists and others 982

Total 2012 100% = 1,963

Papers classified according to their raw IF* 2009

33

2010

31 48

2012

42 0

2010

230

77

2011

2009

192

65

55

IF>10

100

2011

256 99

50

150 IF5-10

275 200

250 IF<5

Competitive funding

300

350

400 450

2012 0

1000 Industry

2000

3000

Charities

4000

5000

Italian public grants

6000

mln euro

7000

International public grants

29

Translational research Immunity and inflammation Oncology Neuroscience Cardiovascular

30

31

Immunity and inflammation

32

Research on immunology.

Does “miR” stand for microRegulation?

Interview with Alberto Mantovani

Professor of General Pathology at the Faculty of Medicine at the Università degli Studi di Milano and Scientific Director of Humanitas

» Why cannot this view be considered valid any

longer, and why does it need to be updated or revised?

Recently, this view has progressively and drastically changed because evidence is being gathered of a crucial role for the so-called junk-DNA, that has a huge responsibility in regulating the programs of gene expression. Paradoxically speaking, we are not so different from a worm or a petunia – I’m taking as an example beings commonly used for experimental models – in terms of gene number. The order of magnitude of the encoding genes is, in fact, comparable.

Thus, at the moment, the basic tenet is that, as organisms become more complex, it is the regulation of the genes that increases, rather than their number.

» Now, shall we move on from theoretical aspects to practical examples?

A balance of the year that has just gone by shows that Humanitas research once again ranked at the forefront of immunology, inflammation and immunodegenerative diseases.

» Shall we draw an outline of these past

12 months of research on immunity and inflammation?

One of the most exciting advances is the understanding of the subtle regulatory mechanisms of gene activation and silencing. We have to bear in mind that in “our” human DNA, a really long double strand, the number of protein-encoding genes is relatively small. However, this minority fraction, which does not exceed 1-2% of the human genome has been considered the single protagonist of genetics for quite a long time, being the only one able to express clearly decoded messages.

Similarly, the switching-on and switching-off of genes has been considered the only regulatory mechanism. This long-lasting gene centered view also implied a marginal role for the remaining, even if quantitatively prevalent, genomic material.

Once the general picture has been framed, one of the subtle tuning mechanisms is represented by those small non-coding RNA molecules, universally known as microRNA (miR) because of their length, which function in transcriptional and post-transcriptional regulation of gene expression.

In other words, they don’t regulate the on-off status of the bulb. Rather, the light intensity.

Another case in point is that of a thermostat: miRs may be regarded as the microthermostats of gene expression.

This is a crucial signpost for the knowledge of mechanisms of life, where advances have been made possible thank to the precious contribution of the Italian researcher Carlo Croce. These molecules play a fundamental role in oncogenesis, accounting for one of the genetic mechanisms for cancer development and progression. More recently, they have been implied in fine tuning and regulation of the human immune system. The order of magnitude of identified miRs is at the moment of a thousand, but we are experiencing an animated phase, where miRs are increasingly being discovered. Also the knowledge of their functions and biological meaning is increasing, suggesting a potential role as diagnostic and/or therapeutics tools.

33

Immunity and inflammation | Interview with Alberto Mantovani

» Which phase of research on miRs is Humanitas experiencing at the moment, and what is the extent of its contribution?

HIGHLIGHT

Humanitas has made a substantial contribution to the advances in research, since new miRs have been identified and characterized in our laboratories.

In particular, it has been defined how these subtle regulators exert a fundamental role in modulating certain functions of the immune system, more specifically of innate immunity and inflammation.

34

Pietro Invernizzi, Principal Investigator of Laboratory of Hepatobiliary Immunopathology, Unit of Hepatology and Center for Autoimmune Liver Disease

At the same time, another research activity focused on miRs is being conducted – at Humanitas as well as all over the world – where the molecules are monitored as biomarkers in different human conditions, i.e. as diagnostic tools. Their study can find a diagnostic application, since they are produced at a cellular level and thereafter released into the systemic circulation. One cannot exclude, in a near future, to measure their circulating levels to obtain important and reliable practical – and bedside – information. For a clinical diagnosis, it

Epatology translational research: the role of microRNAs as biomarkers

«MicroRNAs (miRs) are a group of small, endogenous noncoding RNAs involved in the control of cell differentiation processes, with a demonstrated role as biomarkers. Recently, this emerging research field has discovered that miRs can also be efficiently evaluated in serum. Humanitas’ Center for Autoimmune Liver Diseases is committed to the study of different hepatic conditions, the aforementioned autoimmune diseases, e.g. primary sclerosing cholangitis. Thus it follows patients at risk of developing cholangiocarcinoma, a rare but often fatal malignancy of the bile duct epithelium, strongly associated with chronic biliary inflammation. Unfortunately, no useful serum markers specific for primary sclerosing cholangitis and cholangiocarcinoma are available. In addition, cholangiocarcinoma is characterized by a very poor prognosis (the 5-year survival rate after diagnosis is 7-8%). For these reasons, there is a strong need for accurate serum diagnostic markers for both primary sclerosing cholangitis diagnosis and cholangiocarcinoma screening at an early stage or, better still, for a pre-cancer biomarker in primary sclerosing cholangitis. Based on these premises, we started a project to identify specific serum miRs with a role as diagnostic markers of primary sclerosing cholangitis and a role of pre- or early-cancer biomarkers of human cholangiocarcinoma in patients with primary sclerosing cholangitis. We currently highlighted 3 liver-specific miRs which have been upregulated in both the diseases compared to a control group of healthy subjects, 4 primary sclerosing cholangitisspecific miRs, and 3 cholangiocarcinoma-specific miRs. We also highlighted a set of 2 miRs, altered in cholangiocarcinoma compared to primary sclerosing cholangitis, thus representing the disease transformation into cancer. Our studies provide a basis for the use of miRs as biomarkers for the diagnosis of primary sclerosing cholangitis and for the early detection of cholangiocarcinoma in high risk patients. At the Center for Autoimmune Liver Diseases we are now extending the search for serum miRs to other liver diseases.»

HIGHLIGHT

Massimo Locati, Principal Investigator of Laboratory of Leukocyte Biology

MicroRNAs: new tiny players with a huge impact on immunity «At the end of the last century impressive economic and intellectual efforts led to one of the greatest achievements of basic science: the human genome was finally completely uncovered. The definition of our genome map was considered the key missing information to boost our understanding of life. For this reason, as you can imagine, at the beginning it was a bit disappointing to realize that only less than 5% of our genome in fact encodes for a protein, and that the rest of it was so “mysterious” to us that for a long time we considered it as “garbage DNA”. In 2006 the Nobel Prize in Medicine was awarded jointly to Andrew Z. Fire and Craig C. Mello for their discovery of RNA interference, an unexpected biological process by which RNA exerts a silencing effect on the messenger RNA (mRNA), the DNA copy which encodes for proteins. All of a sudden we started understanding that DNA was indeed more than simply the template for mRNA. Today we know that over 90% of our genome encodes non-coding RNA, which don’t encode for proteins but exert a sophisticated and entirely new level of regulation on gene expression. It is interesting to note that, looking at life in evolution terms, most of the difference among living organisms does not lay in their “building blocks” (represented by their protein-encoding genome), but on the tiny details at this new overlaying regulatory network. We are just now starting our journey in this new world, and already some key elements have been established. It is now clear that in this new scenario a major player is represented by small non-coding RNA molecules conserved in evolution in plants and animals called microRNAs (miRs in short), whose function is to operate a post-transcriptional regulation of gene expression. miRs function via base-pairing with complementary sequences within mRNA, causing their silencing via translational repression or their degradation. Our genome encodes for over 1,000 miRs, which are predicted to target over 60% of our coding genes. They are involved in all fundamental biological processes, from cell replication to death, and evidence indicating their role in several human diseases is also accumulating. In 2008 the Laboratory of Leukocyte Biology started searching in this “black box” with an immunological question in mind: are miRs also involved in the development and function of our immune system, and do they play any role in human diseases sustained by immunomediated mechanisms?

In this field in the last years we have identified previously unknown miRs, we have understood their role during immune responses, and have associated them with human diseases. miRs are presently under development as diagnostic/prognostic markers in the oncology field, and we are confident that their emerging role as key regulators of immune processes will soon lead to the exploitation of their diagnostic/prognostic and therapeutic potentials also in the immunology field.»

35

Immunity and inflammation | Interview with Alberto Mantovani

will be possible to take fingerprints of miRs, exactly as we do at present for traditional biomarkers, e.g. haemoglobin or cholesterol; this is the really intriguing hypothesis about them.

» Are any other projects taking place?

We have recently made relevant progress in translational research on immunology and inflammation, a field characterized – especially with reference to innate immunity – by both an intense productivity in our country and an historical top ranking position of Humanitas. In this context, a research project funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and called “AIRC 5 x 1.000”, is of great interest: here, the Fondazione Humanitas per la Ricerca, following its mission plays the role of coordinator and several distinguished national institutions participate: Istituto Gaslini di Genova, Università di Roma La Sapienza, Ospedali Riuniti di Bergamo, Ospedale San Gerardo di Monza, and Università di Milano Bicocca.

Significant advances have been seen, which potentially prelude to experimental clinical studies on early use of molecules or cells of the innate immune system against some haematological malignancies (leukemias or lymphomas) or against bone marrow transplant-associated infections, which represent the worst complications in patients who undergo that procedure.

» What has Humanitas Research got in store in the long term future?

The future has in store novel and various perspectives, in line with Humanitas’ vocation to reach the forefront, and, this year in particular, following the recent entry of research groups with a strong background and a unique competence in degenerative central nervous system diseases and heart diseases.

It’s more than a hope, rather a certainty, that “our” – traditional – specific knowledge, skill, and expertise in immunology will merge and operate in synergy with “theirs” – newly acquired – in neurology and cardiology, thus providing the best opportunities to understand, diagnose and treat degenerative non communicable diseases, which at present are having a considerable impact on public health issues.

This is the most recent intriguing – however demanding – perspective. Besides, we have to address many challenges in order to carry on with the transfer of experimental results into daily practice and – as if in a two way-street – the learning process from bedside.

top paper Danese S, Vetrano S.

Colitis, microbiota and colon cancer: an infernal triangle Gastroenterology. 2013;144(2):461-3. Epub 2012 Dec 19.

36

HIGHLIGHT

Paola Allavena, Principal Investigator of Laboratory of Cellular Immunology

A new anti-tumour drug of marine origin

ÂŤNatural products from plants and microorganisms have been the cornerstone of anti-cancer pharmacology since the very beginning of industrial development and are still used today for the treatment of tumour patients. The sea is a vast source of biodiversity which is yet to be fully exploited by modern pharmacology. A Spanish company, leader in the discovery and development of new drugs of marine origin has several compounds in its pipeline as potential anti-tumour agents. One such compound, trabectedin, was recently approved in Europe and in several other countries for the treatment of soft tissue sarcoma and ovarian cancer, and is the first anticancer drug of marine origin to have reached the market. As an anti-tumour agent, trabectedin kills tumour cells and blocks their proliferation by interacting with DNA. Trabectedin, however, is more than a conventional cytotoxic agent. Scientists in Milano, coordinated by myself at Humanitas and by Maurizio Dâ&#x20AC;&#x2122;Incalci at the Mario Negri Institute for Pharmacological Research, in collaboration with the Tumour Institute, have now discovered that trabectedin has additional mechanisms of action and its anti-tumour efficacy relies also on the ability to target the tumour microenvironment. Specifically, trabectedin kills a subset of immune cells (macrophages) that populate the tumour tissue and are known as tumour-associated macrophages (TAMs). These immune cells, instead of defending the body, as they should do, have been corrupted by tumours and help cancer cells in several different ways, for instance by producing growth factors that stimulate tumour proliferation and the development of new vessels, or tumour cell spreading. In the last decade, it has become increasingly clear that the presence of TAMs in the tumour microenvironment is significantly associated with resistance to chemotherapy and disease progression. The study, published in Cancer Cell, shows that trabectedin is able to kill macrophages and their precursor cells (circulating monocytes) while sparing other immune cells. In patients with soft tissue sarcoma, trabectedin reduces the number of TAMs and inhibits their pro-tumour activities. The new results demonstrate that trabectedin has dual anti-tumour effects: it targets both cancer cells and the pro-tumoural TAMs. These findings disclose a new mode of action of a clinically useful and already available anti-cancer agent, and open new perspectives for the exploitation of this unique property in therapeutic settings.Âť

37

Gerry Scotti supports 4 research projects Fondazione Humanitas per la Ricerca Four grants for four talented young researchers. Gerry Scotti, one of the most famous TV presenters, “adopted” four young researchers at Humanitas, and is financing their research studies against cancer for a year. Four cheques accounting for € 25,000 each, for a total of € 100,000 have been donated by the presenter to Angela Ceribelli, Silvia D’Alessio, Giuseppe Favacchio, and Manuela Quintavalle, who practised their skills and experience in prestigious structures abroad.

Their research projects address fundamental challenges in Immunology.

Novel mechanisms and biomarkers for lymphoma transformation in Siögren’s syndrome: a translational approach Angela Ceribelli, MD, specialized in Rheumatology. She has worked as a post-physicianal associate at the University of Florida (Gainesville, USA), studying extensively autoantibodies/ autoantibody profile in patients with rheumatologic diseases. At Humanitas, she is carrying out her research project working at the Laboratory of Rheumatology directed by Carlo Selmi.

«Sjögren’s syndrome (SS) is a chronic autoimmune disease that affects exocrine glands, causing dry mouth (xerostomia) and dry eyes (xerophtalmia), but also involving internal organs in some patients. Sjögren’s syndrome is also the autoimmune disease which is most commonly associated with cancer, with a risk 44 times higher than in the general population to develop lymphoma (mainly the B-cell non-Hodgkin lymphoma).

The mechanisms of Sjögren’s syndrome pathogenesis and its neoplastic evolution are not clear. Our project aims at studying these aspects, and for this reason we are currently: • collecting samples (serum and peripheral blood mononuclear cells) from Sjögren’s syndrome patients with and without diagnosis of lymphoma; • setting up the method of RNA and protein immunoprecipitation, in order to better identify the target(s) of autoantibodies produced by Sjögren’s syndrome patients.

Our study will potentially allow the identification of Sjögren’s syndrome patients with higher risk of developing non-Hodgkin lymphoma, and this could help in their follow-up and therapeutic choices.»

38

The “molecular scissors” which enable colorectal cancer invasion of surrounding tissues Sivia D’Alessio studied for over 10 years in Europe and the US, analysing extracellular matrix degrading protease systems, focussing on the plasminogen activation (PA) system, a mechanism involved both in tissue repair and in tumour progression. She has been at Humanitas since 2011, and works at the Laboratory of Gastrointestinal Immunopathology directed by Silvio Danese.

«Colorectal cancer is one of the most serious and frequent complications of long-standing inflammatory bowel disease (IBD). Several lines of evidence indicate that chronic inflammation predisposes the tissue to cancer by inducing gene mutation, inhibiting apoptosis or stimulating angiogenesis and cell proliferation. However, chronic inflammation also implies a considerable degree of tissue remodeling. Extracellular matrix degrading protease systems, such as the plasminogen activation system, are indeed up-regulated in inflamed and injured tissues and take an active part in the remodeling processes during tissue repair, and in tumour invasion during metastatic colonization.

The urokinase plasminogen activator and its receptor have been known for a long time to be involved in inflammation and tumour progression. However, their exact role in cancer, particularly in the early stages, and in inflammation-associated cancer is far from being understood.

My research is focussed on the role of the plasminogen activation system components in colitis-associated colorectal cancer, using both in vivo and in vitro approaches. This study is relevant for the discovery of new markers assessing colon carcinoma risk in inflammatory bowel disease patients (early detection and prevention). Additional molecular genetic analysis of this system is likely to reveal more insights into the early pathogenesis of dysplasia and the different molecular mechanisms of carcinogenesis operating in inflammatory bowel disease cancers.»

Continuos subcutaneous therapy via micro infusion pump in type 2 diabetic non nephropatic patients

Discovering molecular bases of tumour progression

Giuseppe Favacchio, MD, specialized in Geriatrics. After work

Chemistry and technology, PhD in Cellular and Molecular Biology.

Working as a post-physicianal fellow at Stanford-Burnham Institute in San Diego (USA), she focussed her research on the identification of genes involved in metastatization processes of different tumours (e.g. breast cancer and malignant melanoma), and their potentiality for targeted therapeutic strategies.

experience in different Operational Units, he is currently working at Humanitas’ Nephrology and Dialysis Division directed by Salvatore Badalamenti.

«Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both.

Latent autoimmune diabetes in adults (LADA) is a type of autoimmune diabetes that resembles type 1 diabetes (T1D), however, it shows a later onset and slower progression towards insulin necessity. Epidemiological studies suggest that latent autoimmune diabetes in adults may account for 2–12% of all cases of diabetes in adult population.

Some patients require intensive therapy regimes known as multiple daily injection (MDI) programs, in which insulin is injected three or more times a day. Alternatively, intensive therapy regimes can be administered by continuous insulin infusion (CSII) pumps. These devices attempt to closely mimic the behaviour of the pancreas, continuously providing an insulin basal level to the body with additional boluses at meal times.

Therefore, in collaboration with the Division of Diabetes and Nutritional Sciences at King’s College in London, we intend to study the effect of continuous insulin infusion in adult patients with latent autoimmune diabetes to improve glycemic control and prevent diabetic complications (in particular nephropathy and progression towards renal impairment).

This study could give new insight in the understanding the metabolic behaviour of these diabetic patients in order to formulate analytical algorithms which may be useful to create an “artificial pancreas”.

Such mechanical device would be able to automatically regulate blood glucose and greatly improve the lives of individuals with diabetes.»

Manuela Quintavalle, PhD, graduated in Pharmaceutical

«Cancer is responsible for 34% of all deaths in Italy. Most of the pain, suffering and mortality are associated with cancer metastasis. The ability of cancer cells to invade is associated with the presence of actin-rich membrane protrusions named invadopodia (see picture). Their function is to collect and regulate the activity of proteases that remodel the extracellular matrix. We developed and ran a high content, cellbased screening in order to identify regulators of invadopodia formation. The screening identified Cdk5 as an important regulator of cancer invasion in vitro. Our hypothesis is that Cdk5’s inhibition might be a viable anti-metastatic strategy to treat invasive cancers. Our goal is now to further evaluate the therapeutic potential of Cdk5 and our specific aim is to test the effect of Cdk5’s knockdown on tumour progression in vivo, using orthotopic models of cancer and transgenic mouse models. The present study will provide proof-of-concept that the identification of invadopodia regulators can lead to new strategies for the management of metastatic cancer growth.»

39

Oncology

40

New allies in the fight against cancer

Interview with Armando Santoro

Director of Humanitas Cancer Center

From translational research to targeted therapies: the new approach to oncological and haemato-oncological diseases has evolved during the last two decades and, accordingly, the profile of patients candidate to treatment has changed.

» What can be considered the most significant

changes in the therapeutic approach against cancer?

We have seen a dramatic and increasingly more prominent change of therapeutical strategies in oncology and haemato-oncology. If at first the focus was on traditional chemotherapeutic drugs, alone or in combination with surgery and/or radiotherapy, in the last 10-15 years we have experienced an increasing interest in targeted drugs (also called molecular or biological drugs).

No doubt, this has been one of the most important results of translational research.

» What do we mean by translational research?

That profitable integration of laboratory research and clinical practice, which allows the translation of findings and results directly from basic research to the patients’ bed, thus providing their fast application into clinical practice and vice versa.

In the last two decades, it has had such a sharp increase, that it became regular practice.

Moreover, translational research offers the unique possibility to reach a deep knowledge of the inner workings of tumoural growth and to characterize the different phases of each cancer progression and even to isolate the different phases of progression for each tumoural type.

The identification of these peculiar characteristics, either biological or molecular, reflects the alteration at the basis of the disease, be it a mutation, a rearrangement, a translation, or an increase in the expression of certain biomarkers, which become the target of the intervention. The following step is the construction of new targeted drugs, which specifically interfere with or block the different phases of tumoural progression.

This new therapeutical strategy has dramatically improved the prognosis of several neoplasms, opening more hopeful perspectives.

» Could you provide any examples?

Let’s start with a historical overview. Everything started with breast cancer treatment by trastuzumab, a monoclonal antibody directed against the Human Epidermal Growth Factor Receptor 2 (HER2), immediately followed by imatinib used for the treatment of chronic myelogenous leukemia.

Research and applications of targeted therapies have been progressively expanded and evidence of efficacy has been gathered. At the moment, a great number of molecular drugs is available.

For instance, considering hepatocellular carcinoma, two drugs have been shown to be able to provide a significant prognostic benefit: sorafenib, registered for the advanced unresectable stages of hepatocellular carcinoma, and tivantinib, a small molecule inhibitor of c-Met. This latter drug, which represents an innovative alternative for the cases which are unresponsive to sorafenib and express high levels of c-MET, has been extensively studied

by Humanitas researchers who coordinated a multicenter international project (see also the highlight by Lorenza Rimassa).

Encouraging results have been obtained also for thoracic neoplasms. In lung adenocarcinoma, which is the most common type of non-smokers lung

41

Oncology | Interview with Armando Santoro

cancer, a mutation of Epidermal Growth Factor Receptor (EGFR) is often found. A satisfactory and long-term control of the disease may be obtained using targeted drugs i.e. anti-EGFR molecules like gefitinib or erlotinib. More recently, cases of advanced non-small-cell lung cancer carrying the translocation of the ALK (Anaplastic Lymphoma Kinase) gene have shown impressive responses to ALK-targeted therapy.

Âť What is encouraging, is that your examples

refer to tumour types for which there used to be few treatment options.

42

Exactly. The same is true for brain cancer, and especially for high malignant undifferentiated glioblastoma, where, recently, antiangiogenic drugs have proven effective, in terms of prognostic outcomes and survival. The clinical advantage results from the combination of several improvements and innovations in the therapeutical approach, namely sophisticated and precise radiation therapy, whose association to targeted therapy has led to increasing optimism towards this disease.

Big advances have been introduced for the management of melanoma, whose metastatic stage was burdened by an extremely severe prognosis.

Two innovative treatments became available, with significant improvement in survival, which is considerably better than that obtained with conventional chemotherapy. The first is ipilimumab, a biological drug endowed with an immunogical mechanism of action, while the second is an antiBRAF, targeted against a BRAF mutation found in 40% of melanomas.

A similar consideration should be made for neuroendocrine tumours, even if they show a slow progression. In fact, until recently, the therapeutic options were few and endowed with a limited efficacy: chemotherapy, the somatostatin analogue named octreotide and interferon. Today, we have verified the positive effects brought about by some biological drugs, most of which are presently passing the phase of registration or authorization for this indication, e.g. anti-EGFR small molecules and antibodies, antiangiogenetic agents, mTOR inhibitors.

Âť In terms of haemato-oncology, an area of

excellence at Humanitas, could you specify any significant advances?

A revolution has begun also in this field.

For two decades, imatinib has been an established option for chronic myelogenous leukemia. We have a consolidated experience with rituximab, alone or in combination with chemotherapy, for the treatment of different types of non Hodgkin lymphoma. Beyond these two therapeutic strategies, that may by now be considered as milestones of haemato-oncology, I could mention a considerable amount of drugs for just as many diseases.

Multiple myeloma is, at present, controlled by agents which provide a high probability of remission and a relevant improvement in survival, e.g. bortezomib, lenalidomide, and thalidomide.

Favourable perspectives for Hodgkin lymphoma are arising thanks to the availability of brentuximab, a monoclonal antibody, which represents a bridge towards allogenic transplantions. In fact, in cases which are refractory to chemotherapy, it is able to obtain high remission rates, thus allowing for an adequate planning of the transplantation.

A series of promising drugs for chronic lymphocytic leukemia and acute leukemias is at the moment in an advanced experimental phase. Also these new molecules offer the advantage of a frequent induction of remission and the consequent possibility to address a high number of patients for transplantation.

Âť The fact that an increasing number of patients will receive transplantation is another revolutionary aspect.

There is no doubt. And, we have to consider that many new aspects come into play here.

Transplantations will be available to a greater number of patients for different reasons: the excellent support therapies, the availability of alternative sources of stem cells, the increasing number of patients candidate for allogeneic transplantation.

This results in a higher rate of healed patients (more than 50%) or long-term survivors

HIGHLIGHT

Ercole Brusamolino, Head of Haematology, Division of Oncology

New perspectives in lymphoma therapy with new agents ÂŤNew perspectives in lymphoma therapy arose after the introduction of monoclonal antibodies targeted therapy, of immunomodulators and drugs interfering with intracellular pathways including NFk-B, m-TOR and Bruton kynase. At Humanitas Cancer Center, two prospective trials on relapsing follicular lymphoma are ongoing, combining chemotherapy with new antibodies. In the first study, the radio-immuno-conjugate ibritumomab is compared to high-dose chemotherapy followed by autologous stem cell transplant; in a second study, bendamustine, a newly registered drug very active in Hodgkin and non-Hodgkin lymphoma, is combined with ofatumomab, a new anti-CD20 antibody. Besides, at Humanitas Cancer Center, the role of rituximab as maintenance treatment in patients with complete molecular response is being assessed in a cooperative Italian study. The proteasome targeting bortezomib and the immunomodulator lenalidomide are being studied in clinical trials for resistant mantle cell and diffuse large B cell lymphomas. Yttrium immuno-conjugate anti-CD20 antibody (ibritumomab) is utilised after bendamustine in patients with relapsed follicular lymphoma; while the hystone acetylase inhibitor panobinostat, coupled with IGEV (iphosphamide, gemcytabine, vinorelbine) combination (generated at Humanitas Cancer Center), is being tested in patients with Hodgkin lymphoma relapsing after autologous transplantation. A new anti-CD30 antibody coupled with the antitubulin agent auristatin (brentuximab/vedotin) has recently been introduced at Humanitas Cancer Center to treat patients with Hodgkin lymphoma relapsing after autologous stem cell transplant, and will be evaluated in a global study as first line therapy associated with the classical ABVD combination.Âť

43

Oncology | Interview with Armando Santoro

HIGHLIGHT

(approximately 70-80%). On the other hand, it implies emerging challenges in the clinical management of these patients, in terms of lifestyle, preventive interventions, psychosocial and

44

Lorenza Rimassa, Head of Gastrointestinal Oncology, Division of Oncology

emotional needs. Fertility preservation represents a peculiar problem. To face that complexity, at Humanitas we have activated a multidisciplinar and multispecialistic approach.

The Liver Unit for the translational research on hepatocellular carcinoma

«Humanitas Cancer Center is actively involved in translational research on hepatocellular carcinoma. Its laboratories and clinical divisions are investigating several aspects of this cancer and many efforts are directed to knowledge and treatment.

Considering the large number of patients with liver cancer treated at our center each year, we created a “Liver Unit” with all the specialists dedicated to this disease (medical oncologists, liver surgeons, radiation oncologists, hepatologists, radiologists, nuclear medicine physicians, pathologists) offering a multidisciplinary approach to the patients.

At Humanitas Cancer Center, the patients with hepatocellular carcinoma find the possibility to receive, in different setting of the disease, the standard treatment as well as new biological targeted therapies, as first line therapy and as second or subsequent lines. We are actively involved in phase I-II-III national and international clinical trials, evaluating new agents that block tumoural cell growth by interfering with specific target molecules involved in the process of carcinogenesis. These new agents can represent new therapeutic options for patients with hepatocellular carcinoma, a disease for which a single drug (i.e. sorafenib) has been approved.

We have evaluated the role of tivantinib, a small molecule inhibitor of c-Met, which has been implicated in cancer cell proliferation, migration, invasion, and metastasis, in the treatment of pretreated advanced hepatocellular carcinoma. We had a principal role in international phase I-II clinical trials with this new agent, and we published promising clinical and translational results. Based on these positive results, we are running an international phase III trial with the aim of confirming them and to offer a new therapeutic option to the patients with this worldwide prevalent disease.

We have also investigated the association of the alpha-fetoprotein blood levels, the expression of pERK, pAKT and Mcl-1 and the amplification of certain genes (MYC and MET) to the clinical outcome of patients treated with sorafenib, and we have published the results of these studies. Furthermore, we assessed the effect of new agents, e.g. mTOR inhibitors, HDAC inhibitors, and anti-angiogenetic drugs on specific pathways in pretreated hepatocellular carcinoma patients. In the same population, we have also considered the expression of E-cadherin, pSMAD, β-integrin as prognostic and predictive biomarkers of the response to a TGF-β receptor kinase inhibitor.

The integration of translational research into clinical trials will improve clinical outcomes, and will identify potential markers of response, to transform care into a more selective and personalized management based on the individual patient’s cancer biology, allowing patients who are likely to respond positively, to receive optimal care, while sparing those with a low probability of a benefit from unnecessary toxicity and cost.»

HIGHLIGHT

Guido Torzilli, Head of Liver Surgery, Division of General Sugery, and Associate Professor of Surgery of the Università di Milano

Advances in surgical treatment of hepatocellular carcinoma «The common coexistence of liver cirrhosis with hepatocellular carcinoma has been often considered a relative contraindication for surgery; as a consequence, other local treatments have expanded their role.

However, it is well established that in tertiary referral centres liver resections for hepatocellular carcinoma can be carried out with minimal mortality and morbidity, even in patients with cirrhosis. This is an achievable goal, mainly because of technical improvements, allowing tumour removal and maximal sparing of functioning parenchyma. From an oncological perspective, any local treatment should address the need for removing or ablating not just the tumour but also the feeding portal area where the tumour itself is located, which is considered to be the main gate for intrahepatic tumour spread. Thus, removal of the subsegmental or segmental area where the tumour is located should be considered the optimal compromise between the oncological requirement and the need for being conservative in order to minimize the risk of surgery. The possibility of carrying out anatomical resections is provided by ultrasound- guided techniques, which have been further simplified recently, with a net gain in feasibility and – hopefully – diffusion. Furthermore, ultrasound guidance enables surgeons to obtain relevant intraprocedural information, which can help to develop new approaches, to standardize their applicability and, theoretically, to extend their use for more advanced diseases. This further expansion of surgical indications for hepatocellular carcinoma, if managed by a specialized worldwide surgical team, is now offering long-term survivals. They cannot be considered anecdotal and will probably impact the therapeutic flow-charts for this disease.»

45

Oncology | Interview with Armando Santoro

Paolo Zucali, Head of Clinical Pharmacology; Division of Oncology

The multidisciplinary fight against mesothelioma

«Humanitas Cancer Center is a reference center for the diagnosis and treatment of malignant pleural mesothelioma, which is a rare cancer disease of the chest. In view of the large number of patients diagnosed with this disease each year and treated at our center, we have created a “Mesothelioma Unit” with all the specialists dedicated to this disease (medical oncologists, thoracic surgeons, radiation oncologists, radiologists, nuclear medicine physicians and pathologists) offering the patient a multidisciplinary approach.

In our center, the patients with malignant mesothelioma have the possibility to receive standard treatments as well as new therapeutic agents – novel chemotherapies or biological targeted therapies – in different disease settings, as first line therapy, as maintenance therapy, and as second line. These agents block tumoural cell growth by interfering with specific targeted molecules involved in the process of carcinogenesis. They can be better tolerated and are more effective than standard agents in improving the outcome of the disease. Moreover, we are also involved in the investigation of molecular predictors of response to standard chemotherapy in patients with malignant mesothelioma. In fact, the identification of these pharmacogenomic factors will enable the tailoring of treatment to patients most likely to benefit. This would lead to a significant improvement in response and survival, with a commensurate reduction in futile therapy delivery with its associated morbidity and costs.»

46

» In short, where are we heading to? What is the future perspective?

HIGHLIGHT

Talking about interventions, we have an intense research on targeted therapies which may be considered the future for oncological treatments, as demonstrated by the fact that each year new options for molecular drugs are being added to the list.

As far as patients are concerned, a new profile of patients is apparent, characterized by the presence of comorbidities together with a longer lifetime expectancy, which require increasingly effective treatments. Moreover, targeted therapies are endowed with a lower toxicity, an advantage that improves the eligibility of a higher number of patients to a certain treatment.

Marco Alloisio, Director of Thoracic Surgery Division

» How important is it for such patients to refer to

a comprehensive Cancer Center, so as to find adequate responses to their healthcare and clinical, as well as personal needs, and so forth?

It’s fundamental, as the profile of oncological patients with multifaceted needs – as the one described above – becomes more widespread. In fact, complexity includes diagnosis, staging, combined interventions, innovation, management of comorbidities and longterm survival. Higher standard levels in the quality of treatments and research are mandatory. And they can be granted at Humanitas, a polyclinic offering high specialization in oncology in parallel to an integrated multidisciplinary clinical assistance.

Malignant pleural mesothelioma: a challenging surgery

«Malignant mesothelioma is a relative rare tumour involving the serosals and associated to asbestos exposure.

At present, there is no known curative treatment for this malignancy, thus the majority of patients are offered palliative therapies.

However, patients with early-stage disease and good performance status are suitable for multimodality treatment involving surgery, chemotherapy and radiotherapy.

Extrapleural pneumonectomy (EPP) gained wide acceptance following the publications of Rusch (1991) and Sugarbaker (1999), showing a prolonged survival in patients with epithelioid histology in the early stages.

Large experience has recently been accumulated at our Institution offering chemotherapy, surgery, and radiotherapy.

In the past, extrapleural pneumonectomy was considered the most appropriate procedure to achieve the radical tumour removal. The post-operative course, however, is frequently troublesome and the post-operative quality of life is often impaired.

In the last two years, the Thoracic Surgery Unit carried out a study to evaluate the impact on long-term quality of life and disease control of an alternative surgical procedure, i.e. pleurectomy/decortication (P/D) technique.

It involves en-bloc resection of the affected visceral and parietal pleurae, ipsilateral pericardium, anterior mediastinal fat, and diaphragm, saving the lung.

The goal in all patients which undergo pleurectomy/decortication interventions was to achieve the maximal cytoreduction and a complete macroscopic resection together with the lowest morbidity.

The preliminary results, in terms of surgical outcomes, lead us to consider pleurectomy/ decortication a good and promising alternative to extrapleural pneumonectomy, even if the latter should not be abandoned too early.»

47

HIGHLIGHT

Oncology | Interview with Armando Santoro

Lorenzo Bello, Head of Neurosurgical Oncology Division, and Professor of the Università di Milano

Multidisciplinary approach in the treatment of CNS tumours «Treatment of CNS tumours is aimed at combining oncological (improved patient survival, delayed onset of recurrences, postponed malignant transformation) and functional endpoints (maintaining patient functional integrity, reducing and making patient seizure free). At Humanitas, these goals have been reached by a multidisclplinary approach which combines surgical, neurophysiological, neuropsychological, medical neuro-oncological, and radio-oncological expertise. The goal is to design targeted therapy schemes.

• Surgery is perfomed with the aid of the so called brain mapping techniques, a comprehensive approach which combines information coming from advanced MR and ultrasound imaging, intraoperative neurophysiology, and neuropsychology.

This approach adapts surgery to the single patient and makes it possible to safely remove brain tumours: also those located in deep or highly eloquent brain regions, still fully preserving the patient’s functional integrity. Particular efforts have been put in studying new intra-operative neurophysiological and neuropsychological tools, capable of investigating complex brain functions, such as complex motor controls, various aspects of memory or emotions. For skull base tumours, a hybrid approach has been developed.

With the aid of a computer-based program, microsurgery is continued till a safe radiosurgical intervention is possible. This enhances surgical removal and maintains the patient’s functional integrity.

• Neuropsychology has been reinforced pre- and post-operatively, with the aim of supporting patients during the whole course of the disease, and to evaluate the effect of treatments, in order to choose the best treatment for each patient at a definite phase of his/her disease.

Specific neuropsychological tests have been developed, that are able to investigate various aspects of brain functions, and to monitor patient performance and response to therapies.

• Various chemotherapy schemes have been developed and chosen on the basis of tumour histology and specific molecular profile, to enhance responses. A large body of research has been performed on chemotherapeutic schemes that are able to reduce tumour infiltration and enhance surgical indications and results. Various advanced MR and PET imaging protocols have been developed and investigated accordingly.

48

• In case of tumour recurrence, surgery has been combined with chemotherapy and radiotherapy to further postpone tumour control and maintaining patient’s functional integrity.

Various combinations have been developed and investigated so far.

Thanks to this multidisciplinary approach, each therapy is targeted to the single patient at the specific phase of his or her disease. This enhances response and maintains patients’ functional integrity in the long-term.»

HIGHLIGHT

Marta Scorsetti, Director of Radiotherapy and Radiosurgery Division

The role of radiotherapy in brain tumours ÂŤRadiation therapy is in the midst of technological developments that are reshaping the role of radiotherapy in various sites, including the brain. At Humanitas, Intensity Modulated Arc therapy has been utilized by the RapidArc technique for primary tumours and metastatic brain disease to maximize dose tumour coverage and minimize involvement of other organs at risk. The RapidArc technique permits the delivery of a precisely sculpted 3D dose distribution with a single 360-degree rotation of the linear accelerator gantry. RapidArc simultaneously changes three parameters during treatment: the rotation speed of the gantry, the shape of the treatment aperture using the movement of multileaf collimator leaves, the delivery dose rate. A crucial phase for the precision of brain radiotherapy is the target volume definition. MRI-CT fusion is usually adopted to define more clearly the anatomical structures for treatment planning. The use of various types of MRI sequences permits to enhance different aspects of the region of interest. The role of FLAIR MRI sequences is also under evaluation for target contouring.

PET imaging with (11)C-methionine (MET), an amino acid tracer, has been implemented at Humanitas Cancer Center for the study of brain tumours.

MET-PET imaging provides a high detection rate and an optimal lesion delineation in radiotherapy planning. Moreover, MET-PET contouring has been integrated in radiation treatment volume definition of primary brain tumours, recurrent brain tumours, and brain metastases. The indications for PET-guided radiotherapy and the imaging results (pseudoprogression or radionecrosis) after radiotherapy, alone or combined with chemotherapy, are also under evaluation using this molecular imaging tool.

Thus, high technology in target definition by means of metabolic aspects enhancement and more precise dose delivery techniques are redefining the role of radiotherapy and opening new promising perspectives in brain tumour management.Âť

49

HIGHLIGHT

Oncology | Interview with Armando Santoro

Luca Castagna, Head of Bone Marrow Transplantation and Cell Therapy, Division of Oncology

What’s new in allogeneic stem cell transplantation «Allogeneic stem cell transplantation is considered the treatment of choice for many hematological malignancies, because of donor immunity and its ability to react against cancer cells. However, one of the most important limits to transplantation is the availability of a donor. Indeed, only 25% of patients has a HLA identical sibling. For the other patients, a matched unrelated donor can be searched in the national or international blood banks.

Overall, for Caucasian patients, the probability to find a well matched donor is almost 50%. However, donor search and acquisition process requires a median of 4 months, which can be too long for the therapeutic need. When related or unrelated donors are unavailable, alternative donors can be required, such as unrelated mismatched or non identical family donors (haploidentical), or even cord blood. Recently, the development of different platforms using haploidentical unmanipulated stem cells (T-cell replete) has renewed the interest for this kind of transplantation. Many differences can be outlined compared to previous experiences with haploidentical transplantation, i.e. the absence of ex vivo manipulation to remove T-cells and B-cells, the use of new immunosuppressive drugs, and the use of chemotherapeutic agents after infusion (cyclophosphamide). These differences seem to reduce the graft versus host incidence, the infectious complications, and to strengthen the anti-tumoural reactivity. Interestingly, Hodgkin lymphoma results exquisitely sensible to the immunological attack after haploidentical transplantation.

More trials are needed to confirm these preliminary results.»

top papers Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C.

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol. 2013 Jan;14(1):55-63. Epub 2012 Nov 20.

50

Background: Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.

Methods: In this completed, multicentre, randomised, placebo-controlled, double-blind, phase 2 study, we enrolled patients with advanced hepatocellular carcinoma and Child-Pugh A cirrhosis who had progressed on or were unable to tolerate first-line systemic therapy. We randomly allocated patients 2:1 to receive tivantinib (360 mg twice-daily) or placebo until disease progression. The tivantinib dose was amended to 240 mg twice-daily because of high incidence of treatment-emergent grade 3 or worse neutropenia. Randomisation was done centrally by an interactive voice-response system, stratified by Eastern Cooperative Oncology Group performance status and vascular invasion. The primary endpoint was time to progression, according to independent radiological review in the intention-to-treat population. We assessed tumour samples for MET expression with immunohistochemistry (high expression was regarded as ≥2+ in ≥50% of tumour cells). This study is registered with ClinicalTrials.gov, number NCT00988741.

Findings: 71 patients were randomly assigned to receive tivantinib (38 at 360 mg twice-daily and 33 at 240 mg twice-daily);

HIGHLIGHT

Andrea Lania, Principal Investigator of Laboratory of Cellular and Molecular Endocrinology, and Associate Professor of the Università di Milano

A variety of approaches for the wide spectrum of neuroendocrine tumours «Neuroendocrine tumours (NETs) are rare neoplasms, showing a wide spectrum of clinical behaviour, from the benign nature of pituitary adenomas, to the slow growth of most carcinoids and the very malignant phenotype of undifferentiated tumours.

Diagnosis is usually late, metastases being identified at presentation in 60-80% of gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Surgical resection is often curative only in patients with early-stage disease, while medical therapy is rarely curative in metastatic forms. Although in vivo and in vitro evidence supports the antiproliferative action of somatostatin in neuroendocrine cells, neuroendocrine tumours show a variable biological response to somatostatin analogues. In particular, octreotide and lanreotide have been demonstrated to control both symptoms and hormone secretion in 50-60% of patients with functioning neuroendocrine tumours. Conversely, somatostatin analogues have been found to stabilize tumour mass in 30-50% of patients, a significant reduction in tumour mass being observed in only 10% of treated subjects. We are now testing the hypothesis that epigenetic events might affect the expression levels of somatostatin receptors, their targeting to the cell membrane, their internalization and their ability to signal. Moreover, we are looking for possible alterations in critical receptor domains and/or downstream effectors, as well as the possible role of polymorphic variants of somatostatin receptors, potentially helpful to predict the outcome of medical treatment in patients with gastroenteropancreatic neuroendocrine tumours.»

36 patients were randomly assigned to receive placebo. At the time of analysis, 46 (65%) patients in the tivantinib group and 26 (72%) of those in the placebo group had progressive disease. Time to progression was longer for patients treated with tivantinib (1·6 months [95% CI 1·4-2·8]) than placebo (1·4 months [1·4-1·5]; hazard ratio [HR] 0·64, 90% CI 0·43-0·94; p=0·04). For patients with MET-high tumours, median time to progression was longer with tivantinib than for those on placebo (2·7 months [95% CI 1·4-8·5] for 22 MET-high patients on tivantinib vs 1·4 months [1·4-1·6] for 15 MET-high patients on placebo; HR 0·43, 95% CI 0·19-0·97; p=0·03). The most common grade 3 or worse adverse events in the tivantinib group were neutropenia (ten patients [14%] vs none in the placebo group) and anaemia (eight [11%] vs none in the placebo group). Eight patients (21%) in the tivantinib 360 mg group had grade 3 or worse neutropenia compared with two (6%) patients in the 240 mg group. Four deaths related to tivantinib occurred from severe neutropenia. 24 (34%) patients in the tivantinib group and 14 (39%) patients in the placebo group had serious adverse events.

Interpretation: Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumours.

Confirmation in a phase 3 trial is needed, with a starting dose of tivantinib 240 mg twice-daily.

Funding: ArQule, Daiichi Sankyo (Daiichi Sankyo Group).

Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, Granata A, Bouabdallah R, Coso D, Chabannon C, Balzarotti M, Santoro A, Blaise D.

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma Bone Marrow Transplant. 2013 Feb;48(2):249-52. doi: 10.1038/bmt.2012.116. Epub 2012 Jun 25.

51

Neuroscience

52

An extraordinary year even in hard times

Interview with Maurizio Fornari

integration and coordination with other clinical and managerial activity.

» If you had to choose among new

improvements, which would emerge as the most innovative?

Director of the Neurosurgery Division

the past year has been extraordinary for Humanitas in terms of its quantitative and qualitative advances in neurosciences.

» How has this dramatic improvement in quality been possible?

The completion of operating theatres has finally allowed us to accomplish our objectives of excellence fully: neuro-oncology, spatial neurosurgery, and endoscopic surgery.

From a clinical point of view, the collaboration in multidisciplinary trials to perform thoracic and abdominal complex surgery has probably been the most important achievement. Among these highspecialized interventions, those on the thoracolumbar segment through anterior or posterior approaches, performed by Marco Alloisio are worth mentioning, as well as those on the abdominal tract, again through anterior or posterior approaches, carried out by Guido Grappiolo.

More generally speaking, we are increasingly improving, thanks to the opportunity to cooperate with all colleagues at Humanitas. This has been made possible thanks to the coordination of the Cancer Center and, mostly, of its director, Armando Santoro.

And this is particularly true for a surgeon since his scarcity of time, by definition, imposes the need of

Radiosurgery has to be considered an absolutely new event.

Humanitas Cancer Center is one of the first European centers equipped with the new Novalis Radiosurgery Program, a last generation technology that combines True Beam accelerator – allowing for extremely fast and precise treatment – and ExacTrac – continuously monitoring the patient by means of an infrared (IR)-based optical positioning system.

Radiosurgery is particularly helpful for the localized treatment of neurological tumours. The precision in the positioning of the patient and in the calculation of dosages, as well as the collimation of the radiation source are outstanding. Its high mechanical accuracy assures that normal structures (vessels or nerves) or the tissues surrounding the neoplastic lesions are relatively spared. It is specifically effective in brain and spine lesions.

Starting from its recent introduction in the assistential facilities at Humanitas, the idea to create a Neuro Center that is able to work in cooperation with Cancer Center and to develop and cultivate neurosciences at their best was born.

This model has been already tested and proven successful at an international level.

» Are there any recently acquired excellencies

in neurosciences, on top of the existing high standards at Humanitas?

No doubt, we can rely on well-established skills as well as on a complex and articulated multicomponent scenario, with a major role of the Department of Neurology with distinguished competences in peripheral nervous system neurophysiology directed

by Eduardo Nobile Orazio and the Stroke Unit directed by Simona Marcheselli.

Thus, this remarkable event can be considered the combination of the availability of high level technology and the presence of extraordinary surgeons.

53

Neuroscience | Interview with Maurizio Fornari

Beyond individual skills, it is the global environment that is valuable.

» So, are you saying that the human component plays a fundamental role?

Well, precisely in relation to this, I would like to make a comment that is not so strictly related to neurosurgery, but can be applied to any medical field. Through my daily professional practice, I have become particularly aware of the importance of an integrated approach based not only on surgical or clinical planning, but on the whole management process. It requires a 360-degree vision of activities, extended beyond merely clinical ones, as well as an overt debate.

This debate allows for an improvement in professional awareness, particularly in a the current recessive phase. The spending review represents a challenge which demands strong and creative reactions.

We must design together excellent proposals and affordable objectives at the same time. All this, always keeping in mind the interaction between academic and teaching activities.

» Any solutions or suggestions?

We need to move ahead, and this progression requests clear leaderships, both in decision-making and clinical processes.

I have to admit that the identification of a referent

54

is more difficult in clinical activities than in management activities; one solution could be an increased role of the scientific-technical Committee towards coordinate and efficient planning.

Moreover, the presence of University is of crucial importance, as well as that of other partners.

As far as the partnerships within Humanitas are concerned, the collaboration with the preclinical area mainly represented by the scientific and research laboratories directed Alberto Mantovani has to be strengthened. As far as external cooperation is concerned, the collaboration with Politecnico di Milano and the Istituto Italiano di Tecnologia (IIT) offer interesting perspectives.

» Then it is possible to carry out ‘Made in Italy’ research in neurosciences even during these hard times.

There actually is a certain scarcity of Italian enterprises for drug and technology development.

On the other hand, we can rely on distinguished research institutions for technology transfer.

Thus, even in a phase with few resources, we are living a profitable time for neurosciences, from cultural, scientific and clinical points of view, and the advances made last year prove it. In addition, the Neuro Center may become a further occasion for improvement.

Sometimes, hard times prompt unexpected creative solutions.

top paper Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M; IMC Trial Group.

Collaborators (33): Nobile-Orazio E, Gallia F, Cocito D, Paolasso I, Jann S, De Toni Franceschini L, Uncini A, Notturno F, Antonini G, Clemenzi A, Fazio R, Bianchi F, Schenone A, Fiorina E, Francia A, Pontecorvo S, Pareyson D, Marchesi C, Santoro L, Manganelli F, Tamburin S, Praitano ML, Cavaletti G, Piatti M, Giannini F, Greco G, Sabatelli M, Luigetti M, Beghi E, Messina P, Macchia R, Guarnieri C, Fiorentino B.

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Lancet Neurol. 2012 Jun;11(6):493-502. Epub 2012 May 10.

Background: Intravenous immunoglobulin (IVIg) and corticosteroids are effective as initial treatment in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but little is known about the comparative risk-benefit profile of their long-term use in this disease. We compared the efficacy and tolerability of 6-month therapy with IVIg versus that with intravenous methylprednisolone.

Methods: We did a multicentre, randomised, double-blind, placebo controlled, parallel-group study in patients with CIDP. We assessed efficacy and tolerability of IVIg (0·5 g/kg per day for 4 consecutive days) and intravenous methylprednisolone (0·5 g in 250 mL sodium chloride solution per day for 4 consecutive days) given every month for 6 months. Eligible patients had to be in an active or stationary phase of the disease. Allocation to treatment was centrally managed with a computer-generated, 1:1 randomisation scheme with a sequential block size of four. All patients and assessors were unaware of the treatment assignment. After therapy discontinuation, patients were followed up for 6 months to assess relapses. The primary outcome was the difference in the number of patients discontinuing either therapy owing to inefficacy or intolerance. Secondary endpoints included the difference in the proportion of patients experiencing adverse events or worsening after therapy discontinuation. This study is registered with EUDRACT, number 2005-001136-76.

Findings: 45 patients (24 IVIg, 21 intravenous methylprednisolone) completed the study; one was excluded for inappropriate inclusion. More patients stopped methylprednisolone (11 [52%] of 21) than IVIg (three [13%] of 24; relative risk 0·54, 95% CI 0·34-0·87; p=0·0085). When adjusted for sex, age, disease duration, comorbidity, modified Rankin scale and ONLS scores at enrolment, and previous treatment with IVIg and steroids, the difference between the two groups remained significant (odds ratio 7·7, 95% CI 1·7-33·9; p=0·0070). Reasons for discontinuation were lack of efficacy (eight in the methylprednisolone group vs three in the IVIg group), adverse events (one in the methylprednisolone group), or voluntary withdrawal (two in the methylprednisolone group). Two patients on IVIg died during follow-up after the 6-month assessment. The proportion of patients with adverse events did not differ between the intravenous methylprednisolone group (14 [67%] of 21) and the IVIg group (11 [46%] of 24; p=0·1606).

After therapy discontinuation, more patients on IVIg worsened and required further therapy (eight [38%] of 21) than did those on methylprednisolone (none of ten; p=0·0317).

Interpretation: Treatment of CIDP with IVIg for 6 months was less frequently discontinued because of inefficacy, adverse events, or intolerance than was treatment with intravenous methylprednisolone. The longer-term effects of these treatments on the course of CIDP need to be addressed in future studies.

Funding: Kedrion 55

Neuroscience | Interview with Maurizio Fornari

56

HIGHLIGHT

Michela Matteoli, Principal Investigator of the Unit of Pharmacology and Brain Pathology, Professor at the Università di Milano

In search of answers from synapses «Synapses are fundamental brain structures that mediate information transfer between nerve cells. Signal transmission and information processing at synapses control all body functions and all aspects of cognition, including attention, perception, learning, decision making, as well as mood and emotions. For several years it has been widely acknowledged that many psychiatric and neurodegenerative disorders such as schizophrenia, autism and even Alzheimer’s disease are synaptopathies, i.e. pathological conditions originating from the deregulation of the molecular and cellular pathways operating at the synaptic level. More recently, however, evidence has emerged that inflammation can also heavily contribute to these processes, modifying the risk and the severity of a variety of brain diseases.

For many years the CNS and peripheral immune system have been thought to act independently and only recently has inflammation emerged as an important factor operating in the nervous system. Indeed, inflammation does not always resolve without any harmful effects on the brain, but, when shifted to a chronic state, it contributes to injury, enhances CNS vulnerability and adversely affects brain development, even modifying the risk or severity of a variety of brain diseases.

Several questions are now open. First, we need to understand through detailed cellular and molecular analysis the possibility that inflammatory cascades, either alone or in combination with a susceptible genetic background, directly impact on synapse formation and plasticity, thus leading to a synaptopathic condition. Secondly, the factors that trigger a prolonged or exaggerated neuroinflammatory response are yet to be determined. Since peripheral inflammatory events initiate the process that leads to neuroinflammation, the most obvious candidate would be the occurrence of prolonged or repeated peripheral inflammatory challenges that produce continuous immune-to-CNS signaling.

Our laboratory is addressing these issues using mice models of synaptopathies and mice models of immune deregulation. Molecular, electrophysiological and behavioural approaches are being combined with the study of cell-cell interactions in order to define whether immune challenges, associated or not with susceptible genetic backgrounds, impact the functional organization of the synapse. The final goal of our research is to prospectively identify new targets for drug development to combat these disorders. Indeed, blockade of inflammation in the periphery or reduced activation of microglia, the immune cells in the brain, might turn out to represent important therapies for brain disorders, which are not often thought of as mediated by these factors.»

57

Cardiovascular

Specific Instruments of Humanitas Laboratories: • High frequency, high resolution VeVo 2100 digital imaging platform with linear array technology and Color Doppler Mode • Mikro-Tip Pressure Volume System (MPVS)-Ultra Foundation System • Telemetry for blood pressure and ECG assessment • Scanning Ion Conductance Microscopy • Optical Mapping for electrical Impulse Propagation • IonOptix for Ca2+ transient and contractile assessment 58

• Patch-Clamp instruments for studies on action potential

A total dedication to heart

Interview with Gianluigi Condorelli

Principal Investigator of the Inflammation and Immunology in Cardiovascular Laboratory, Professor at the Università di Milano

the cardiovascular Research Laboratories dedicated to the advanced molecular and cellular research in cardiovascular diseases are a figurehead for Humanitas and one of its most recent relevant strategic assets.

» Are we speaking of a promising start-up project?

Precisely. The planning and set-up phase has almost been completed, with a steady state reached very recently, no more than a couple of months ago when the last equipment was delivered and activated.

Even if this initial period was primarily spent sowing what will be harvested in a near future, a significant number of papers of our research results have been already published in distinguished international journals, as shown in the “highlights” section. As for funding, our research relies on relevant, mostly international, highly selective and peer-reviewed grants (e.g. ERC Advanced Grants, Fondation LeDucq – a French foundation – and Fondazione Cariplo, among others), with a significant contribution coming from private, non-profit foundations beside those from the Ministero della Salute e del Ministero dell’Istruzione, dell’Università e della Ricerca.

» And what will you be dealing with after the

start-up phase, once the project is up and running?

Following this start-up phase, after the foundations of the basic research activity have been firmly set, we will be able to develop a broad range of competitive, high-quality projects. We can take advantage of different factors, such as instruments and technology that provide information unachievable even a decade ago; a large and composite work team that carries out several parallel research projects, optimizes resources, and shares experimental results; and our involvement in cooperation networks at an international level, with a continuous exchange of foreign researchers and Italian researchers who have returned after an experience abroad.

During this more dynamic phase, the real challenge will be the creation of a stable connection and a profitable cross-talk between molecular medicine and clinical medicine. In other words, a constant interaction between bench-side (molecular cardiology) and bedside (clinical cardiology).

» Could you fill us in on some of these projects?

Firstly, it must be said that most of them require a broad-based effort. When studying the interaction between genes and ischemic heart disease, we need a clinical database integrated with biobanks – collections of data from thousands of patients – in order to reach statistical significance, and both a longitudinal and cross-sectional approach.

On the other hand, even less complex projects have provided relevant results. For instance, we have recently studied, among the biomarkers of cardiac diseases, those small RNA molecules that function in the post-transcriptional regulation of gene expression, better known as microRNAs (miRs).

From a clinical standpoint, we are studying whether they can be used as biomarkers of cardiac diseases: for instance, we found that they are released by myocardial cells under stressful conditions, and thus circulating levels may be an index of myocardial diseases; in addition, it is conceivable that miRs can also vehiculate messages from myocardial cells to cells of distant organs. These experimental observations lead to intriguing hypotheses about their role and, what’s more, are not restricted to

59

Cardiovascular | Interview with Gianluigi Condorelli

myocardial diseases but extend to cardiovascular pathologies as a broader spectrum of conditions (see also the highlight by Daniele Catalucci).

» Can you provide more examples of ongoing studies?

We are determining the role of epigenetics in human cardiac diseases. Epigenetic alterations are chromatin-based modifications that affect the expression of genes without altering the DNA sequence itself. We are studying how environmental factors are able to induce epigenetic effects, i.e. the activation in myocardial cells of specific genetic programs in response to external stimuli. Stress due to high blood pressure was found by our group to reflect on cardiac cells, modifying the epigenome and consequently inducing changes in gene expression.

Data from our group also suggest that a change in dietary content induces epigenetic changes, modulating gene expression in target organs, such as arterial walls: thus, high blood cholesterol levels or the stress consequent to a rise in blood pressure are able to modify gene expression of arterial cells or the molecular characteristics of myocardial cells.

To perform these studies, massive DNA sequencing analysis is needed, an effort conducted at the moment thanks to a strong cooperation with the Institute of Genetics and Biomedical Research of the Consiglio Nazionale delle Ricerche, in Cagliari, which has developed a unique competence in the field of human genetics.

Another research project we are working on involves induced pluripotent stem (iPS) cells – the same cells, to put it simply, that were discovered by the Japanese physician and researcher Shinya Yamanaka,

60

who, for this result, was awarded the 2012 Nobel Prize in Medicine.

» Clearly, the use of those cells requires complex experimental methods and procedures.

Still, could you provide a description of what happens in labs when you work on them?

They are derived from adult cells, skin or blood for instance, of individual patients, which are modified in vitro by adding a few genes that are highly expressed during the embryonic stage, and then are induced to differentiate into cardiomyocytes, the cells in charge of myocardial contraction. iPS cells represent a promising model that ideally applies to genetic disorders and, particularly, to orphan or rare disease.

Their use can overcome a number of technical and ethical issues (among which is the scarcity of viable myocardial cells when a heart biopsy is performed) and allow to obtain differentiated adult cardiomyocytes that recapitulate in vitro the features of the individual patients’ cells, included the specific genetic defect. Thanks to this model, we have already studied distinct human forms of cardiac disease (see also the highlight by Elisa Di Pasquale) and studied their causative gene defects.

Thus, we can evaluate the effects of each genetic defect for individual patients, exploring functional cardiac parameters in the test tube, such as the contractility or transmission of the electrical impulse (the action potential). Results are obtained in vitro, but they reliably replicate what is observed in vivo.

» From what you are describing, it appears

that research is increasingly oriented towards a personalized approach, moving

HIGHLIGHT

Daniele Catalucci, Principal investigator of Laboratory of Signal transduction in cardiac pathology

Novel molecular mechanisms of heart failure ÂŤHeart failure is a chronic, progressive condition resulting from impaired ability of the heart to pump sufficient blood to the body. Despite considerable therapeutic progress in the treatment of this condition, heart failure is still a major killer with a 5-year survival rate as low as 25% and sudden death in up to 50% of patients. The challenge of our group at Humanitas is to provide new insights into the molecular mechanisms underlying cardiac pathologies, which can form the basis for the development of novel, more effective therapeutic approaches for the treatment, cure, and prognosis of primary and secondary cardiac diseases. Our research is particularly focused on microRNAs, small molecules that negatively regulate protein expression, often at several levels within specific biological pathways. This is of particular clinical relevance as it offers the opportunity to modify disease processes in a manner distinct from that of classical drugs, which are typically directed towards single cellular targets.

In line with this, phase I-II clinical trials, testing the therapeutic efficacy of approaches based on the restoration of dysregulated microRNAs in patients with non-cardiovascular diseases, have recently shown promising results. At our center, we have identified novel mechanisms for microRNA processing and function and developed potential microRNA-directed therapeutic applications for the treatment of myocardial pathological conditions, such as ventricular hypertrophy and heart failure. Furthermore, we are collaborating with an international therapeutic company in evaluating the use of cardiacspecific microRNA-conjugates for obtaining systemic and selective delivery of microRNAs to the heart. Finally, we are evaluating the use of circulating microRNA signatures as biomarkers for diagnostic, prognostic, and therapeutic purpose. Thus, microRNAs are emerging as promising targets for therapeutic interventions in cardiovascular diseases.Âť

61

Cardiovascular | Interview with Gianluigi Condorelli

from the observation and description of the characteristics of general population to those of individuals?

No doubt, this is one of the most intriguing future prospects in medicine. In fact, the evaluation of the individual’s response to a drug and the opportunity to select tailored therapies – i.e. personalized medicine – is of great interest. Similarly to what has already been extensively described about the predisposition to a disease, evidence is accumulating of a predisposition to drug responsiveness. This significant variability, which has a genetic basis, is the subject

62

of an emergent discipline – pharmacogenomics.

Interestingly, there are biomarkers that reflect on the individual’s responsiveness to a given drug.

For instance, the efficacy of clopidogel, one of the most prescribed anti-platelet drugs administered after coronary stent application, is dependent upon the specific genotype of each individual for a liver enzyme that metabolizes and activates the drug: a certain genotype does not metabolize the drug properly and, thus, administration to these patients predisposes to hemorrhaging. A simple genetic test can prevent all this, readdressing therapy toward other molecules.

HIGHLIGHT HIGHLIGHT

Patrizia Presbitero, Director of Division of Haemodynamics, invasive cardiology, and coronary care

Maurizio Gasparini, Director of the Division of Electrophysiology and Electrostimulation

Translational research in cardiovascular disease

«Cardiovascular disease is the leading cause of mortality in many countries, accounting for 16.7 million deaths each year. It is the main consequence of atherosclerosis, a chronic inflammatory disease of blood vessels. The long pentraxin PTX3, identified and characterized in Humanitas, is a molecule of the innate immune system and a member of the pentraxin superfamily, as is C reactive protein (CRP). In a translational study, the Departments of Inflammation and Immunology and Interventional Cardiology showed that PTX3 represents a useful marker of cardiovascular pathology complementary to C reactive protein, thus rapidly and better reflecting the vascular damage. In particular, PTX3 has emerged as a diagnostic and prognostic marker in several conditions, including acute coronary syndromes and chronic heart failure. Since acute myocardial infarction has long been known to “run in families”, we recently analysed the role of PTX3 genetic variations in modulating the risk of acute myocardial infarction with a multicentre study.

Despite the lack of association between PTX3 polymorphisms and the susceptibility to this condition, we paved the way for further studies directed to evaluate their role in other pathological conditions in which atherosclerosis is the main substrate such as stable angina and carotid and peripheral obstructive disease. Recently, it has been hypothesized that degenerative calcified aortic stenosis in the elderly can also have an inflammatory basis. The relation between PTX3 and this pathology will be our next field of research.»

How technology can treat heart failure

«Cardiac resynchronization therapy is an established treatment for symptomatic patients with mild to severe heart failure, a prolonged QRS duration and an impairment in left ventricular systolic function, able to improve symptoms, exercise capacity and quality of life, to induce left ventricular reverse remodelling, and to decrease hospitalizations and mortality rate due to heart failure. In our Division of Electrophysiology and Electrostimulation we recently reached the figure of 1,000 cardiac resynchronization therapy implants. We are involved in several national and international clinical trials aiming to test different left ventricular leads, to optimize implantable cardioverter-defibrillator programming, to identify the best candidates to cardiac resynchronization therapy (excluding the non responders, thus saving health care’s resources) and to define the strategy of treatment of atrial fibrillation in patients with heart failure. This interesting interaction of two common diseases – it is well recognized that the development of atrial fibrillation in heart failure heralds a poor prognosis – shows the importance of performing atrioventricular nodal ablation to optimize cardiac resynchronization therapy delivery.

Another area of interest recently developed at Humanitas is the treatment of atrial fibrillation with the use of stereotaxis for pulmonary vein isolation, allowing to obtain the best results from radiofrequency ablation. The primary advantage is that robotic control provides very precise catheter navigation, right to the spot where the operator intends to go. Moreover, once the catheter gets there, it is extremely stable. Therefore, differently to a hand-controlled procedure, where the operator is often unable to keep the catheter stable long enough to create a permanent lesion, the robotically controlled catheter is associated to a less frequent recovery of conduction following the procedure and a lower rate of atrial fibrillation recurrence and complications.»

63

Cardiovascular | Interview with Gianluigi Condorelli

» How do you think the lab and the ongoing

projects and activities in Humanitas are going to interact in the near future?

A remarkable project, to be developed in collaboration with Humanitas Cancer Center, arises from the observation that many oncologic patients experience adverse cardiologic events due to the treatment received. The new field of cardiooncology is emerging from this. Besides, a long and highly qualified tradition in oncology makes Humanitas the most appropriate location where to work on this field. It is well known that drugs broadly used for curing cancer can induce cardiac failure if not properly administered. New types of drugs acting on specific target molecules have been recently developed for cancer treatment. However, their targeting is not specific in that the molecules they aim to inhibit, usually enzymes – kinases, for instance – are ubiquitously distributed. Thus, a drug targeting a kinase of a tumoural cell displays, almost unavoidably, an effect also on the same kinase expressed in healthy myocardial cells. This is an off-target effect, from a clinical point of view, but is substantially expectable in physiological terms.

Thus, one useful application of iPS cells could be to experiment the effects of a specific chemotherapeutic agent on human cardiomyocytes in order to better understand the mechanisms of action of these drugs on myocardial cells, enabling preventive strategies against cardiotoxicity.

Another promising research field, which has also been traditionally explored at Humanitas, is the role of the immune response in cardiovascular disease, in particular in atherosclerosis and heart failure. The presence of leading international figures in the field of immunology will be a fantastic chance for us to develop this field of interest.

Finally, we are developing skills on human genome sequencing and bioinformatics analysis in order to improve the current diagnostic power on primary cardiomyopathies (primary diseases of the myocardium). We are accomplishing this through sequencing the part of the genome that transcribes into RNA – called the exome – which accounts for

64

approximately only 1.5% of the whole genome. In the near future, our next step will be to perform whole genome sequencing for disease prevention. Of note, Humanitas has been awarded a grant for acquiring instruments necessary for expanding the existing biobank and performing high-throughput analyses on molecular biomarkers of human diseases, including DNA sequencing and bioinformatics.

» Are all these projects aiming at an innovative approach to research in cardiology?

The final step in completing this complex and stimulating scenario is the creation of a Heart Center, following the successful Comprehensive Medical Center model widely tested in the U.S. and all over the world, in which patient care and research, from bench to bedside, are integrated.

This model is able to comply with the concept of continuing medical care, a modern one for cardiovascular medicine, which combines acute interventions with careful follow-up in order to prevent secondary events and, thus, in-hospital treatments. The outstanding diagnostic tools and clinical setting currently available at Humanitas will surely make this possibility a reality.

At Humanitas we have all the ingredients for reproducing the same setting as in the most cutting-edge academic centers in the world, where research, education, and healthcare coexist and synergize. Regarding human resources, this means that undergraduates and post-graduates, including medical resident fellows, can work shoulder to shoulder with excellent clinicians and experienced researchers. Academic teaching and on-the-job training are offered concurrently to physicians and researchers. The International MiMed qualification – the Medicine and Surgery University Degree taught in English – is an important added value. Moreover, virtuous cooperation with both public (e.g. Università di Milano and the Consiglio Nazionale delle Ricerche) and private entities, and an efficient management, enable researchers to express themselves at their best in terms of scientific productivity and career progression.

top paper Gasparini M, Galimberti P.

AV junction ablation in heart failure patients with atrial fibrillation treated with cardiac resynchronization therapy: the picture is now clear!

J AM Coll Cardiol.2012 Feb 21;59(8):727-9.

HIGHLIGHT

Cardiac resynchronization therapy (CRT) improves left ventricular (LV) function and reduces morbidity and mortality. Randomized controlled trials enroll virtually only sinus rhythm (SR) patients, establishing CRT as a class IA indication for patients in New York Heart Association (NYHA) functional class II through IV despite optimal medical therapy, with ejection fraction (EF) ≤35%, wide QRS, and SR. However, approximately 25% of patients eligible for CRT experience concomitant atrial fibrillation (AF). After several observational studies and 2 metaanalyses, the most recent guidelines qualify patients with AF as class IIA. Therefore, while there is now general agreement on the indication for CRT in AF patients, their optimal management may remain a matter of discussion.

Elisa Di Pasquale , Researcher in the Laboratory of Inflammation and immunology in cardiovascular

Induced pluripotent stem cells as a tool for in vitro models of human heart diseases and therapeutic discoveries «The discovery of induced Pluripotent Stem (iPS) cells is revolutionizing the field of regenerative medicine. They are embryonic-like cells that can be generated from mature cells of any individual through the introduction of defined “pluripotency” factors. These cells possess the potential to proliferate indefinitely and to become any cell type of the body. Therefore, iPS cells can be used to model human diseases in vitro.

Our laboratory has developed skills in generating cardiomyocytes, the cells of the heart responsible for contraction, from iPS cells with the aim to study the molecular mechanisms underlying malfunctioning in inherited forms of cardiomyopathy, including arrhythmias, cardiac hypertrophy and dilatation, and to test experimental drugs that may then enter the clinical arena. Together with this technology, our laboratory has developed skills in next-generation DNA sequencing and bioinformatic analysis in order to identify variants or mutations underlying primary cardiomyopathies by scanning the exome, the part of the genome that translates into protein.

The combination of these two methodologies – iPS cells generation and exome sequencing – will lead to the definitive identification of diseasecausing mutations and to the understanding of how the genotype translates into cardiac malfunctioning. Moreover, the interaction between our laboratory and clinicians has the potential to turn findings into better diagnostic procedures and prognoses of patients with primary forms of cardiomyopathy. Knowledge of the molecular events driving cardiac differentiation and dysfunctions can also lead to the use of iPS-derived cardiomyocytes for heart failure treatment.»

65

66

Clinical & Research Departments

Board of Directors President

Gianfelice Rocca

Scientific Superintendent Nicola Dioguardi

Vice President

Scientific Director

Ivan Colombo

Alberto Mantovani

Chief Executive Officer

Clinical Research Director Humanitas Cancer Center Director

Luciano Ravera

Armando Santoro Medical Director

Norberto Silvestri

Education

Research Advisory Board

Piero Melodia

Rolf Zinkernagel (President) Charles Dinarello Fabio Cominelli Lorenzo Moretta

67

Departments and teams Clinical Area Updated to April 2013

Cancer Center director: Armando Santoro BREAST UNIT division director: Corrado Tinterri Claudio Andreoli Marco Eboli Carlos Garcia Etienne (°) Wolfgang Gatzemeier (•) Carlo Marco Rossetti Arianna Rubino Andrea Sagona MEDICAL ONCOLOGY AND HAEMATOLOGY division director: Armando Santoro

(*) Physician dealing with activity in the Research laboratories too (**) Research staff (***) Research nurse (****) Biomedical Engineer (•) Head of unit (°) Consultant

68

■ Divisions that join in the Humanitas Cancer Center

Margherita Autuori Monica Balzarotti Monica Bertossi (**) Alexia Francesca Bertuzzi Silvia Bozzarelli Stefania Bramanti Ettore Brusamolino (•) Carmelo Carlo-Stella (•) (*) Carlo Carnaghi Luca Castagna Raffaele Cavina (•) Elisa Crotti (**) Rita De Sanctis Fabio De Vincenzo Gabriella Delvecchio (**) Barbara Ercoli (**) Giuseppe Fatuzzo (***) Giovanna Finocchiaro Rita Finotto (**) Chiara Gandini Isabella Garassino Milena Gasco Laura Giordano (**) Nathalia Locopo (**) Massimo Magagnoli Giovanna Masci Rita Mazza Emanuela Mencaglia Lucio Morabito Angela Nardozza (***) Andrea Nozza Nicola Personeni Tiziana Pressiani Lorenza Rimassa (•) Luca Rubino (**) Alessandra Russo (**)

Barbara Sarina Nadia Sessarego (**) Matteo Simonelli Licia Siracusano Orsola Sironi Elisabetta Todisco Rosalba Torrisi (•) Luca Toschi Maria Chiara Tronconi Laura Velutti Paolo Andrea Zucali (•) Monica Zuradelli PET AND NUCLEAR MEDICINE division director: Arturo Chiti Lidja Antunovic Egesta Lopci Barbara Nardi Giovanna Pepe Marcello Rodari Giovanni Tosi RADIOTHERAPY AND RADIOSURGERY division director: Marta Scorsetti Filippo Alongi Anna Maria Ascolese Tiziana Comito Anna Gaudino Cristina Iftode Francesca Lobefalo Pietro Mancosu Pierina Navarria Valentina Palumbo Sara Pentimalli Giacomo Reggiori Stefano Tomatis Angelo Tozzi Elisa Villa THORACIC SURGERY division director: Marco Alloisio Umberto Cariboni Valentina Errico Giorgio Maria Ferraroli Giulia Giannini Simone Grappolini (°) Maurizio Valentino Infante (•) Alberto Testori (•) Roberto Travaglini (°)

Cardiovascular Department CARDIac SURGERY division director: Giuseppe Tarelli Alessandro Barbone Alessio Basciu Antioco Cappai Enrico Citterio Diego Ornaghi (•) Fabrizio Settepani CLINICAL CARDIOLOGY division director: Maddalena Lettino Tiziana Anita Ammaturo Laura Ardino (***) Monica Bocciolone (•) Margherita Calcagnino Alessio Cappelleri Augusto Foresti (°) Veronica Fusi Daniela Guiducci Maurizio Mangiavacchi Manuel Marconi (•) Barbara Nardi Roberta Paliotti Daniela Pini Michele Randazzo Cinzia Santucciu Maria Luisa Stella Luisa Ulian ECHOCARDIOGRAPHY division director: Renato Maria Bragato Sara Anna Cioccarelli Mirko Curzi Lara Di Diodoro Aurelio Sgalambro

ELECTROPHYSIOLOGY AND ELECTROSTIMULATION division director: Maurizio Gasparini Mario Bellocchio (****) Carlo Ceriotti Paola Galimberti Edoardo Gandolfi Luca Poggio HAEMODYNAMICS, INVASIVE CARDIOLOGY AND CORONARY CARE division director: Patrizia Presbitero Cristina Barbaro Guido Belli (•) Elena Corrada (coronary care) (•) Arianna Di Pizzo (**) Giuseppe Ferrante (*) Gabriele Luigi Gasparini Veronica Lisignoli Paolo Pagnotta (•) Marco Luciano Rossi Dennis Zavalloni Parenti VASCULAR SURGERY I division director: Pier Luigi Giorgetti Elisa Casabianca Giorgio Luca Poletto Athos Popovich VASCULAR SURGERY II division director: M. Grazia Bordoni Giuseppe Carella Vittorio Danesino Alessandra La Penna Alberto Morandi Paolo Spada

Diagnostic Imaging Department director: Luca Balzarini DIAGNOSTIC radiology division director: Luca Balzarini Alberto Bizzi (neuroradiology) (•) Marcello Cadioli (neuroradiology) (****) Daniela Distefano (neuroradiology) Marco Grimaldi (neuroradiology) Felice Rognone (neuroradiology) (°) Cristiana Bonifacio Giorgio Brambilla (°) Valentina Carrera Alice Carla Castelli Elisabetta Colombo Mariagiorgia Farina Sara Imparato Paolo Malerba (•) Lorenzo Monti Oana Codrina Moscovici Federica Mrakic Sposta Maria Alessandra Pestalozza Raffaele Petrillo (°) Manuel Profili Italia Traluci Nicola Trenti (°) ECHOGRAPHY division director: Paola Magnoni Isabella Maria Botea Caterina Comola Manuela Cira De Crescenzo Daniela Dell’Aglio Pasquale De Nittis Jean Claude Foteuh Milena Galardo Margherita Lunelli Caterina Claudia Pedicino Cinzia Pianigiani Laura Saltarin Chiara Valsania Katia Elena Zoccolan oncology & Interventional Radiology division director: Romano Lutman Vittorio Pedicini (•) Dario Poretti (•) Marco Tramarin

69

Diagnostic Laboratory Services

Gastroenterology Department

General Anaesthesia and Intensive Care Department

director: Alberto Malesci

director: Ferdinando Raimondi

LABORATORY TESTS division director: Alessandro Montanelli

GASTROENTEROLOGY AND DIGESTIVE ENDOSCOPY

General anaesthesia and intensive care Department

Valentina Achille Barbara Barbieri Daniela Bettio Simona Brambilla Elena Bredi Erminia Anna Casari Elisabetta Corsi Concetta De Luca Antonella Ferrario Rossana Mineri Marta Noemi Monari Carla Barbara Ripamonti Roberta Temporiti Maria Luisa Valente PATHOLOGY division director: Massimo Roncalli Silvia Armenia Serena Battista Paola Bossi Tatiana Brambilla Serena Carlucci Piergiuseppe Colombo (•) Annarita Destro Luca Di Tommaso Bethania Fernandes Andrea Ferretti Barbara Fiamengo Chiara Lo Russo Sofia Manara Daoud Rahal (•) Paola Spaggiari

70

division director: Alberto Malesci Mariangela Allocca (*) Elisa Carlani Silvio Danese (*) Gionata Fiorino Daniela Gilardi (**) Luigi Laghi (*) Paolo Dario Omodei (•) Giuseppina Portale (***) Paoletta Preatoni Beatrice Salvioli Orsola Sociale (***) Maurizio Alessandro Tomassini (°) DIGESTIVE ENDOSCOPY service division director: Alessandro Repici Alessandra Carlino Silvia Carrara Camilla Ciscato Giuseppe Strangio Eva Maria Vitetta GENERAL MEDICINE AND HEPATOLOGY Ilaria Bianchi (*) Roberto Ceriani (•) Giovanni Covini (•) Pietro Invernizzi (*) Ana Lleo De Nalda (*)

(*) Physician dealing with activity in the Research laboratories too (**) Research staff (***) Research nurse (****) Biomedical Engineer (•) Head of unit (°) Consultant ■ Divisions that join in the Humanitas Cancer Center

Enrico Arosio (•) Jana Balazova Gian Michele Battistini Francesca Belforti Gabriella Brancato Stefania Brusa Stefania Cantoni Cristina Carlino Vincenzo Cesina Francesco Corazzi Paola Matilde De Pietri Stefania Del Grosso Orazio Difrancesco Cristina Dominoni Andrea Forastieri Molinari Nadia Fusilli Alessandro Gaggianese

Donatella Girardello (•) Enrico Giustiniano Yari Gollo Stefania Grimaldi Valeria Lascari Sabrina Malara Silvia Eleonora Malossini Juan Carlos Pastore Francesco Pellegrino Laura Rocchi Nadia Ruggieri Maria Rosaria Spoto (•) Guido Paolo Turio Giuseppe Vecchi (°) Massimo Vecchietti (°) Paola Cosma Zito

Anaesthesia I division director: Franco Cancellieri Anaesthesia II division director: Valentina Bellato Anaesthesia III division director: Vittorio Gavazzeni ANAESTHESIA AND CARDIOSURGERY INTENSIVE CARE division director: Angelo Bandera Graziano Cortis Pietro Ferrara Licia Melis Carlo Solimando Maria Cristina Soriano Rodrigo Rodrigo Paolo Francesco Tosi Maria Maddalena Visigalli (•)

General Surgery Department director: Marco Montorsi GENERAL AND MINIMALLY INVASIVE SURGERY division director: Riccardo Rosati Fabio Baticci (•) Martina Ceolin Ugo Elmore (•) Uberto Fumagalli Romario (•) Pietro Dante Muselli Alberto Peracchia (°) Matteo Porta GENERAL AND ONCOLOGIC SURGERY division director: Vittorio Quagliuolo Antonella Ardito Pietro Francesco Bagnoli Andrea Brocchi Luca Cozzaglio (•) Chiara Erminia Mussi Ombretta Nucca GENERAL SURGERY III division director: Marco Montorsi Piero Bazzi Stefano Bona (•) Daniele Del Fabbro Matteo Donadon Francesca Gavazzi Angela Palmisano Fabio Procopio Antonino Spinelli Guido Torzilli (liver surgery) (•) Alessandro Zerbi (pancreatic surgery) (•)

Gynaecology Department director: Paolo E. Levi Setti GYNAECOLOGY division director: Domenico Vitobello Antonio Accardi Barbara Bianchini Gianluigi Bresciani Cinzia Bulletti Nicoletta Iedà Costantino Mangioni (°) Gabriele Siesto GYNAECOLOGY AND REPRODUCTIVE MEDICINE division director: Paolo Emanuele Levi Setti Elena Albani Annamaria Baggiani Renzo Benaglia Raffaella De Cesare Alessia De Mita Alessandra Drovanti Valeria Liprandi Luciano Negri Maria Rosaria Parisen Toldin Laura Sacchi Cristina Specchia Alberto Vaiarelli (°) Elena Zannoni Irene Zerbetto

Internal Medicine Department director: Mauro Podda vice director: Salvatore Badalamenti ACCIDENT & EMERGENCY UNIT division directors: Salvatore Badalamenti, Antonio Voza Andrea Annoni Giuseppe Biancofiore Gianluigi Citterio Luca Contu Carlo Fedeli Giovanni Giorgino Alberto Grassi Hayato Kurihara Elisabetta Lavezzi Alfonso Maiorino Silvia Oldani Stefano Ottolini Maria Gioia Lea Pich Marta Ripoll Pons Miguel Sohl (°) DERMATOLOGY division director: Marcello Monti Luca Livio Mancini Francesco Sacrini Federica Sanna Francesca Savalli Luca Speroni ENDOCRINOLOGY AND DIABETOLOGY division director: Andrea Lania (*) Paolo Colombo GENERAL MEDICINE AND pneumology division director: Michele Ciccarelli Maria Francesca Barmina Massimo Crippa Alessandra Ibba Alessia Marseglia (°) Francesca Puggioni Lucia Testoni

INTERNAL MEDICINE division director: Raffaello Furlan Franca Barbic (°) Enrico Brunetta (*) Franca Dipaola Francesca Meda (*) NEPHROLOGY AND DIALYSIS division director: Salvatore Badalamenti Claudio Angelini (•) Paola Arosio Cesare Berra (•) Albania Calvetta Giuseppe Favacchio Silvia Finazzi Giorgio Graziani (°) Marco Mirani Rosa Pedale Bruno Pessano (°) Silvia Santostasi Rossella Valentino Simona Verdesca RHEUMATOLOGY and clinical immunology division director: Carlo Francesco Selmi (*) Angela Ceribelli (*) Maria De Santis (*) Gianluigi Fabbriciani Bianca Marasini (°) Marco Sergio Massarotti THROMBOSIS Centre division director: Lidia Rota Monica Bacci Anna Colombo Monica Demarco Paola Ferrazzi Luca Librè Corrado Lodigiani Grazia Loredana Mendolicchio Ilaria Quaglia

71

Neuroscience Area

Orthopaedic Area

EMERGENCY NEUROLOGY AND STROKE UNIT division director: Simona Marcheselli

Arthroscopic SURGERY of the knee division director: Enrico Arnaldi

knee ORTHOPAEDICS and sport traumatology division director: Piero Volpi

Stefano Bertora (°) Andrea Bruno Andrea Bruno Massimo De Donato Paolo Dupplicato Alexander Kirienko (°) Antonio Orgiani (°) Paolo Pesenti (°)

Corrado Bait Matteo Cervellin Matteo G.M. Denti Emanuele Prospero

Beatrice Albano Elisa Coloberti Manuel Corato Lara Fratticci Maria Luisa Soardi (°) NEUROLOGY II division director: Eduardo Nobile Orazio Mariangela Bianco Mohamed Ziad Fayoumi (°) Francesca Gallia Claudia Giannotta (**) Fabrizia Terenghi NEUROSURGERY division director: Maurizio Fornari Luca Attuati Lorenzo Bello (oncologic neurosurgery) (•) Simonetta Beluffi (°) Massimo Borroni (°) Marco Brayda Bruno (°) Andrea Cardia (•) Paola Carmagnini (°) Francesco Costa Giuseppe D’Aviri (°) Enrica Maria Fava Giovanni Battista Lasio (•) Guido Menasce (°) Davide Milani Alessandro Ortolina Claudia Ottardi (****) Armando Pellanda (°) Federico Pessina Alberto Pollini (°) Stefania Radice Riccardo Rodriguez Y Baena (°) Giorgio Savoia (°) Massimo Tomei (°)

72

FOOT SURGERY division director: Leonardo Maradei Ignazio Bagnoli (°) Antonio Giardella Nikolaos Markopoulos Luigi Milano (•) Alfonso Maria Romano (°) HAND SURGERY division director: Alberto Lazzerini Alessandra Martano Luciana Marzella Ilaria Papini Zorli Pier Luigi Raimondi (°) Angela Trabucco Fabiana Zura Puntaroni HIP AND KNEE PROsTHEtIC SURGERY division director: Guido Grappiolo Franco Astore Andrea Baldini (°) Giovanna Borello (°) Emanuele Caldarella Gianluca Cusmà Federico D’Aria (°) Federico Della Rocca Matteo Carlo Ferrari Antonino Gurgone Giuseppe Mazziotta Damiano Ricci Giuseppe Santoro Marco Scardino Francesco Traverso

PaEDIATRIC AND NEUROORTHOPAEDICS SURGERY division director: Nicola Portinaro Maurizio Mori Artemisia Panou shoulder, elbow and foot surgery division director: Alessandro Castagna Mario Borroni Silvana De Giorgi (°) Giacomo Delle Rose Paolo Renato Rolla Alfonso Maria Romano (°) TRAUMATOLOGY division director: Marco Berlusconi Matteo Cavanna Lorenzo Di Mento Davide Marchettini Antonella Pieroni Josè Antonio Puchol Incertis Ivano Scarabello

Rehabilitation Department director: Stefano Respizzi Cardiac & Respiratory Rehabilitation division director: Stefano Aglieri Anna Beretta Alessandro Eusebio Ornella Riccardi Franco Rusconi (°) Neurologic Rehabilitation division director: Bruno Bernardini Giovanna Cerina Viviana Colantonio Carla Corsini Simona Farina Sara Ghirmai Marco Augusto Pagani Orthopaedic Rehabilitation division director: Stefano Respizzi Barbara Baroni Francesca Clemson Marco Conti (°) Maria Cristina D’Agostino Gianluca Galimberti (•) Paolo Maria Parenti (°) Veronica Maria Polelli Elisabetta Tibalt

Specialised Divisions of Surgery OPHTHALMOLOGY division director: Paolo Vinciguerra Elena Albè Laura Balia Fabrizio Ivo Camesasca Carlo Castellani Marco Criscito (°) Alessandra Di Maria Marco Gramigna Emanuela Legrottaglie Grazia Maria Quaranta (°) Alessandro Randazzo Mario Romano Pietro Rosetta Adriana Sergio Maria Ingrid Torres Munoz Rosario Urso Josè Luis Vallejo Garcia Pietro Paolo Vico OTORHINOLARYNGOLOGY division director: Arturo Poletti Filippo Barucca (°) Fabio Bertone Giovanni Colombo Gioavanni Cugini Susanna Di Pietro Luca Malvezzi Stefano Miceli Vanessa Rossi PLASTIC SURGERY division director: Marco Klinger

SURGICAL DAY HOSPITAL division director: Roberta Monzani Marco Aldo Babbini Benedetta Basta Francesco Carrera Aljosa Ciarloni Laura Crozzoli Michele De Ruvo Chiara Ferrari Stefania Gherardi Fabio Intelligente (°) Annarita Larocca Marco Maiola Oreste Davide Montino Rossana Peretti Maria Del Carmen Rodriguez Beatrice Rossi Claudio Sacchi Alessandro Scafella UROLOGY division director: Pierpaolo Graziotti Alessio Benetti Luigi Castaldo Guido Giusti (•) Rodolfo Hurle Luisa Pasini Roberta Peschechera Alessandro Pizzocaro Silvia Proietti Mauro Seveso Gianluigi Taverna (•) Silvia Zandegiacomo De Zorzi

Valeria Bandi Barbara Banzatti Silvia Giannasi Ombretta Nucca Alessandra Veronesi

(*) Physician dealing with activity in the Research laboratories too (**) Research staff (***) Research nurse (****) Biomedical Engineer (•) Head of unit (°) Consultant ■ Divisions that join in the Humanitas Cancer Center

73

Departments and teams Scientific Research and Laboratories Updated to April 2013

Scientific Superintendence

Adaptive Immunity principal investigator: Antonella Viola junior principal investigator: Marinos Kallikourdis Stefano Garetto Elisa Martini Cristina Mazzon Cristina Ploia Giuliana Roselli Cristiana Soldani Anna Elisa Trovato Chiu-Hui Wang Lucia Zanotti

director: Nicola Dioguardi Sonia Di Biccari Barbara Franceschini Carlo Russo

ANATOMY AND IMAGING principal investigator: Cristiano Rumio Claudia Sardi

Scientific Direction and Research Laboratories

CELLULAR AND MOLECULAR ENDOCRINOLOGY principal investigator: Andrea Lania (1) Valeria Cambiaghi Eleonora Vitali

director: Alberto Mantovani

CELLULAR IMMUNOLOGY principal investigator: Paola Allavena

Annunciata Vecchi

Clinical trials office director: Michele Tedeschi Alessandra Giampà Francesco Minuti Emanuela Morenghi Silvia Spagnoli

Grant office Monica Di Meglio Danilo Petroni

Cristina Belgiovine Francesca Bergomas Marco Erreni Manuela Liguori Giulia Marelli Federica Marchesi Samantha Angela Pesce Imran Siddiqui

(•) Group leader (1) MD-PhD. In addition to research s/he works as a clinician in Endocrinology (2) MD-PhD. In addition to research s/he works as a clinician in Rheumatology (3) MD-PhD. In addition to research s/he works as a clinician in Internal Medicine (4) M D-PhD. In addition to research s/he works as a clinician in Gastroenterology (5) MD-PhD. In addition to research s/he works as a clinician in Epathology

74

(6) MD-PhD. In addition to research s/he works as a clinician in Medical Oncology and Haematology

CLINICAL AND EXPERIMENTAL IMMUNOLOGY principal investigator: Domenico Mavilio Francesca Calcaterra Silvia Della Bella (•) Kelly Lorraine Hudspeth Enrico Lugli Irene Mattiola Joanna Mikulak Elena Pontarini Alessandra Roberto Paolo Francesco Tentorio CLINICAL IMMUNOLOGY AND AUTOIMMUNITY AND METABOLISM principal investigator: Carlo Francesco Selmi (2) Francesca Cavaciocchi Angela Ceribelli (2) Maria De Santis (2) Francesca Meda (3) EXPERIMENTAL IMMUNOPATHOLOGY principal investigator: Cecilia Garlanda Elisa Barbati Eduardo Bonavita Francesca Feruglio Maria Rosaria Galdiero Stefania Gentile Sebastien Jaillon Fabio Pasqualini Nadia Polentarutti Marcello Rubino GASTROINTESTINAL IMMUNOPATHOLOGY principal investigator: Silvio Danese (4) Javier Cibella Carmen Correale Silvia D’Alessio Alessandro Gandelli Marco Genua Patrizia Naccarato Carlotta Tacconi Stefania Vetrano HEPATOBILIARY IMMUNOPATHOLOGY principal investigator: Pietro Invernizzi (5) Francesca Bernuzzi Ilaria Bianchi (5) Ana Lleo De Nalda (5) Chiara Raggi Ilaria Sogno

IMMUNOPHARMACOLOGY principal investigator: Barbara Bottazzi Patrick Brennecke Antonio Inforzato Ilaria Laface Roberto Leone Marina Sironi Sonia Valentino LEUKOCYTE BIOLOGY principal investigator: Massimo Locati Raffaella Bonecchi (•) Cinzia Cancellieri Nicoletta Caronni Graziella Curtale Florian Pesant Stefania Recalcati Tiziana Renzi Benedetta Savino Naths Grazia Sukubo Federica Tomay Alessandro Vacchini LEUKOCYTE MIGRATION principal investigator: Silvano Sozzani Annalisa Del Prete Li Wang MOLECULAR GASTROENTEROLOGY principal investigator: Luigi Laghi (4) Gianluca Basso Paolo Bianchi Giuseppe Celesti Giuseppe Di Caro Fabio Grizzi MOLECULAR IMMUNOLOGY principal investigator: Antonio Sica Sara Morlacchi Elena Riboldi Laura Strauss Gabor Szebeni Maria Grazia Totaro ONCOLOGY EXPERIMENTAL THERAPIES principal investigator: Carmelo Carlo-Stella (6) Irene Bertolini Donata De Marco Alessandra Inguscio Silvia Laura Locatelli Elena Saba

PHARMACOLOGY AND BRAIN PATHOLOGY principal investigator: Michela Matteoli Chiara Elia Fabia Filippello Giuliana Fossati Elisabetta Menna Raffaella Morini Davide Pozzi Ilaria Prada Romana Tomasoni Claudia Verderio Stefania Zambetti PHYSIOLOGY principal investigator: Elisabetta Cerri BIOBANK Giorgia Ceva Grimaldi Nina Patricia Machado Torres Valentina Paleari Alice Pezzoni Daniela Pistillo COMMON RESEARCH SERVICES Achille Anselmo Chiara Buracchi Andrea Doni Gianpaolo Milite Diego Morone Monica Rimoldi Silvia Tartari

NATIONAL RESEARCH COUNCIL (CNR) HUMAN GENOME AND medical biotechnologies human genome principal investigator: Anna Villa Barbara Cassani Maria Luisa Focarelli Nadia Lo Iacono Virginia Maina Stefano Mantero Alessandra Pangrazio Rosita Rigoni Cristina Sobacchi Dario Strina

MEDICAL BIOTECHNOLOGIES principal investigator: Paolo Vezzoni Maria Elena Caldana Alessandra Castelli Laura Crisafulli Francesca Faggioli Francesca Ficara Michela Lizier Sharon Muggeo Tui Anna Neri Giovanni Pacchiana Marianna Paulis Lucia Susani INFLAMMATION AND IMMUNOLOGY IN CARDIOVASCULAR principal investigator: Gianluigi Condorelli Pierluigi Carullo Elisa Di Pasquale Leonardo Elia Carolina Greco Paolo Kunderfranco Michele Latronico Michele Miragoli Hiroko Nakahama Roberto Papait (•) Manuela Quintavalle Giuliano Stirparo Giacomo Viggiani

sarcomers in CARDIAC PATHOLOGY ) principal investigator: Marie Louise Bang Maria Carmela Filomeno Giuseppina Mastrototaro Fabio Piaser SIGNAL TRANSDUCTION IN CARDIAC PATHOLOGY principal investigator: Daniele Catalucci Barbara Gargano Alessandra Rodanò

75

Papers published 2012

Papers published 2012 As of 31 January 2013 * = Corresponding author

P r e c l i n i c a l Adaptive Immunity Mazzon C*, Anselmo A, Soldani C, Cibella J, Ploia C, Moalli F, Burden SJ, Dustin ML, Sarukhan A, Viola A.

Agrin is required for survival and function of monocytic cells.

Blood. 2012;119(23):5502-11.

Raw IF: 9.898 Normalized IF: 8 Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A*, Sica A.

Hypoxia-mediated regulation of macrophage functions in pathophysiology.

International Immunology 2013;25(2):67-75.

Raw IF: 3.415 Normalized IF: 4 Savino B, Castor MG, Caronni N, Sarukhan A, Anselmo A, Buracchi C, Benvenuti F, Pinho V, Teixeira MM, Mantovani A, Locati M*, Bonecchi R.

Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6.

Blood. 2012;119(22):5250-60 Raw IF: 9.898 Normalized IF: 8 Viola A, Sarukhan A, Bronte V, Molon B.

The pros and cons of chemokines in tumor immunology.

Trends in Immunology 2012;33(10):496-504.

Raw IF: 10.403 Normalized IF: 8 Zanotti L*, Sarukhan A, Dander E, Castor M, Cibella J, Soldani C, Elisa Trovato A, Ploia C, Luca G, Calvitti M, Mancuso F, Arato I, Golemac M, Jonjic N, Biondi A, Calafiore R, Locati M, D’Amico G, Viola A.

Encapsulated mesenchymal stem cells for in vivo immunomodulation.

Leukemia 2013;27(2):500-3: Raw IF: 9.561 Normalized IF: 4

Anatomy and Imaging Marcucci F, Bellone M, Rumio C, Corti A.

Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

76

Mabs-Monoclonal antibodies 2013;5(1):34-46.

Raw IF: 3.174 Normalized IF: 3

R e s e a r c h Rossini A, Zanobbio L, Sfondrini L, Cavalleri A, Secreto G, Morelli D, Palazzo M, Sommariva M, Tagliabue E, Rumio C, Balsari A.

Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/neu transgenic mice.

Journal of Cellular Physiology 2013;228(1):242-9.

Raw IF: 3.874 Normalized IF: 2

Clinical and Experimental Immunology Cappelletti M, Giannelli S, Martinelli A, Cetin I, Colombo E, Calcaterra F, Mavilio D, Della Bella S*.

Lack of activation of peripheral blood dendritic cells in human pregnancies complicated by intrauterine growth restriction.

Placenta 2013;34(1):35-41.

Raw IF: 3.693 Normalized IF: 6 Cappelletti M, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Villa ML, Della Bella S.

Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi’s Sarcoma.

The Journal of Investigative Dermatology 2012;132(10):2414-21.

Raw IF: 6.314 Normalized IF: 6 Cruz AR, Ramirez LG, Zuluaga AV, Pillay A, Abreu C, Valencia CA, La Vake C, Cervantes JL, Dunham-Ems S, Cartun R, Mavilio D, Radolf JD, Salazar JC.

Immune evasion and recognition of the syphilis spirochete in blood and skin of secondary syphilis patients: two immunologically distinct compartments.

PLoS Neglected Tropical Diseases 2012;6(7):e1717.

Raw IF: 4.716 Normalized IF: 3 Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S, Silva-Santos B, Mavilio D*.

Engagement of NKp30 on Vδ1 T-cells induces the production of CCL3, CCL4 and CCL5 and suppresses HIV-1 replication.

Blood.2012;119(17):4013-6.

Raw IF: 9.898 Normalized IF: 8 Lugli E*, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M.

Identification, isolation and in vitro expansion of human

and nonhuman primate T stem cell memory cells.

Nature Protocols 2012;8(1):33-42.

Raw IF: 9.924 Normalized IF: 8

Malu S, De Ioannes P, Kozlov M, Greene M, Francis D, Hanna M, Pena J, Escalante CR, Kurosawa A, ErdjumentBromage H, Tempst P, Adachi N, Vezzoni P, Villa A, Aggarwal AK, Cortes P.

Mezzani A, Grassi B, Jones AM, Giordano A, CorrĂ U, Porcelli S, Della Bella S, Taddeo A, Giannuzzi P.

Artemis C-terminal region facilitates V(D)J recombination through its interactions with DNA Ligase IV and DNA-PKcs.

Speeding of pulmonary VO(2) on-kinetics by light-tomoderate-intensity aerobic exercise training in chronic heart failure: clinical and pathophysiological correlates.

International Journal of Cardiology 2012. Epub ahead of print.

Raw IF: 7.078 Normalized IF: 4 Tomasello E, Yessaad N, Gregoire E, Hudspeth K, Luci C, Mavilio D, Hardwigsen J, Vivier E.

Mapping of NKp46(+) Cells in healthy human lymphoid and non-lymphoid tissues.

Frontiers in Immunology 2012;3:344.

Raw IF: 0

Normalized IF: 0.1

Varchetta S, Brunetta E, Roberto A, Mikulak J, Hudspeth KL, Mondelli MU, Mavilio D*.

Engagement of Siglec-7 Receptor induces a proinflammatory response selectively in monocytes.

Plos One 2012.Epub ahead of print.

Raw IF: 4.092

Normalized IF: 6

The Journal of Experimental Medicine 2012;209(5):955-63.

Raw IF: 13.853 Normalized IF: 5

Marrella V, Poliani PL, Fontana E, Casati A, Maina V, Cassani B, Ficara F, Cominelli M, Schena F, Paulis M, Traggiai E, Vezzoni P, Grassi F, Villa A.

Anti-CD3{varepsilon} mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.

Blood. 2012;120(5):1005-14.

Raw IF: 9.898 Normalized IF: 8

Pangrazio A, Caldana ME, Lo Iacono N, Mantero S, Vezzoni P, Villa A*, Sobacchi C.

Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications.

Osteoporosis International 2012;23(11):2713-8.

Raw IF: 4.58 Normalized IF: 6

Human Genome; Medical Biotechnologies Gioia R, Panaroni C, Besio R, Palladini G, Merlini G, Giansanti V, Scovassi IA, Villani S, Villa I, Villa A, Vezzoni P, Tenni R, Rossi A, Marini JC, Forlino A.

Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta (OI), a new target for OI pharmacological therapy.

Stem Cells 2012;30(7):1465-76.

Raw IF: 7.781 Normalized IF: 4 Lo Iacono N, Blair HC, Poliani PL, Marrella V, Ficara F, Cassani B, Facchetti F, Fontana E, Guerrini MM, Traggiai E, Schena F, Paulis M, Mantero S, Inforzato A, Valaperta S, Pangrazio A, Crisafulli L, Maina V, Kostenuik P, Vezzoni P, Villa A, Sobacchi C*.

Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKLdependent ARO. Journal of Bone and Mineral Research 2012;27(12):2501-10.

Raw IF: 6.373 Normalized IF: 6

Pangrazio A, Frattini A, Valli R, Maserati E, Susani L, Vezzoni P, Villa A, Al-Herz W, Sobacchi C*.

A homozygous contiguous gene deletion in chromosome 16p13.3 leads to autosomal recessive osteopetrosis in a jordanian patient.

Calcified Tissue International 2012;91(4):250-4.

Raw IF: 2.376 Normalized IF: 2

Pangrazio A, Fasth A, Sbardellati A, Orchard PJ, Kasow KA, Raza J, Albayrak C, Albayrak D, Vanakker OM, De Moerloose B, Vellodi A, Notarangelo LD, Schlack C, Strauss G, KĂźhl JS, Caldana E, Iacono NL, Susani L, Kornak U, Schulz A, Vezzoni P, Villa A, Sobacchi C*.

SNX10 mutations define a subgroup of human Autosomal Recessive Osteopetrosis with variable clinical severity.

Journal of Bone and Mineral Research 2012. Epub ahead of print.

Raw IF: 6.373 Normalized IF: 6

77

Papers published 2012

Sfaihi L, Aissa K, Sobacchi C, Kanoun F, Gorbel M, Hachicha M.

Choanal atresia: think about osteopetrosis International Journal of Pediatric Otorhinolaryngology Extra 2011;6(4):422-4.

Raw IF: 0 Normalized IF: 0.1

Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G.

CaMK4 gene deletion induces hypertension.

Journal of the American Heart Association 2012;1:e001081.

Raw IF: 0 Normalized IF: 0.1

Stark Z, Pangrazio A, McGillivray G, Fink AM.

Association of severe autosomal recessive osteopetrosis and structural brain abnormalities: a case report and review of the literature.

European Journal of Medical Genetics 2013;56(1):36-8.

Raw IF: 2.178 Normalized IF: 2

Inflammation and Immunology in Cardiovascular Cittadini A, Monti MG, Iaccarino G, Castiello MC, Baldi A, Bossone E, Longobardi S, Marra AM, Petrillo V, Saldamarco L, During MJ, Saccà L, Condorelli G.

SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.

Cardiovascular Research Raw IF: 6.064

2012;96(3):381-90.

Normalized IF: 6

Di Pasquale E, Latronico MV, Jotti GS, Condorelli G.

Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function.

Gene Therapy 2012;19(6):642-8.

Raw IF: 3.71 Normalized IF: 6 Latronico MVG, Condorelli G*.

The might of MicroRNA in mitochondria.

Bazzan E, Saetta M, Turato G, Borroni EM, Cancellieri C, Baraldo S, Savino B, Calabrese F, Ballarin A, Balestro E, Mantovani A, Cosio MG, Bonecchi R, Locati M.

Expression of the atypical chemokine receptor D6 in human alveolar macrophages in Chronic Obstructive Pulmonary Disease.

Chest 2013. Epub ahead of print.

Raw IF: 5.25 Normalized IF: 6 Bonecchi R, Savino B, Mantovani A, Locati M.

Targeting chemokines in cancer.

Current Immunology Reviews 2012;8(2):161-9.

Raw IF: 0 Normalized IF: 0.1 Borroni EM, Cancellieri C, Locati M, Bonecchi R.

Dissecting trafficking and signaling of atypical chemokine receptors.

Methods in Enzymology 2013;521:151-68.

Raw IF: 2.042 Normalized IF: 2 Cancellieri C, Caronni N, Vacchini A, Savino B, Borroni EM, Locati M, Bonecchi R*.

Review: structure-function and biological properties of the atypical chemokine receptor D6.

Circulation Research 2012;110(12):1540-2.

Raw IF: 9.489 Normalized IF: 8

Molecular Immunology 2012. Epub ahead of print.

Raw IF: 2.897 Normalized IF: 4

Rivera NV, Carreras Torres R, Roncarati R, Viviani Anselmi C, De Micco F, Mezzelani A, Koch W, Hoppmann P, Kastrati A, Stewart AFR, Chen L, Roberts R, Karssen L, Amin N, Trimarco N, Izzo R, Iccarino G, Condorelli G, Puca AA, Pagnotta P, Airoldi F, Trimarco B, van Duijn CM, Condorelli G, Briguori C.

Cochain C, Auvynet C, Poupel L, Vilar J, Dumeau E, Richart A, Récalde A, Zouggari Y, Yin KY, Bruneval P, Renault G, Marchiol C, Bonnin P, Lévy B, Bonecchi R, Locati M, Combadière C, Silvestre JS.

Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes 78

Leukocyte Biology

BMC Medical Genetics 2013;14(1):11.

Raw IF: 2.328 Normalized IF: 1

The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction.

Arteriosclerosis, Thrombosis, and Vascular Biology 2012;32(9):2206-13.

Raw IF: 6.368 Normalized IF: 3

Graham G, Locati M*, Mantovani A, Rot A, Thelen M.

The biochemistry and biology of the atypical chemokine receptors.

Rossato M, Curtale G, Tamassia N, Castellucci M, Mori L, Gasperini S, Mariotti B, De Luca MC, Mirolo M, Cassatella MA, Locati M, Bazzoni F.

Immunology Letters 2012;145(1-2):30-8.

Raw IF: 2.526 Normalized IF: 2

IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4stimulated monocytes.

Graham G, Locati M.

Proceedings of the National Academy of Sciences of the United States of America 2012;109(45):e3101-10.

Raw IF: 9.681 Normalized IF: 8

Regulation of the immune and inflammatory responses by the ’atypical’ chemokine receptor D6.

Journal of Pathology 2013;229(2):168-75.

Raw IF: 6.318 Normalized IF: 6 Mantovani A, Locati M, Uguccioni M.

Chemokines in immunopathology: from dark sides to clinical translation.

Immunology Letters 2012;145(1-2):1.

Raw IF: 2.526 Normalized IF: 2 Mantovani A*, Biswas SK, Galdiero MR, Sica A, Locati M.

Macrophage plasticity and polarization in tissue repair and remodelling Journal of Pathology 2013;229(2):176-85.

Raw IF: 6.318 Normalized IF: 6 Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, Ten Hacken NH, Cobos Jiménez V, Kootstra NA, Hamann J, Greaves DR, Locati M, Mantovani A, Gordon S.

Savino B, Castor MG, Caronni N, Sarukhan A, Anselmo A, Buracchi C, Benvenuti F, Pinho V, Teixeira MM, Mantovani A, Locati M*, Bonecchi R.

Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6.

Blood. 2012;119(22):5250-60.

Raw IF: 9.898 Normalized IF: 8 Zanotti L*, Sarukhan A, Dander E, Castor M, Cibella J, Soldani C, Elisa Trovato A, Ploia C, Luca G, Calvitti M, Mancuso F, Arato I, Golemac M, Jonjic N, Biondi A, Calafiore R, Locati M, D’Amico G, Viola A.

Encapsulated mesenchymal stem cells for in vivo immunomodulation.

Leukemia 2013;27(2):500-3.

Raw IF: 9.561 Normalized IF: 4

leucocyte migration

Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences.

Zaccagnino P, Saltarella M, Maiorano S, Gaballo A, Santoro G, Nico B, Lorusso M, Del Prete A*.

Blood 2013. Epub ahead of print.

Raw IF: 9.898 Normalized IF: 3.5

An active mitochondrial biogenesis occurs during dendritic cell differentiation.

Meda C, Molla F, De Pizzol M, Regano D, Maione F, Capano S, Locati M, Mantovani A, Latini R, Bussolino F, Giraudo E.

The International Journal of Biochemistry & Cell Biology 2012;44(11):1962-9.

Raw IF: 4. 634 Normalized IF: 6

Semaphorin 4A exerts a pro-angiogenic effect by enhancing VEGF-A expression in macrophages.

Journal of Immunology 2012;188(8):4081-92.

Raw IF: 5.788 Normalized IF: 6

Molecular Immunology

Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G.

Larghi P, Porta C, Riboldi E, Totaro MG, Carraro L, Orabona C, Sica A*.

Iron levels in polarized macrophages: Regulation of immunity and autoimmunity

The p50 subunit of NF-κB orchestrates dendritic cell lifespan and activation of adaptive immunity.

Autoimmunity Reviews 2012;11(12):883-9.

Raw IF: 6.624 Normalized IF: 6

Plos One 2012;7(9):e45279.

Raw IF: 4.092

Normalized IF: 6

79

Papers published 2012

Mantovani A*, Biswas SK, Galdiero MR, Sica A, Locati M.

Macrophage plasticity and polarization in tissue repair and remodeling.

Journal of Pathology 2013;229(2):176-85.

Raw IF: 6.318 Normalized IF: 6 Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A*, Sica A.

Hypoxia-mediated regulation of macrophage functions in pathophysiology.

International Immunology 2013;25(2) 67-75.

Raw IF: 3.415 Normalized IF: 4 Rusca N, Deho L, Montagner S, Zielinski CE, Sica A, Sallusto F, Monticelli S.

MiR-146a and NF-kB1 regulate mast cell survival and T lymphocyte differentiation.

Cracking down on inhibition: selective removal of GABAergic interneurons from hippocampal networks.

The Journal of Neuroscience 2012;32(6):1989-2001.

Raw IF: 7,115 Normalized IF: 4 Bianco F, Tonna N, Lovchik RD, Mastrangelo R, Morini R, Ruiz A, Delamarche E, Matteoli M.

Overflow microfluidic networks: application to the biochemical analysis of brain cell interactions in complex neuroinflammatory scenarios.

Analytical Chemistry 2012;84(22):9833-40.

Raw IF: 5.856 Normalized IF: 6

Molecular and Cellular Biology. 2012;32(21):4432-44.

Raw IF: 5.527 Normalized IF: 3

Corradini I, Donzelli A, Antonucci F, Welzl H, Loos M, Martucci R, De Astis S, Pattini L, Inverardi F, Wolfer D, Caleo M, Bozzi Y, Verderio C, Frassoni C, Braida D, Clerici M, Lipp HP, Sala M, Matteoli M*.

Sica A, Mantovani A.

Epileptiform activity and cognitive deficits in SNAP25+/- mice are normalized by antiepileptic drugs.

Macrophage plasticity and polarization: in vivo veritas.

The Journal of Clinical Investigation 2012;122(3):787-95.

Raw IF: 13.069 Normalized IF: 10 Spence S, Fitzsimons A, Boyd CR, Kessler J, Fitzgerald D, Elliott J, Gabhann JN, Smith S, Sica A, Hams E, Saunders SP, Jefferies CA, Fallon PG, McAuley DF, Kissenpfennig A, Johnston JA.

Suppressors of Cytokine Signaling 2 and 3 diametrically control macrophage polarization.

Immunity 2013;38(1):66-78.

Raw IF: 21.637 Normalized IF: 7.5

Pharmacology and Brain Pathology Antonucci F, Turola E, Riganti L, Caleo M, Gabrielli M, Perrotta C, Novellino L, Clementi E, Giussani P, Viani P, Matteoli M, Verderio C.

Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism.

The EMBO Journal. 2012;31(5):1231-40.

Raw IF: 9.205

80

Antonucci F, Alpár A, Kacza J, Caleo M, Verderio C, Giani A, Martens H, Chaudhry FA, Allegra M, Grosche J, Michalski D, Erck C, Hoffmann A, Harkany T, Matteoli M, Härtig W.

Normalized IF: 4

Cerebral Cortex 2012. Epub ahead of print.

Raw IF: 6.544 Normalized IF: 6 Gelsomino G, Menna E, Antonucci F, Rodighiero S, Riganti L, Mulle C, Benfenati F, Valtorta F, Verderio C, Matteoli M*.

Kainate induces mobilization of synaptic vesicles at the growth cone through the activation of protein kinase A. Cerebral Cortex 2012;23(3):531-41.

Raw IF: 6.544 Normalized IF: 6 Locatelli E, Gil L, Israel LL, Passoni L, Naddaka M, Pucci A, Reese T, Gomez-Vallejo V, Milani P, Matteoli M, Llop J, Lellouche JP, Franchini MC.

Biocompatible nanocomposite for PET/MRI hybrid imaging.

International Journal of Nanomedicine 2012;7:6021-33.

Raw IF: 3.13 Normalized IF: 3 Senatore A, Colleoni S, Verderio C, Restelli E, Morini R, Condliffe SB, Bertani I, Mantovani S, Canovi M, Micotti E, Forloni G, Dolphin AC, Matteoli M, Gobbi M, Chiesa R.

Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α(2)δ-1 Subunit.

Neuron 2012;74(2):300-13.

Raw IF: 14.736 Normalized IF: 5

Turola E, Furlan R, Bianco F, Matteoli M, Verderio C.

Microglial microvesicle secretion and intercellular signaling.

Frontiers in Physiology 2012;3(149):1-11.

Raw IF: 0 Normalized IF: 0.1 Verderio C, Cagnoli C, Bergami M, Francolini M, Schenk U, Colombo A, Riganti L, Frassoni C, Zuccaro E, Danglot L, Wilhelm C, Galli T, Canossa M, Matteoli M.

TI-VAMP/VAMP7 is the SNARE of secretory lysosomes contributing to ATP secretion from astrocytes.

Biology of the Cell. 2012;104(4):213-28.

Raw IF: 3.6 Normalized IF: 4 Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, Riganti L, Corradini I, Francolini M, Garzetti L, Maiorino C, Servida F, Vercelli A, Rocca M, Dalla Libera D, Martinelli V, Comi G, Martino G, Matteoli M, Furlan R.

Myeloid microvesicles are a marker and therapeutic target for neuroinflammation.

Annals of Neurology 2012;72(4):610-24.

Raw IF: 11.089

Normalized IF: 4

Scientific Research Laboratories Allavena P*, Mantovani A.

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.

Clinical and Experimental Immunology 2012;167(2):195-205.

Raw IF: 3.36 Normalized IF: 4 Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-González S, Corbera-Bellalta M, Comite GD, Papa I, Dell’antonio G, Ammirati E, Cuccovillo I, Vecchio V, Mantovani A, Rovere-Querini P, Sabbadini MG, Cid MC, Manfredi AA.

Selective up-regulation of the soluble patternrecognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia.

Arthritis and Rheumatism 2012;64(3):854-65.

Raw IF: 7.866 Normalized IF: 4

Barbati E, Specchia C, Villella M, Rossi ML, Barlera S, Bottazzi B, Crociati L, d’Arienzo C, Fanelli R, Garlanda C, Gori F, Mango R, Mantovani A, Merla G, Nicolis EB, Pietri S, Presbitero P, Sudo Y, Villella A, Franzosi MG.

Influence of Pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels.

Plos One 2012;7(12):e53030.

Raw IF: 4.092

Normalized IF: 6

Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A.

Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.

Journal of Pathology 2013;229(1):87-98.

Raw IF: 6.318 Normalized IF: 3 Bazzan E, Saetta M, Turato G, Borroni EM, Cancellieri C, Baraldo S, Savino B, Calabrese F, Ballarin A, Balestro E, Mantovani A, Cosio MG, Bonecchi R, Locati M.

Expression of the atypical chemokine receptor D6 in human alveolar macrophages in Chronic Obstructive Pulmonary Disease.

Chest 2013. Epub ahead of print.

Raw IF: 5.25 Normalized IF: 6 Bellora F, Castriconi R, Doni A, Cantoni C, Moretta L, Mantovani A, Moretta A, Bottino C.

M-CSF induces the expression of a membranebound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages.

European Journal of Immunology 2012;42(6):1618-26.

Raw IF: 5.103 Normalized IF: 3 Biswas SK, Mantovani A*.

Orchestration of metabolism by macrophages.

Cell Metabolism 2012;15(4):432-7.

Raw IF: 13.668

Normalized IF: 10

Bonecchi R, Savino B, Mantovani A, Locati M.

Targeting chemokines in cancer.

Balkwill FR, Mantovani A.

Cancer-related inflammation: common themes and therapeutic opportunities.

Seminars in Cancer Biology 2012;22(1):33-40.

Raw IF: 6.475 Normalized IF: 6

Current Immunology Reviews 2012;8(2):161-9.

Raw IF: 0 Normalized IF: 0.1

81

Papers published 2012

Cozzi V, Garlanda C, Nebuloni M, Maina V, Martinelli A, Calabrese S, Cetin I.

PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta 2012;33(12):1039-44.

Raw IF: 3.693 Normalized IF: 6 Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A*.

Interactions of the humoral pattern recognition molecule PTX3 with the complement system.

Immunobiology 2012;217(11):1122-8 Raw IF: 3.205

Normalized IF: 4

Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A*.

Tumor associated macrophages and neutrophils in tumor progression.

Journal of Cellular Physiology 2012. Epub ahead of print.

Raw IF: 3.874 Normalized IF: 6 Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, Marra F, Mantero S, Roncalli M, Invernizzi P, Pinzani M.

Role of the Stromal-derived factor-1 (SDF-1) - CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma.

Journal of Hepatology 2012;57(4):813-20.

Raw IF: 9.264 Normalized IF: 8

Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials.

Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.

European Journal of Heart Failure 2012;14(9):992-9.

Raw IF: 4.896 Normalized IF: 6 Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.

Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.

Arteriosclerosis, Thrombosis, and Vascular Biology.

2012;32(3):696-703.

Raw IF: 6.368 Normalized IF: 6 Lo Iacono N, Blair HC, Poliani PL, Marrella V, Ficara F, Cassani B, Facchetti F, Fontana E, Guerrini MM, Traggiai E, Schena F, Paulis M, Mantero S, Inforzato A, Valaperta S, Pangrazio A, Crisafulli L, Maina V, Kostenuik P, Vezzoni P, Villa A, Sobacchi C*.

Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKLdependent ARO. Journal of Bone and Mineral Research 2012;27(12):2501-10.

Raw IF: 6.373 Normalized IF: 6

Graham GJ, Locati M*, Mantovani A, Rot A, Thelen M.

The biochemistry and biology of the atypical chemokine receptors.

Immunology Letters 2012;145(1-2):30-8.

Raw IF: 2.526 Normalized IF: 2

Mantovani A, Locati M, Uguccioni M.

Chemokines in Immunopathology: from dark sides to clinical translation.

Immunology Letters 2012;145(1-2):1.

Raw IF: 2,526 Normalized IF: 2

Inforzato A, Bottazzi B, Garlanda C, Valentino S, Mantovani A. Mantovani A.

Pentraxins in humoral innate immunity Advances in Experimental Medicine and Biology 2012;946:1-20.

Raw IF: 1.093 Normalized IF: 2

Pentraxin-3 in COPD: innocent bystander or amplifier?

The European Respiratory Journal 2012;39(4):795-6.

Raw IF: 5.895 Normalized IF: 6

Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, Xiao Q, Gasperi A, Mayr A, Kehrer M, Willeit J, Wick G.

Pentraxin-3 as a marker of advanced atherosclerosis.

Results from the Bruneck, ARMY and ARFY Studies.

Plos One 2012;7(2):e31474.

Raw IF: 4.092

82

Normalized IF: 3

Mantovani A.

MSCs, macrophages, and cancer: a dangerous ménageà-trois.

Cell Stem Cell 2012;11(6) 730-2.

Raw IF: 25.421 Normalized IF: 15

Mantovani A*, Biswas SK, Galdiero MR, Sica A, Locati M.

Macrophage plasticity and polarization in tissue repair and remodeling.

Journal of Pathology 2013;229(2):176-85.

Raw IF: 6.318 Normalized IF: 6 Marchesi F, Grizzi F, Laghi L, Mantovani A, Allavena P*.

Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.

Current Pharmaceutical Design. 2012;18(17):2432-8.

Raw IF: 3.87 Normalized IF: 6 Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, Ten Hacken NH, Cobos JimĂŠnez V, Kootstra NA, Hamann J, Greaves DR, Locati M, Mantovani A, Gordon S.

novel mutations in the TCIRG1 gene and diagnostic implications.

Osteoporosis International 2012;23(11):2713-8.

Raw IF: 4.58 Normalized IF: 6 Paroni M, Moalli F, Nebuloni M, Pasqualini F, Bonfield T, Nonis A, Mantovani A, Garlanda C, Bragonzi A.

Response of CFTR-deficient mice to long-term Pseudomonas aeruginosa chronic infection and PTX3 therapeutic treatment.

The Journal of Infectious Diseases 2012. Epub ahead of print.

Raw IF: 6.41 Normalized IF: 6 Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A*, Sica A.

Hypoxia-mediated regulation of macrophage functions in pathophysiology.

Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences.

International Immunology 2013;25(2) 67-75.

Raw IF: 3.415 Normalized IF: 4

Blood2013. Epub ahead of print.

Raw IF: 9.898 Normalized IF: 3.5

Riva F, Bonavita E, Barbati E, Muzio M, Mantovani A, Garlanda C*.

Mayi TH, Daoudi M, Derudas B, Gross B, Bories G, Wouters K, Brozek J, Caiazzo R, Raverdi V, Pigeyre M, Allavena P, Mantovani A, Pattou F, Staels B, Chinetti-Gbaguidi G.

Human adipose tissue macrophages display activation of cancer-related pathways.

The Journal of Biological Chemistry 2012;287(26):21904-13.

Raw IF: 4.773 Normalized IF: 3

TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor family member with regulatory functions in inflammation and immunity.

Frontiers in Immunology. 2012;3:322.

Raw IF: 0

Normalized IF: 0.1

Savino B, Castor MG, Caronni N, Sarukhan A, Anselmo A, Buracchi C, Benvenuti F, Pinho V, Teixeira MM, Mantovani A, Locati M*, Bonecchi R.

Mazzon C*, Anselmo A, Soldani C, Cibella J, Ploia C, Moalli F, Burden SJ, Dustin ML, Sarukhan A, Viola A.

Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6.

Agrin is required for survival and function of monocytic cells.

Blood.2012;119(22):5250-60.

Raw IF: 9.898 Normalized IF: 8

Blood. 2012;119(23):5502-11.

Raw IF: 9.898 Normalized IF: 8

Sica A, Mantovani A.

Macrophage plasticity and polarization: in vivo veritas.

Meda C, Molla F, De Pizzol M, Regano D, Maione F, Capano S, Locati M, Mantovani A, Latini R, Bussolino F, Giraudo E.

Semaphorin 4A exerts a pro-angiogenic effect by enhancing VEGF-A expression in macrophages.

Journal of Immunology 2012;188(8):4081-92.

Raw IF: 5.788 Normalized IF: 6 Pangrazio A, Caldana ME, Lo Iacono N, Mantero S, Vezzoni P, Villa A*, Sobacchi C.

Autosomal recessive osteopetrosis: report of 41

The Journal of Clinical Investigation 2012;122(3):787-95.

Raw IF: 13.069 Normalized IF: 10 Van den Bossche J, Malissen B, Mantovani A, De Baetselier P, Van Ginderachter JA.

Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood. 2012;119(7):1623-33.

Raw IF: 9.898 Normalized IF: 4

83

Papers published 2012

White ES, Mantovani AR.

Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution.

Journal of Pathology 2013;229(2):141-4.

Raw IF: 6.318 Normalized IF: 6

Signal Transduction in Cardiac Pathology Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, Sjaastad I, Liu N, Catalucci D, Mikoshiba K, Hisatsune C, Okkenhaug H, Andrews SR, Bootman MD, Roderick HL.

Mutual antagonism between IP3RII and miRNA-133a regulates calcium signals and cardiac hypertrophy.

Journal of Cell Biology 2012;199(5):783-98.

Raw IF: 10.264 Normalized IF: 8 Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P.

APJ acts as a dual receptor in cardiac hypertrophy.

Nature 2012;488(7411):394-8.

Raw IF: 36.28 Normalized IF: 7.5 Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Catalucci D, Castoldi G, Jones WK, Gupta S.

NF-ÎşB mediated miR-26a regulation in cardiac fibrosis.

Journal of Cellular Physiology 2012. Epub ahead of print.

Raw IF: 3.874 Normalized IF: 3

84

Papers published 2012 * = Corresponding author

T r a s l a t i o n a l Cellular and Molecular Endocrinology Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania A, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P.

GH replacement improves Quality of Life and metabolic parameters in cured acromegalic patients with Growth Hormone Deficiency The Journal of Clinical Endocrinology and Metabolism 2012;97(11):3983-8.

Raw IF: 5.967 Normalized IF: 3

Lania A*, Mantovani G, Spada A.

cAMP pathway and pituitary tumorigenesis.

Annales dâ&#x20AC;&#x2122;Endocrinologie 2012;73(2):73-5.

Raw IF: 0 Normalized IF: 0.1 Lania A*, Beck-Peccoz P.

Pituitary incidentalomas. Best Practice & Research Clinical Endocrinology & Metabolism 2012;24(4):395-403.

Raw IF: 4.121 Normalized IF: 6 Locatelli M, Bertani G, Carrabba G, Rampini P, Zavanone M, Caroli M, Sala E, Ferrante E, Gaini SM, Spada A, Mantovani G, Lania A.

The trans-sphenoidal resection of pituitary adenomas in elderly patients and surgical risk.

Pituitary 2012. Epub ahead of print.

Raw IF: 1.83 Normalized IF: 2

Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, Laws ER, Della Mina P, Villa A, Beck-Peccoz P, Spada A, Lania A.

Filamin-A is essential for Dopamine D2 Receptor expression and signaling in tumorous lactotrophs.

The Journal of Clinical Endocrinology and Metabolism 2012;97(3):967-77.

Raw IF: 5.967 Normalized IF: 6

Clinical Immunology and Autoimmunity and Metabolism

R e s e a r c h Achenza MI, Meda F, Brunetta E, Selmi C*.

Serum autoantibodies for the diagnosis and management of autoimmune liver diseases.

Expert Review of Gastroenterology & Hepatology 2012;6(6):717-29.

Raw IF: 0 Normalized IF: 0.1

Agmon-Levin N, Selmi C.

The autoimmune side of heart and lung diseases.

Clinical Reviews in Allergy and Immunology. 2013;44(1):1-5.

Raw IF: 3.677 Normalized IF: 6

Bogdanos DP, Smyk DS, Rigopoulou EI, Mytilinaiou MG, Heneghan MA, Selmi C, Gershwin ME.

Twin studies in autoimmune disease: genetics, gender and environment.

Journal of Autoimmunity. 2012;38(2-3):J156-69.

Raw IF: 7.368 Normalized IF: 4

Carp HJ, Selmi C, Shoenfeld Y.

The autoimmune bases of infertility and pregnancy loss.

Journal of Autoimmunity 2012;38(2-3):J266-74.

Raw IF: 7.368 Normalized IF: 8

Fujimoto M, Tsuneyama K, Fujimoto T, Selmi C*, Gershwin ME, Shimada Y.

Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome.

Digestive and Liver Disease 2012;44(9):767-74.

Raw IF: 3.054 Normalized IF: 4

Graziani G*, Cucchiari D, Aroldi A, Angelini C, Gaetani P, Selmi C.

Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.

Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(5):510-2.

Raw IF: 4.764 Normalized IF: 6

Insawang T, Selmi C, Chaâ&#x20AC;&#x2122;on U, Pethlert S, Yongvanit P, Areejitranusorn P, Boonsiri P, Khampitak T, Tangrassameeprasert R, Pinitsoontorn C, Prasongwattana V, Gershwin ME, Hammock B.

Autoimmunity and cancer.

Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population.

Asian Pacific Journal of Cancer Prevention 2012;13:25-36.

Raw IF: 0.659 Normalized IF: 1

Nutrition & Metabolism 2012;9(1):50.

Raw IF: 2.885 Normalized IF: 4

Achenza MI, Selmi C*.

85

Papers published 2012

Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, Franke A, Bossa F, Amos CI, Gregersen PK, Siminovitch KA, Cusi D, de Bakker PI, Podda M, Gershwin ME, Seldin MF; Italian PBC Genetics Study Group.

Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis.

Genes and Immunity 2012;13(6):461-8.

Raw IF: 3.872 Normalized IF: 6

Mangano K, Fagone P, Di Mauro M, Ascione E, Maiello V, Milicic T, Jotic A, Lalic NM, Saksida T, Stojanovic I, Selmi C, Farina C, Stosic-Grujicic S, Meroni P, Nicoletti F.

The immunobiology of apotransferrin in type 1 diabetes.

Clinical and Experimental Immunology 2012;169(3):244-52.

Raw IF: 3.36 Normalized IF: 2

The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.

Clinical Reviews in Allergy & Immunology 2012;43(3):207-10.

Raw IF: 3.677 Normalized IF: 6

Selmi C*, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, Rose NR, Gershwin ME.

Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop.

Journal of Autoimmunity. 2012;39(4):272-84.

Raw IF: 7.368 Normalized IF: 8

Selmi C*, Lu Q, Humble MC.

Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, Humble MC, Rose NR.

Heritability versus the role of the environment in autoimmunity.

Criteria for environmentally associated autoimmune diseases.

Journal of Autoimmunity. 2012;39(4):249-52.

Raw IF: 7.368 Normalized IF: 8

Journal of Autoimmunity. 2012;39(4):253-8.

Raw IF: 7.368 Normalized IF: 4

Nguyen MT, Borchers A, Selmi C, Naguwa S, Cheema G, Gershwin ME.

The SAPHO Syndrome.

Shapira Y, Agmon-Levin N, Selmi C, PetrĂ­kovĂĄ J, Barzilai O, Ram M, Bizzaro N, Valentini G, Matucci-Cerinic M, Anaya JM, Katz BS, Shoenfeld Y.

Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases.

Seminars in Arthritis and Rheumatism 2012;42(3):254-65.

Raw IF: 4.969 Normalized IF: 3

Journal of Autoimmunity. 2012;39(1-2):112-6.

Raw IF: 7.368 Normalized IF: 4

Selmi C.

Wang Q, Selmi C, Zhou X, Qiu D, Li Z, Miao Q, Chen X, Wang J, Krawitt EL, Gershwin ME, Han Y, Ma X.

Cutting-edge issues in autoimmunity and allergy of the digestive system.

Clinical Reviews in Allergy & Immunology 2012;42(3):265-8.

Raw IF: 3.677 Normalized IF: 6 Selmi C, Ceribelli A, Vierling JM.

Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis.

Seminars in Immunopathology 2013;35(1):1-5.

Raw IF: 6.274 Normalized IF: 6

86

Selmi C*, Gershwin ME.

Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.

Journal of Autoimmunity. 2012. Epub ahead of print Raw IF: 7.368 Normalized IF: 8

You Z, Wang Q, Bian Z, Liu Y, Han X, Peng Y, Shen L, Chen X, Qiu D, Selmi C, Gershwin ME, Ma X.

The immunopathology of liver granulomas in primary biliary cirrhosis.

Selmi C*, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi F, Zammataro L, Mitchell MM, Lasalle JM, Medsger T Jr, Gershwin ME.

Journal of Autoimmunity. 2012;39(3):216-21.

Raw IF: 7.368 Normalized IF: 4

X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma.

Clinical and Experimental Immunology 2012;169(3):253-62.

Raw IF: 3.36 Normalized IF: 4

Gastrointestinal Immunopathology Bianchieri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota S, Vetrano S, Vidali F, Pasini A, Danese S, Corazza G, MacDonlad TT.

Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn’s disease.

Inflammatory Bowel Diseases 2013;19(2):259-64 Raw IF: 4.855 Normalized IF: 3 Chevaux JB, Fiorino G, Frédéric M, Peyrin-Biroulet L.

Capsule endoscopy in Crohn’s disease.

Current drug targets 2012;13(10):1261-7.

Raw IF: 0 Normalized IF: 0.1

Danese S, Peyrin-Biroulet L.

IBD: Mucosal healing-EXTENDing our knowledge in Crohn’s disease.

Nature Reviews Gastroenterology & Hepatology 2012;9(6):309-11.

Raw IF: 8.102 Normalized IF: 8 Danese S, Peyrin-Biroulet L.

Imaging inflammatory bowel disease: looking beyond the mucosa.

Current Drug Targets 2012;13(10): 1223 Raw IF: 3.553 Normalized IF: 6 Danese S, Fiorino G, Rutella S.

Regulatory T-cell therapy for Crohn’s disease: in vivo veritas.

Cleynen I, Figueroa C, Francke A, McGovern D, Bortik M, Crusius J, Vecchi M, Artieda M, Szczypiorka M, Arteta D, Ayala E, Gonzales JR, Danese S, van Hogez RA, Pena AS, Lukas M, Jewell D, Schreiber S, Vermerire S, Sans M.

Gastroenterology 2012;143(5):1135-8.

Raw IF: 11.675 Normalized IF: 8

Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype. Results from the IBDchip European Project

Mesenchymal stromal cells in IBD: conspirators within the “colitogenic niche”?

Gut 2012. Epub ahead of print.

Raw IF: 10.111

Normalized IF: 8

Danese S*, Rutella S, Vetrano S.

Gut 2012. Epub ahead of print.

Raw IF: 10.111

Normalized IF: 8

Danese S, Vetrano S.

Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Biroulet LP, Caprioli F, Passini N, PaninaBordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S*.

Colitis, microbiota and colon cancer: an infernal triangle.

The bacterial sensor Triggering Receptor Expressed on Myeloid Cells-2 regulates the mucosal inflammatory response.

De Cassan C, Fiorino G, Danese S*.

Gastroenterology. 2012. Epub ahead of print.

Raw IF: 11.675 Normalized IF: 10 D’Alessio S, Genua M, Vetrano S.

The protein C pathway in intestinal barrier function: challenging the hemostasis paradigm.

Annals of the New York Academy of Sciences.

2012;1258(1):78-85.

Raw IF: 3.155 Normalized IF: 6

Danese S.

Adalimumab in Ulcerative Colitis: ready for prime time.

Digestive and Liver Disease 2012;45(1):8-13.

Raw IF: 3.054

Normalized IF: 4

Gastroenterology. Epub ahead of print Raw IF: 11.675 Normalized IF: 8

Second generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects.

Digestive Diseases 2012;30(4):368-75.

Raw IF: 2.373 Normalized IF: 4 D’Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases IOIBD and the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organization ECCO.

Challenges to the design, execution, and analysis of randomized controlled trials for Inflammatory Bowel Disease.

Gastroenterology 2012;143(6):1461-9.

Raw IF: 11.675 Normalized IF: 8

87

Papers published 2012

Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S*.

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.

Inflammatory Bowel Diseases 2012;18(6):1042-47.

Raw IF: 4.855 Normalized IF: 6

Fiorino G, Cesarini M, Malesci A, Danese S, Sorrentino D.

The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn’s disease.

Current Drug Targets 2012;13(10):1273-9.

Raw IF: 3.553 Normalized IF: 6

Fiorino G, Peyrin-Biroulet L, Danese S*.

Bowel damage assessment in Crohn’s disease by Magnetic Resonance Imaging.

Current Drug Targets 2012;13(10):1300-7.

Raw IF: 3.553 Normalized IF: 6

Jovani M, Fiorino G, Danese S.

Associations between immune activation, intestinal permeability and irritable bowel syndrome: “ménage a trois”.

Alimentary Pharmacology & Therapeutics 2013;37(2):277-8.

Raw IF: 3.769 Normalized IF: 6

Mazzon C*, Anselmo A, Soldani C, Cibella J, Ploia C, Moalli F, Burden SJ, Dustin ML, Sarukhan A, Viola A.

Agrin is required for survival and function of monocytic cells.

Blood. 2012;119(23):5502-11.

Raw IF: 9.898 Normalized IF: 8

Mikocka-Walus AA, Andrews JM, Bernstein CN, Graff LA, Walker JR, Spinelli A, Danese S, van der Woude CJ, Goodhand J, Rampton D, Moser G.

Integrated models of care in managing inflammatory bowel disease: a discussion.

88

Peyrin-Biroulet L, Danese S.

Stopping infliximab in Crohn’s disease: still an ongoing STORI. Inflammatory Bowel Diseases 2012;18(11):2201-2.

Raw IF: 4.855 Normalized IF: 6 Peyrin-Biroulet L, Billioud V, D’Haens G, Panaccione R, Feagan B, Panès J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins P, Beaugerie L, Chovers Y, Louis E, Reinish V, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ.

Development of the Paris Definition of Early Crohn’s Disease for Disease-Modification Trials: Results of an International Consensus.

American Journal of Gastroenterology 2012;107(12):1770-6.

Raw IF: 7.282 Normalized IF: 8

Ponziani FR, Cazzato IA, Danese S, Fagiuoli S, Gionchetti P, Annicchiarico BE, D’Aversa F, Gasbarrini A.

Folate in gastrointestinal health and disease.

European Review for Medical and Pharmacological Sciences 2012;16(3):376-85.

Raw IF: 1.04 Normalized IF: 0.5

Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, Danese S, Cittadini A, Sgambato A.

Increased expression of CD133 is a strong predictor of poor outcome 3 in stage I colorectal cancer patients.

Scandinavian Journal of Gastroenterology 2012;47(10):1211-7.

Raw IF: 2.019 Normalized IF: 1

Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group.

(Collaborators: Danese S).

Ustekinumab induction and maintenance therapy in refractory Crohn’s disease.

The New England Journal of Medicine 2012;367(16):1519-28.

Raw IF: 53.298 Normalized IF: 3

Inflammatory Bowel Diseases 2012;18(8):1582-7.

Raw IF: 4.855 Normalized IF: 3

Sorrentino D, Terrosu G, Paviotti A, Geraci M, Avellini C, Zoli G, Fries W, Danese S, Occhipinti P, Croatto T, Zarifi D.

Peyrin-Biroulet L, Danese S.

Leukoapheresis in Crohn’s disease: the final curtain?

Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s Disease: partial benefit by infliximab. A pilot Study.

Gut 2012. Epub ahead of print.

Raw IF: 10.111

Digestive Diseases and Sciences 2012;57(5): 1341-8.

Raw IF: 2.117 Normalized IF: 1

Normalized IF: 8

Spinelli A*, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M.

Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfled Y.

Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn’s Disease: a case-matched analysis.

Infectome: a platform to trace infectious triggers of autoimmunity.

Journal of Gastrointestinal Surgery 2013;17(1):126-32.

Raw IF: 2.826 Normalized IF: 6

Spinelli A*, Sacchi M, Bazzi P, Leone N, Danese S, Montorsi M.

Laparoscopic surgery for recurrent Crohn’s diseas.

Gastroenterology Research and Practice 2012. Epub ahead of print.

Raw IF: 0.978 Normalized IF: 1 Spinelli A*, De Cassan C, Sacchi M, Bazzi P, Danese S, Malesci A, Balzarini L, Montorsi M.

Imaging modalities for perianal Crohn’s disease.

Current Drug Targets 2012;13(10):1223 Raw IF: 3.553 Normalized IF: 6

Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations.

Journal of Crohn’s & Colitis 2013;7(1):1-33.

Raw IF: 2.566 Normalized IF: 2

Zanotti L*, Sarukhan A, Dander E, Castor M, Cibella J, Soldani C, Elisa Trovato A, Ploia C, Luca G, Calvitti M, Mancuso F, Arato I, Golemac M, Jonjic N, Biondi A, Calafiore R, Locati M, D’Amico G, Viola A.

Autoimmunity Reviews 2012. Epub ahead of print.

Raw IF: 6.624 Normalized IF: 3 Chen RC, Naiyanetr P, Shu SA, Wang J, Yang GX, Kenny TP, Guggenheim KC, Butler JD, Bowlus C, Tao MH, Kurth MJ, Ansari AA, Kaplan M, Coppel RL, Lleo A, Gershwin ME, Leung PS.

AMA heterogeneity and the xenobiotic etiology of primary biliary cirrhosis.

Hepatology 2012;46(5):1436-42.

Raw IF: 11.665 Normalized IF: 8

Fenoglio D, Bernuzzi F, Battaglia F, Parodi A, Kalli F, Negrini S, De Palma R, Invernizzi P, Filaci G.

Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases.

Autoimmunity Reviews 2012;12(2):300-4.

Raw IF: 6.624 Normalized IF: 6

Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, Marra F, Mantero S, Roncalli M, Invernizzi P, Pinzani M.

Role of the Stromal-Derived Factor-1 (SDF-1) - CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma.

Journal of Hepatology 2012;57(4):813-20.

Raw IF: 9.264 Normalized IF: 8

Encapsulated mesenchymal stem cells for in vivo immunomodulation.

Invernizzi P, Gershwin ME.

Leukemia 2013;27(2):500-3.

Raw IF: 9.561 Normalized IF: 4

Digestive Diseases and Sciences 2012;57(3):599-601.

Raw IF: 2.117 Normalized IF: 2

Hepatobiliary Immunopathology Achenza MI, Meda F, Brunetta E, Selmi C*.

Serum autoantibodies for the diagnosis and management of autoimmune liver diseases.

Expert Review of Gastroenterology & Hepatology 2012;6(6):717-29.

Raw IF: 0 Normalized IF: 0.1

Primary biliary cirrhosis: bad genes, bad luck.

Invernizzi P*, Alessio MG, Smyk DS, Lleo A, Sonzogni A, Fabris L, Candusso M, Bogdanos DP, Iorio R, Torre G.

Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature.

BMC Gastroenterology 2012;12(1):92.

Raw IF: 2.422 Normalized IF: 4

89

Papers published 2012

Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, Franke A, Bossa F, Amos CI, Gregersen PK, Siminovitch KA, Cusi D, de Bakker PI, Podda M, Gershwin ME, Seldin MF; Italian PBC Genetics Study Group.

Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis.

Iron levels in polarized macrophages: regulation of immunity and autoimmunity.

Autoimmunity Reviews 2012;11(12):883-9.

Raw IF: 6.624 Normalized IF: 6

Genes and Immunity 2012;13(6):461-8.

Raw IF: 3.872 Normalized IF: 6

Selmi C*, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi F, Zammataro L, Mitchell MM, Lasalle JM, Medsger T Jr, Gershwin ME.

Jin Q, Moritoki Y, Lleo A, Tsuneyama K, Invernizzi P, Moritoki H, Kikuchi K, Lian ZX, Hirschfield GM, Ansari AA, Coppel RL, Gershwin ME, Niu J.

X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma.

Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis Hepatology. 2012;55(5):1495-506.

Raw IF: 11.665 Normalized IF: 4

Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, Deandrade M, Amos CI; The Italian PBC Genetics Study Group, Lazaridis KN, Seldin MF, Siminovitch KA.

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants.

Human Molecular Genetics 2012;21(23):5209-21.

Raw IF: 7.636 Normalized IF: 8

Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, Ma L, Lanzi G, Ansari AA, Coppel RL, Zhang P, Li Y, Zhou Z, Lu Q, Gershwin ME.

Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis.

Hepatology. 2012;55(1):153-60.

Raw IF: 11.665 Normalized IF: 8

Persani L, Bonomi M, Lleo A, Pasini S, Civardi F, Bianchi I, Campi I, Finelli P, Miozzo M, Castronovo C, Sirchia S, Gershwin ME, Invernizzi P*.

Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis.

90

Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G.

Journal of Autoimmunity. 2012;38(2-3):J193-6.

Raw IF: 7.368 Normalized IF: 8

Clinical and Experimental Immunology 2012;169(3):253-62.

Raw IF: 3.36 Normalized IF: 4 Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP.

Sex differences associated with primary biliary cirrhosis.

Clinical & Developmental Immunology 2012. Epub ahead of print.

Raw IF: 1.838 Normalized IF: 0.5

Smyk DS, Rigopoulou EI, Pares A, Mytilinaiou MG, Invernizzi P, Bogdanos DP.

Familial primary biliary cirrhosis: like mother, like daughter?

Acta Gastro-Enterologica Belgica 2012;75(2):203-9.

Raw IF: 0.638 Normalized IF: 0.5

Zingaretti C, Arigoâ&#x20AC;&#x2122; M, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJ, Marcatili P, Marconi M, Zignego A, Muratori P, Invernizzi P, Colombatto P, Brunetto M, Bonino F, De Francesco R, Geginat J, Pagani M, Muratori L, Abrignani S, Bombaci M.

Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis.

Molecular and Cellular Proteomics 2012;11(12):1885-97.

Raw IF: 7.398 Normalized IF: 4

Molecular Gastroenterology Di Ieva A, Matula C, Grizzi F, Grabner G, Trattnig S, Tschabitscher M.

Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks.

World Neurosurgery 2012;77(5-6):e11-21.

Raw IF: 0.846 Normalized IF: 1

Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, Oâ&#x20AC;&#x2122;Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, Dâ&#x20AC;&#x2122;Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

Cancer classification using the Immunoscore: a worldwide task force.

Journal of Translational Medicine 2012;10(1):205.

Raw IF: 3.474 Normalized IF: 3 Grizzi F*, Bianchi P, Laghi L.

Grizzi F*, Celesti G, Basso G, Laghi L.

Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope?

World Journal of Gastroenterology 2012;18(45):6532-6.

Raw IF: 2.471 Normalized IF: 4

Laghi L, Bianchi P, Delconte G, Celesti G, Di Caro G, Pedroni M, Chiaravalli AM, Jung B, Capella C, de Leon MP, Malesci A.

MSH3 Protein expression and nodal status in MLH1deficient colorectal cancers.

Clinical Cancer Research 2012;18(11):3142-53.

Raw IF: 7.742 Normalized IF: 8 Laghi L*, Malesci A.

Microsatellite instability and therapeutic consequences in colorectal cancer.

Digestive Diseases 2012;30(3):304-9.

Raw IF: 2.373 Normalized IF: 4 Laghi L, Beghelli S, Spinelli A, Bianchi P, Basso G, Di Caro G, Brecht A, Celesti G, Turri G, Bersani S, Schumacher G, Rocken C, Grantzdorffer I, Roncalli M, Zerbi A, Neuhaus P, Bassi C, Montorsi M, Scarpa A, Malesci A*.

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

Plos One 2012;7(9):e46002.

Raw IF: 4.092

Normalized IF: 6

On the prognostic & predictive impact of immune cells system in colorectal cancer.

Malesci A*, Laghi L.

Indian Journal of Medical Research 2012;135(2):147-9.

Raw IF: 1.837 Normalized IF: 6

Digestive Diseases 2012;30(3):296-303.

Raw IF: 2.373 Normalized IF: 4

Grizzi F.

Marchesi F, Grizzi F, Laghi L, Mantovani A, Allavena P*.

On the reversal of liver cirrhosis: mystery or reality?

Clinical and Experimental Pharmacology & Physiology 2012;39(5):401-3.

Raw IF: 1.851 Normalized IF: 2

Novel prognostic biomarkers in colorectal cancer.

Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.

Current Pharmaceutical Design 2012;18(17):2432-8.

Raw IF: 3.87 Normalized IF: 6

Grizzi F*, Di Ieva A, Di Biccari S, Ceva-Grimaldi G, Colombo P, Tschabitscher M.

Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, Laghi L, Roncalli M*.

Sperm Protein 17: is it a useful target antigen in human pituitary adenomas?

Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.

Procedia in Vaccinology 2012;6:39-46.

Raw IF: 0

Cancer 2013;119(2):266-76.

Raw IF: 4.771 Normalized IF: 6

Normalized IF: 0.1

91

Papers published 2012

Taverna G*, Benecchi L, Grizzi F, Seveso M, Giusti G, Piccinelli A, Benetti A, Colombo P, Minuti F, Graziotti P.

Can a Gleason 6 or less microfocus of prostate cancer in one biopsy and Prostate-Specific Antigen level <10 ng/ mL be defined as the archetype of low-risk prostate disease?

Journal of Oncology 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Wittmann T, Stockbrugger R, Herszényi L, Jonkers D, Molnár B, Saurin JC, Regula J, Malesci A, Laghi L, Pintér T, Teleky B, Dítě P, Tulassay Z.

New European Initiatives in Colorectal Cancer Screening: Budapest Declaration. Official Appeal during the Hungarian Presidency of the Council of the European Union under the Auspices of the United European Gastroenterology Federation, the European Association for Gastroenterology and Endoscopy and the Hungarian Society of Gastroenterology.

Digestive Diseases. 2012;30(3):320-2.

Raw IF: 2.373 Normalized IF: 4

92

Oncology Experimental Therapies Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM.

Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

American Journal of Blood Research Raw IF: 0

2012;2(2):105-12.

Normalized IF: 0.1

Physiology Cerri G*, Montagna M, Madaschi L, Merli D, Borroni P, Baldissera F, Gorio A.

Erythropoietin effect on sensorimotor recovery after contusive spinal cord injury: an electrophysiological study in rats.

Neuroscience 2012; 219:290-301.

Raw IF: 3.38 Normalized IF: 4

Papers published 2012 * = Corresponding author

C l i n i c a l

R e s e a r c h

Anaesthesia and Cardiosurgery Intensive Care Barbone A*, Malvindi PG, Sorabella RA, Cortis G, Tosi PF, Basciu A, Ferrara P, Raffa G, Citterio E, Settepani F, Ornaghi D, Tarelli G, Vitali E.

6 months of “temporary” support by Levitronix left ventricular assist device.

Artificial Organs 2012;36(7):639-42.

Raw IF: 2 Normalized IF: 4

Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Radiat Oncol 2012; 28(7):145.

Raw IF: 2.321 Normalized IF: 4 Torzilli G*, Cimino M, Del Fabbro D, Procopio F, Donadon M, Botea F, Garcia-Etienne C, Montorsi M.

Biobank Grizzi F*, Di Ieva A, Di Biccari S, Ceva-Grimaldi G, Colombo P, Tschabitscher M.

Sperm Protein 17: is it a useful target antigen in human pituitary adenomas?

Procedia in Vaccinology 2012;6:39-46.

Raw IF: 0

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne CA, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C*.

Normalized IF: 0.1

Anatomical resection of segment 8 by means of ultrasound-guided vessel compression.

Annals of Surgical Oncology 2013;20(2):474.

Raw IF: 4.166 Normalized IF: 6 Torzilli G*, Procopio F, Donadon M, Del Fabbro D, Cimino M, Garcia-Etienne CA, Montorsi M.

Upper transversal hepatectomy.

Annals of Surgical Oncology;2012:19(11):3566.

Raw IF: 4.166 Normalized IF: 6

Breast Unit Cardiac and Respiratory Rehabilitation

Garcia-Etienne CA*, Tinterri C.

Reply to Dr. Zucca Matthes et al.

Breast 2012;21(4):614.

Raw IF: 2.491

Normalized IF: 0

Garcia-Etienne CA*, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A; eusomaDB Working Group.

Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database.

European Journal of Cancer 2012;48(13):1947-56.

Raw IF: 5.536 Normalized IF: 6 Meroni S, Moscovici OC, Rahal D, Malerba P, Balzarini L, Tinterri C.

Synchronous bilateral primary breast lymphoma.

The Breast Journal2012;18(4):378-9.

Raw IF: 1.643 Normalized IF: 4

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O’Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators. (Collaborators: Eusebio A, Raffa G, Tarelli G)

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of post-operative Atrial Fibrillation (OPERA) randomized trial.

JAMA2012;308(19):2001-11.

Raw IF: 30.026

Normalized IF: 7.5

Cardiac Surgery Barbone A*, Malvindi PG, Sorabella RA, Cortis G, Tosi PF, Basciu A, Ferrara P, Raffa G, Citterio E, Settepani F, Ornaghi D, Tarelli G, Vitali E.

6 months of “temporary” support by Levitronix left ventricular assist device.

Artificial Organs 2012;36(7):639-42.

Raw IF: 2 Normalized IF: 4

93

Papers published 2012

Cappai A, Malvindi PG, Raffa GM, Basciu A, Monti L.

Raffa GM*, Tarelli G, Patrini D, Settepani F.

Left ventricular cleft.

Sutureless repair for postinfarction cardiac rupture: a simple approach with a tissue-adhering patch.

European Heart Journal Cardiovascular Imaging 2012;14(1):14.

Raw IF: 2.317 Normalized IF: 4 Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V; FREEDOM Trial Investigators. (Collaborators: Presbitero P, Ornaghi D, Micieli G, Genovese S, Citterio E, Belli G, Pagnotta P).

Strategies for multivessel revascularization in patients with diabetes.

The New England Journal of Medicine 2012;367(25):2375-84.

Raw IF: 53.298 Normalized IF: 3 Malvindi PG*, Raffa GM, Basciu A, Citterio E, Cappai A, Ornaghi D, Tarelli G, Settepani F.

Bicuspidy does not affect reoperation risk following aortic valve reimplantation.

Interactive Cardiovascular and Thoracic Surgery 2012;14(6):717-20.

Raw IF: 0 Normalized IF: 0.1 Malvindi PG, Ornaghi D, Tarelli G, Raffa GM*.

Left ventricular pseudoaneurysm following aortic valve prosthesis endocarditis.

Journal of Cardiovascular Medicine 2012;13(7):457-9.

Raw IF: 1.51 Normalized IF: 2 Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, Oâ&#x20AC;&#x2122;Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators. (Collaborators: Eusebio A, Raffa G, Tarelli G).

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of post-operative Atrial Fibrillation (OPERA) randomized trial.

JAMA2012;308(19):2001-11.

Raw IF: 30.026

Normalized IF: 7.5

Raffa GM*, Malvindi PG, Settepani F, Melotti F, Monti L, Spaggiari P, Basciu A, Cappai A, Citterio E, Tarelli G.

Hamartoma of mature cardiac myocytes in adults and young: case report and literature review.

94

International journal of cardiology 2013;163(2):e28-30.

Raw IF: 7.078 Normalized IF: 4

Journal of Thoracic and Cardiovascular Surgery 2013;145(2):598-9.

Raw IF: 3.406 Normalized IF: 6 Raffa GM, Malvindi PG, Ornaghi D, Basciu A, Barbone A, Tarelli G, Settepani F*.

Postsurgical aortic false aneurysm: pathogenesis, clinical presentation and surgical strategy.

Journal of Cardiovascular Medicine 2012. Epub ahead of print.

Raw IF: 1.51 Normalized IF: 2

Clinical Cardiology Lettino M.

[Intra-aortic balloon counterpulsation in acute coronary syndromes: the thin line between use and over-use: intra-aortic balloon counterpulsation is an essential tool if properly used].

Giornale Italiano di Cardiologia2012;13(10):690-4.

Raw IF: 0 Normalized IF: 0.1 Rossini R, Bramucci E, Castiglioni B, De Servi S, Lettieri C, Lettino M, Musumeci G, Visconti LO, Piccaluga E, Savonitto S, Trabattoni D, Buffoli F, Angiolillo DJ, Bovenzi F, Cremonesi A, Scherillo M, Guagliumi G; SocietĂ Italiana di Cardiologia Invasiva; Associazione Nazionale Medici Cardiologi Ospedalieri.

[Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation].

Giornale Italiano di Cardiologia2012;13(7-8):528-51.

Raw IF: 0 Normalized IF: 0.1

Coronary Care Ferrante G*, Presbitero P, Corrada E, Campo G, Bolognese L, Vassanelli C, Colangelo S, De Cesare N, E Rodriguez A, Bramucci E, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Ferrari R, Valgimigli M.

Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with STelevation myocardial infarction undergoing primary

percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial.

Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. (Collaborators: Corrada E).

American Heart Journal 2012;163(1):104-111.

Raw IF: 4.651 Normalized IF: 6

New England Journal of Medicine 2012;366(1):20-33.

Raw IF: 53.298 Normalized IF: 3

Grieco N, Sesana G, Corrada E, Ieva F, Paganoni A, Marzegalli M.

Zavalloni D, Presbitero P, Lodigiani C, Mango R, Cogliati T, Quaglia I, Corrada E, Mendolicchio GL, Gasparini GL, Rossi ML, Ferrazzi P, Belli G, Pagnotta P, Rota LL*.

Mortality and ST resolution in patients admitted with STEMI: The MOMI survey of emergency service experience in a complex urban area.

European Heart Journal: Acute Cardiovascular Care 2012;1(3):192-9.

Raw IF: 0 Normalized IF: 0.1 Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2Pâ&#x20AC;&#x201C;TIMI 50 Steering Committee and Investigators. (Collaborators: Corrada E, Monzini N, Marcheselli S).

Vorapaxar in the secondary prevention of atherothrombotic events.

New England Journal of Medicine 2012;366(15):404-13.

Raw IF: 53.298 Normalized IF: 3 Panico C, Pagnotta P, Mennuni M, Corrada E, Barbaro C, Rossi M, Lisignoli L, Zavalloni V, Parenti D, Belli G, Gasparini G, Presbitero P.

Predictors of mortality in patients undergoing percutaneous aortic valve implantation.

Minerva Cardioangiologica 2012;60(6):561-71.

Raw IF: 0 Normalized IF: 0.1 Rossi ML*, Bocchi R, Barbaro C, Pagnotta P, Mennuni M, Zavalloni D, Gasparini G, Presbitero P.

Successful treatment by transcatheter aortic valve implantation of severe aortic regurgitation in a patient with ascending aorta prosthesis.

Heart, Lung & Circulation 2012. Epub ahead of print.

Raw IF: 1.196 Normalized IF: 2 Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF,

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Prevalence of inherited thrombophilia in patients with documented stent thrombosis.

Circulation Journal2012;76(8):1874-9.

Raw IF: 3.766 Normalized IF: 6

Dermatology Omazzi B, Prada A, Borroni G, Sacrini F.

Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: case report and published work review.

Hepatology Research 2012;42(12):1248-51.

Raw IF: 2.199 Normalized IF: 4 Simonelli M*, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

European Journal of Cancer 2012. Epub ahead of print.

Raw IF: 5.536 Normalized IF: 6

Diagnostic Radiology Calandrino R, Ardu V, Corletto D, Del Vecchio A, Origgi D, Signorotto P, Spinelli A, Tosi G, Bolognesi A, Cariati M, Kluzer A, Muscarella S.

Evaluation of second cancer induction risk by CT followup in oncological long-surviving patients.

Health Physics 2013;104(1):1-8.

Raw IF: 1.68 Normalized IF: 6

95

Papers published 2012

Cappai A, Malvindi PG, Raffa GM, Basciu A, Monti L. Left ventricular cleft.

Orlando S, Cornalba G, Brambilla G, Pedicini V, Poretti D, Bordoni MG, Vercellio G.

European Heart Journal Cardiovascular Imaging 2012;14(1):14.

Diagnostic-therapeutic paths and socio-economical remarks in a group of 35 patients affected by arteriovenous malformations.

Raw IF: 2.317 Normalized IF: 4 Catani M, Dellâ&#x20AC;&#x2122;acqua F, Bizzi A, Forkel SJ, Williams SC, Simmons A, Murphy DG, Thiebaut de Schotten M.

Beyond cortical localization in clinico-anatomical correlation.

Cortex 2012;48(10):1262-87.

Raw IF: 6.08

Normalized IF: 3

Cimino M, Mussi C, Colombo P, Lutman F, Quagliuolo V*.

Leiomyosarcoma arising from the inferior mesenteric vein draining in the splenomesenteric angle with a tumour thrombus at the splenomesenteric confluence: a case report and review of the literature.

Updates in Surgery 2012. Epub ahead of print Raw IF: 0 Normalized IF: 0.1

Italian Journal of Vascular and Endovascular Surgery 2012;19(1):41-9.

Raw IF: 0.028 Normalized IF: 1 Pressiani T, Boni C, Rimassa L*, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Annals of Oncology 2013;24(2):406-11.

Raw IF: 6.425 Normalized IF: 6 Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P.

Mauri G, Poretti D, Pedicini V, Lanza E, Brambilla G.

Endovascular treatment of an anastomotic iliac pseudoaneurysm after surgical aortic repair using a Cardiatis multilayer stent.

Vascular 2012;20(5):290-3.

Raw IF: 0.891

Normalized IF: 1

Mauri G, Sconfienza LM, Fiore B, Brambilla G, Pedicini V, Poretti D, Lutman RF, Montorsi M, Sardanelli F.

Post-surgical enteric fistula treatment with imageguided percutaneous injection of cyanoacrylic glue.

Clinical Radiology 2013;68(1):59-63.

Raw IF: 1.952 Normalized IF: 4 Mensi C, Termine L, Garberi A, Meroni S, Levi D, Balzarini L, Riboldi L.

Spinal cord compression: an unusual presentation of malignant pleural mesothelioma. A case report and review of the literature.

Tumori 2012;98(4):e92-7.

Raw IF: 0.606

96

Normalized IF: 0.5

Sporadic human prion diseases: molecular insights and diagnosis.

Lancet Neurology 2012;11(7):618-28.

Raw IF: 23.462 Normalized IF: 15 Raffa GM*, Malvindi PG, Settepani F, Melotti F, Monti L, Spaggiari P, Basciu A, Cappai A, Citterio E, Tarelli G.

Hamartoma of mature cardiac myocytes in adults and young: case report and literature review.

International Journal of Cardiology 2013;163(2):e28-30.

Raw IF: 7.078 Normalized IF: 4 Santoro A*, Comandone A, Basso U, Soto Parra H, De Sanctis R, Stroppa E, Marcon I, Giordano L, Lutman FR, Boglione A, Bertuzzi A.

Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.

Annals of Oncology 2012. Epub ahead of print.

Raw IF: 6.425 Normalized IF: 6

Meroni S, Moscovici OC, Rahal D, Malerba P, Balzarini L, Tinterri C.

Spinelli A*, De Cassan C, Sacchi M, Bazzi P, Danese S, Malesci A, Balzarini L, Montorsi M.

Synchronous bilateral primary breast lymphoma.

Imaging modalities for perianal Crohnâ&#x20AC;&#x2122;s disease.

The Breast Journal2012;18(4):378-9.

Raw IF: 1.643 Normalized IF: 4

Current Drug Targets 2012;13(10):1287-93.

Raw IF: 3.553 Normalized IF: 6

Testori A, Meroni S, Moscovici OC, Magnoni P, Malerba P, Chiti A, Rahal D, Travaglini R, Cariboni U, Alloisio M, Orefice S.

Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Medical Science Monitor2012;18(9):CR543-9.

Raw IF: 0 Normalized IF: 0.1 Tresoldi S, Monti L, Pricolo P. Left circumflex to superior vena cava coronary artery fistula.

European Heart Journal Cardiovascular Imaging 2012;13(9):798.

Raw IF: 2.317 Normalized IF: 4 Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Niamo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.

Phase I and pharmacodynamic study of high-dose NGRhTNF in patients with refractory solid tumours.

British Journal of Cancer2013;108(1):58-63.

Raw IF: 5.042 Normalized IF: 6

Digestive Endoscopy Service Baron TH, Wong Kee Song LM, Repici A.

Role of self-expandable stents for patients with colon cancer (with videos).

Gastrointestinal Endoscopy 2012;75(3):653-62.

Raw IF: 4.878 Normalized IF: 6 Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Biroulet LP, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S*.

The bacterial sensor Triggering Receptor Expressed on Myeloid Cells-2 regulates the mucosal inflammatory response.

Gastroenterology2012. Epub ahead of print.

Raw IF: 11.675 Normalized IF: 10 Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S*.

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.

Inflammatory Bowel Diseases 2012;18(6):1042-47.

Raw IF: 4.855 Normalized IF: 6

Hassan C, Fuccio L, Bruno M, Pagano N, Spada C, Carrara S, Giordanino C, Rondonotti E, Curcio G, Dulbecco P, Fabbri C, Della Casa D, Maiero S, Simone A, Iacopini F, Feliciangeli G, Manes G, Rinaldi A, Zullo A, Rogai F, Repici A.

A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy.

Clinical Gastroenterology and Hepatology 2012;10(5):501-6 Raw IF: 5.627 Normalized IF: 6 Meisner S, González-Huix F, Vandervoort JG, Repici A, Xinopoulos D, Grund KE, Goldberg P; Registry Group TW.

Self-expanding metal stenting for palliation of patients with malignant colonic obstruction: effectiveness and efficacy on 255 patients with 12-month’s follow-up.

Gastroenterology Research and Practice 2012. Epub ahead of print Raw IF: 0.978 Normalized IF: 0.5 Repici A*, Hassan C, Vitetta E, Ferrara E, Manes G, Gullotti G, Princiotta A, Dulbecco P, Gaffuri N, Bettoni E, Pagano N, Rando G, Strangio G, Carlino A, Romeo F, de Paula Pessoa Ferreira D, Zullo A, Ridola L, Malesci A.

Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study.

Endoscopy 2012;44(1):27-31.

Raw IF: 5.21 Normalized IF: 6 Repici A, Hassan C, De Paula Pessoa D, Pagano N, Arezzo A, Zullo A, Lorenzetti R, Marmo R.

Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review.

Endoscopy 2012;44(2):137-50.

Raw IF: 5.21 Normalized IF: 3 Repici A*, Laterra MA, Cisaro F, Pellicano R, Fini L, Ishaq S.

Unveiling cancer in IBD: screening colonoscopy or chromoendoscopy.

Current Drug Targets 2012;13(10):1268-72.

Raw IF: 3.553 Normalized IF: 6 Repici A*, Pagano N, Hassan C, Cavenati S, Rando G, Spaggiari P, Sharma P, Zullo A.

Endoscopic submucosal dissection of gastric neoplastic lesions in patients with liver cirrhosis: a systematic review.

Journal of Gastrointestinal and Liver Diseases 2012;21(3):303-7.

Raw IF: 1.811 Normalized IF: 2

97

Papers published 2012

Repici A, Cestari R, Annese V, Biscaglia G, Vitetta E, Minelli L, Trallori G, Orselli S, Andriulli A, Hassan C.

Zullo A, De Francesco V, Hassan C, Ridola L, Repici A, Bruzzese V, Vaira D.

Randomised clinical trial: low-volume bowel preparation for colonoscopy - a comparison between two different PEG-based formulations.

Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review.

Alimentary Pharmacology & Therapeutics 2012;36(8):717-24.

Raw IF: 3.769 Normalized IF: 6 Repici A, Hassan C.

Commentary: low-volume bowel preparation for colonoscopy - authorsâ&#x20AC;&#x2122; reply.

Alimentary Pharmacology & Therapeutics 2012;36(10):989.

Raw IF: 3.769 Normalized IF: 6 Repici A*, Hassan C, Pagano N, Rando G, Romeo F, Spaggiari P, Roncalli M, Ferrara E, Malesci A.

High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm.

Gastrointestinal Endoscopy 2013;77(1):96-101.

Raw IF: 4.923 Normalized IF: 6

Digestive and Liver Disease 2013;45(1):18-22.

Raw IF: 3.054 Normalized IF: 2

Echocardiography Gasparini M*, Muto C, Iacopino S, Zanon F, Dicandia C, Distefano G, Favale S, Peraldo Neja C, Bragato R, Davinelli M, Mangoni L, Denaro A.

Low-dose dobutamine test associated with interventricular dyssynchrony: a useful tool to identify cardiac resynchronization therapy responders: data from the LOw dose DObutamine stress-echo test in Cardiac Resynchronization Therapy (LODO-CRT) phase 2 study.

American Heart Journal 2012;163(3):422-9.

Raw IF: 4.651 Normalized IF: 6

Repici A*, Hassan C, Zullo A.

Reply to Sarkis et Al. Endoscopy2013;45(1):76.

Raw IF: 5.21

Gasparini M*, Ceriotti C, Bragato R. Normalized IF: 0

Siersema PD, Rastogi A, Leufkens AM, Akerman PA, Azzouzi K, Rothstein RI, Vleggaar FP, Repici A, Rando G, Okolo PI, Dewit O, Ignjatovic A, Odstrcil E, East J, Deprez PH, Saunders BP, Kalloo AN, Creel B, Singh V, Lennon AM, DeMarco DC.

Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup.

World Journal of Gastroenterology 2012;18(26):3400-8.

Raw IF: 2.471 Normalized IF: 4 van Halsema EE, Wong Kee Song LM, Baron TH, Siersema PD, Vleggaar FP, Ginsberg GG, Shah PM, Fleischer DE, Ratuapli SK, Fockens P, Dijkgraaf MG, Rando G, Repici A, van Hooft JE.

Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases.

Gastrointestinal Endoscopy 2013;77(1):18-8.

Raw IF: 4.923 Normalized IF: 6

98

Huge left atrial thrombus after left atrial appendage occlusion with a Watchman device.

European Heart Journal 2012;33(16):1998.

Raw IF: 10.478 Normalized IF: 8

Echography Delle Rose G*, Borroni M, Silvestro A, Garofalo R, Conti M, De Nittis P, Castagna A.

The long head of biceps as a source of pain in active population: tenotomy or tenodesis? A comparison of 2 case series with isolated lesions.

Musculoskeletal Surgery2012;96(s1):47-52.

Raw IF: 0 Normalized IF: 0.1 Testori A, Meroni S, Moscovici OC, Magnoni P, Malerba P, Chiti A, Rahal D, Travaglini R, Cariboni U, Alloisio M, Orefice S.

Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Medical Science Monitor2012;18(9):CR543-9.

Raw IF: 0 Normalized IF: 0.1

Electrophysiology and Electrostimulation Boriani G, Santini M, Lunati M, Gasparini M, Proclemer A, Landolina M, Padeletti L, Botto GL, Capucci A, Bianchi S, Biffi M, Ricci RP, Vimercati M, Grammatico A, Lip GY; Italian ClinicalService Project.

Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverterdefibrillators: the multicentre Italian ANGELS of AF Project.

Circulation. Cardiovascular quality and outcomes 2012;5(2):182-8.

Raw IF: 4.906 Normalized IF: 6 Boriani G, Gardini B, Diemberger I, Bacchi Reggiani ML, Biffi M, Martignani C, Ziacchi M, Valzania C, Gasparini M, Padeletti L, Branzi A.

Meta-analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all-cause mortality and hospitalizations.

European Journal of Heart Failure 2012;14(6):652-60.

Raw IF: 4.896 Normalized IF: 3 Brignole M, Occhetta E, Bongiorni MG, Proclemer A, Favale S, Iacopino S, Calò L, Vado A, Buja G, Mascioli G, Quartieri F, Tritto M, Parravicini U, Castro A, Tomasi C, Villani GQ, D’Acri MG, Klersy C, Gasparini M.

Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first Implantable cardioverter-defibrillator implant.

Journal of the American College of Cardiology 2012;60(11):981-7.

Raw IF: 14.156 Normalized IF: 10

Gasparini M*, Galimberti P.

AV junction ablation in heart failure patients with atrial fibrillation treated with cardiac resynchronization therapy: the picture is now clear!

Journal of the American College of Cardiology 2012;59(8):727-9.

Raw IF: 14.156 Normalized IF: 10 Gasparini M*, Muto C, Iacopino S, Zanon F, Dicandia C, Distefano G, Favale S, Peraldo Neja C, Bragato R, Davinelli M, Mangoni L, Denaro A.

Low-dose dobutamine test associated with interventricular dyssynchrony: a useful tool to identify cardiac resynchronization therapy responders: data from the LOw dose DObutamine stress-echo test in Cardiac Resynchronization Therapy (LODO-CRT) phase 2 study.

American Heart Journal 2012;163(3):422-9.

Raw IF: 4.651 Normalized IF: 6 Gasparini M*, Ceriotti C, Bragato R.

Huge left atrial thrombus after left atrial appendage occlusion with a Watchman device.

European Heart Journal 2012;33(16):1998.

Raw IF: 10.478 Normalized IF: 8 Gasparini M*, Nisam S.

Implantable cardioverter defibrillator harm?

Europace 2012;14(8):1087-93.

Raw IF: 1.98 Normalized IF: 4 Gasparini M, Galimberti P, Ceriotti C, Arosio M.

Left atrial “onion-ring” thrombosis during atrial fibrillation ablation.

De Maria R, Landolina M, Gasparini M, Schmitz B, Campolo J, Parolini M, Sanzo A, Galimberti P, Bianchi M, Brand S-M, Parodi O, Lunati M.

Journal of the American College of Cardiology; 2012:60(22):e39.

Raw IF: 14.156 Normalized IF: 10

Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy.

Gasparini M*, Galimberti P, Ceriotti C.

Journal of Cardiac Failure 2012;18(10):762-8.

Raw IF: 3.66 Normalized IF: 0 Gasparini M*, Galimberti P, Ceriotti C.

The values of defibrillation testing at implantable cardioverter defibrillator implantation: ‘and then there were none’.

Current Opinion in Cardiology 2012;27(1):8-12.

Raw IF: 2.329 Normalized IF: 4

The importance of increased percentage of biventricular pacing to improve clinical outcomes in patients receiving cardiac resynchronization therapy.

Current Opinion in Cardiology 2013;28(1):50-4.

Raw IF: 2.329 Normalized IF: 4 Krum H, Lemke B, Birnie D, Lee KL, Aonuma K, Starling RC, Gasparini M, Gorcsan J, Rogers T, Sambelashvili A, Kalmes A, Martin D.

A novel algorithm for individualized cardiac

99

Papers published 2012

resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial.

American Heart Journal 2012;163(5):747-52e1.

Raw IF: 4.651 Normalized IF: 6 Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, Gasparini M, Starling RC, Milasinovic G, Rogers T, Sambelashvili A, Gorcsan J 3rd, Houmsse M; Adaptive CRT Study Investigators.

Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the adaptive CRT trial.

Heart Rhythm 2012;9(11):1807-14e1.

Raw IF: 4.102

Normalized IF: 6

Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, De Nardis R, Colombo M.

Risk stratification in brugada syndrome: Results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.

Journal of the American College of Cardiology 2012;59(1):37-45.

Raw IF: 14.156 Normalized IF: 10

Emergency Neurology and Stroke Unit Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

(Collaborators: Corrada E, Monzini N, Marcheselli S).

Vorapaxar in the secondary prevention of atherothrombotic events.

New England Journal of Medicine 2012;366(15):404-13.

Raw IF: 53.298 Normalized IF: 3 Paciaroni M, Agnelli G, Caso V, Pieroni A, Bovi P, Cappellari M, Zini A, Nichelli P, Inzitari D, Nesi M, Nencini P, Pezzini A, Padovani A, Tassinari T, Orlandi G, Chiti A, Gialdini G, Alberti A, Venti M, Acciarresi M, D’Amore C, Luda E, Tassi R, Martini G, Ferrarese C, Beretta S, Trentini C, Silvestrelli G, Lanari A, Previdi P, Ciccone A, Delodovici ML, Bono G, Galletti G, Marcheselli S, Del Sette M, Traverso E, Riva M, Silvestrini M, Cerqua R, Consoli D, Monaco S, Toni D.

Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 Study.

100

Cerebrovascular Diseases 2012;34(5-6):430-5.

Raw IF: 2.723 Normalized IF: 4

Gastroenterology and Digestive Endoscopy Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Biroulet LP, Caprioli F, Passini N, PaninaBordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S*.

The bacterial sensor Triggering Receptor Expressed on Myeloid Cells-2 regulates the mucosal inflammatory response.

Gastroenterology2012. Epub ahead of print.

Raw IF: 11.675 Normalized IF: 10 Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S*.

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.

Inflammatory Bowel Diseases 2012;18(6):1042-47.

Raw IF: 4.855 Normalized IF: 6 Fiorino G, Cesarini M, Malesci A, Danese S, Sorrentino D.

The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn’s disease.

Current Drug Targets 2012;13(10):1273-9.

Raw IF: 3.553 Normalized IF: 6 Grizzi F*, Di Ieva A, Di Biccari S, Ceva-Grimaldi G, Colombo P, Tschabitscher M.

Sperm Protein 17: is it a useful target antigen in human pituitary adenomas?

Procedia in Vaccinology 2012;6:39-46.

Raw IF: 0

Normalized IF: 0.1

Jovani M, Fiorino G, Danese S.

Associations between immune activation, intestinal permeability and irritable bowel syndrome: “ménage a trois”.

Alimentary Pharmacology & Therapeutics 2013;37(2):277-8.

Raw IF: 3.769 Normalized IF: 6 Laghi L, Bianchi P, Delconte G, Celesti G, Di Caro G, Pedroni M, Chiaravalli AM, Jung B, Capella C, de Leon MP, Malesci A.

MSH3 Protein expression and nodal status in MLH1deficient colorectal cancers.

Clinical Cancer Research2012;18(11):3142-53.

Raw IF: 7.742 Normalized IF: 8

Laghi L*, Malesci A.

Microsatellite instability and therapeutic consequences in colorectal cancer.

Digestive Diseases2012;30(3):304-9.

Raw IF: 2.373 Normalized IF: 4 Laghi L, Beghelli S, Spinelli A, Bianchi P, Basso G, Di Caro G, Brecht A, Celesti G, Turri G, Bersani S, Schumacher G, Rocken C, Grantzdorffer I, Roncalli M, Zerbi A, Neuhaus P, Bassi C, Montorsi M, Scarpa A, Malesci A*.

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

Plos One 2012;7(9):e46002.

Raw IF: 4.092

Normalized IF: 6

Malesci A*, Laghi L.

Novel prognostic biomarkers in colorectal cancer.

Digestive Diseases2012;30(3):296-303.

Raw IF: 2.373 Normalized IF: 4 Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, Laghi L, Roncalli M*.

Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.

Cancer 2013;119(2):266-76.

Raw IF: 4.771 Normalized IF: 6 Repici A*, Hassan C, Vitetta E, Ferrara E, Manes G, Gullotti G, Princiotta A, Dulbecco P, Gaffuri N, Bettoni E, Pagano N, Rando G, Strangio G, Carlino A, Romeo F, de Paula Pessoa Ferreira D, Zullo A, Ridola L, Malesci A.

Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study.

Endoscopy 2012;44(1):27-31.

Raw IF: 5.21 Normalized IF: 6 Repici A*, Hassan C, Pagano N, Rando G, Romeo F, Spaggiari P, Roncalli M, Ferrara E, Malesci A.

High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm.

Gastrointestinal Endoscopy 2013;77(1):96-101.

Raw IF: 4.923 Normalized IF: 6

Salvioli B*, Bazzocchi G, Barbara G, Stanghellini V, Cremon C, Menarini M, Corinaldesi R, De Giorgio R.

Sigmoid compliance and visceral perception in spinal cord injury patients.

European Journal of Gastroenterology and Hepatology 2012;24(3):340-5.

Raw IF: 1.757 Normalized IF: 2 Spinelli A*, De Cassan C, Sacchi M, Bazzi P, Danese S, Malesci A, Balzarini L, Montorsi M.

Imaging modalities for perianal Crohn’s disease.

Current Drug Targets 2012;13(10):1287-93.

Raw IF: 3.553 Normalized IF: 6 Spinelli A*, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M.

Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn’s Disease: a case-matched analysis.

Journal of Gastrointestinal Surgery 2013;17(1):126-32.

Raw IF: 2.826 Normalized IF: 6 Wittmann T, Stockbrugger R, Herszényi L, Jonkers D, Molnár B, Saurin JC, Regula J, Malesci A, Laghi L, Pintér T, Teleky B, Dítě P, Tulassay Z.

New European Initiatives in Colorectal Cancer Screening: Budapest Declaration. Official Appeal during the Hungarian Presidency of the Council of the European Union under the Auspices of the United European Gastroenterology Federation, the European Association for Gastroenterology and Endoscopy and the Hungarian Society of Gastroenterology.

Digestive Diseases. 2012;30(3):320-2.

Raw IF: 2.373 Normalized IF: 4

General Anaesthesia and Intensive Care Gasparini M, Galimberti P, Ceriotti C, Arosio M.

Left atrial “onion-ring” thrombosis during atrial fibrillation ablation.

Journal of the American College of Cardiology; 2012:60(22):e39.

Raw IF: 14.156 Normalized IF: 10

101

Papers published 2012

Giustiniano E, Morenghi E, Ruggieri N, Pellegrino F, Balazova J, Dominoni C, Marinelli G*.

Spinelli A*, De Cassan C, Sacchi M, Bazzi P, Danese S, Malesci A, Balzarini L, Montorsi M.

Cardiac output by Flotrac/Vigileo(TM) validation trials: are there reliable conclusions?

Imaging modalities for perianal Crohn’s disease.

Reviews on Recent Clinical Trials 2012;7(3):181-6.

Raw IF: 0 Normalized IF: 0.1

Current Drug Targets 2012;13(10):1287-93.

Raw IF: 3.553 Normalized IF: 6

Meco M, Giustiniano E.

Spinelli A*, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M.

Renal Resistivity Index as a guide for treatment of severe postoperative renal failure in cardiac surgery: a case report.

Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn’s Disease: a case-matched analysis.

Journal of Anesthesia & Clinical Research 2012;3(11):260.

Raw IF: 0 Normalized IF: 0.1

Journal of Gastrointestinal Surgery 2013;17(1):126-32.

Raw IF: 2.826 Normalized IF: 6

General and Minimally Invasive Surgery Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, Bärthel A, Långström G, Lind T, Lundell L; LOTUS trial collaborators. (Collaborator: Rosati R).

Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.

Alimentary Pharmacology & Therapeutics 2012;36(10):959-71.

Raw IF: 3.769 Normalized IF: 1.2 Fumagalli Romario U, Ceolin M, Porta M, Rosati R*.

Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, Ludovisi S, Michelone G, Alessiani M, Rosati R, Montorsi M, Mondelli MU.

Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection.

Hepatology2012;56(3):841-9.

Raw IF: 11.665 Normalized IF: 4 Vitobello D, Fattizzi N, Santoro G, Rosati R, Baldazzi G, Bulletti C, Palmara V.

Robotic surgery and standard laparoscopy: a surgical hybrid technique for use in colorectal endometriosis.

The Journal of Obstetrics and Gynaecology Research 2012;39(1):217-2.

Raw IF: 0.942 Normalized IF: 1

Laparoscopic repair of epiphrenic diverticulum.

Seminars in Thoracic and Cardiovascular Surgery 2012;24(3):213-7.

Raw IF: 0 Normalized IF: 0.1 Fumagalli Romario U, Puccetti F, Elmore U, Massaron S, Rosati R.

Self-gripping mesh versus staple fixation in laparoscopic inguinal hernia repair: a prospective comparison.

Surgical Endoscopy 2013. Epub ahead of print.

Raw IF: 4.013 Normalized IF: 6 Spinelli A*, Sacchi M, Bazzi P, Leone N, Danese S, Montorsi M.

General and Oncologic Surgery Bernini M, Bencini L, Sacchetti R, Marchet A, Cristadoro L, Pacelli F, Berardi S, Doglietto GB, Rosa F, Verlato G, Cozzaglio L, Bechi P, Marrelli D, Roviello F, Farsi M; Italian Research Group for Gastric Cancer (IRGGC).

The Cholegas Study: safety of prophylactic cholecystectomy during gastrectomy for cancer: preliminary results of a multicentric randomized clinical trial.

Gastric Cancer 2012. Epub ahead of print.

Raw IF: 2.421 Normalized IF: 2

Laparoscopic surgery for recurrent Crohn’s disease.

102

Gastroenterology Research and Practice 2012. Epub ahead of print.

Raw IF: 0.978 Normalized IF: 1

Bozzetti F, Mariani L, Lo Vullo S; SCRINIO Working Group, Amerio ML, Biffi R, Caccialanza G, Capuano G, Correja I, Cozzaglio L, Di Leo A, Di Cosmo L, Finocchiaro C, Gavazzi C, Giannoni A, Magnanini P, Mantovani G, Pellegrini M, Rovera

L, Sandri G, Tinivella M, Vigevani E.

The nutritional risk in oncology: a study of 1,453 cancer outpatients.

Supportive Care in Cancer 2012;20(8):1919-28.

Raw IF: 2.597 Normalized IF: 6 Cimino M, Mussi C, Colombo P, Lutman F, Quagliuolo V*.

Leiomyosarcoma arising from the inferior mesenteric vein draining in the splenomesenteric angle with a tumour thrombus at the splenomesenteric confluence: a case report and review of the literature.

Updates in Surgery 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P.

Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A.

Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

Cancer 2012;118(23):5957-66.

Raw IF: 4.771 Normalized IF: 3

General Medicine and Hepatology Pressiani T, Boni C, Rimassa L*, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Annals of Oncology 2013;24(2):406-11.

Raw IF: 6.425 Normalized IF: 6

Journal of Clinical Oncology 2012;30(8):850-56.

Raw IF: 18.372 Normalized IF: 15

General Surgery III; Liver Surgery Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG.

Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S.

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma.

Annals of Oncology 2013. Epub ahead of print.

Raw IF: 6.425 Normalized IF: 3

Liver International2012;32(5):772-82.

Raw IF: 3.824 Normalized IF: 6

Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, Bresadola F, Calise F, Dalla Valle R, D’Amico DF, Gennari L, Giulini SM, Guglielmi A, Jovine E, Pellicci R, Pernthaler H, Pinna AD, Puleo S, Torzilli G, Capussotti L; Italian Chapter of the International Hepato-Pancreato-Biliary Association, Cillo U, Ercolani G, Ferrucci M, Mastrangelo L, Portolani N, Pulitanò C, Ribero D, Ruzzenente A, Scuderi V, Federico B.

Bona S, Molteni M*, Montorsi M.

Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.

Minilaparoscopic colorectal resections: technical note.

Minimally invasive surgery 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Biroulet LP, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S*.

Archives of Surgery 2012;147(1):26-34.

Raw IF: 4.422 Normalized IF: 6

The bacterial sensor Triggering Receptor Expressed on Myeloid Cells-2 regulates the mucosal inflammatory response.

Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P,

Gastroenterology.2012. Epub ahead of print.

Raw IF: 11.675 Normalized IF: 10

103

Papers published 2012

Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, Pederzoli P, Di Carlo V, Falconi M.

Leonardi G, Marchi S, Falconi M, Zerbi A, Ussia V, de Bortoli N, Mosca F, Presciuttini S, Del Chiaro M.

Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections.

“PancPro” as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases.

Archives of Surgery 2012;147(3):261-6.

Raw IF: 4.422 Normalized IF: 6

Digestive and Liver Disease 2012;44(7):585-8.

Raw IF: 3.054 Normalized IF: 2

Cucchetti A, Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD.

Mauri G, Sconfienza LM, Fiore B, Brambilla G, Pedicini V, Poretti D, Lutman RF, Montorsi M, Sardanelli F.

A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.

Post-surgical enteric fistula treatment with imageguided percutaneous injection of cyanoacrylic glue.

Annals of Surgical Oncology 2012;19(12):3697-705.

Raw IF: 4.166 Normalized IF: 3

Mikocka-Walus AA, Andrews JM, Bernstein CN, Graff LA, Walker JR, Spinelli A, Danese S, van der Woude CJ, Goodhand J, Rampton D, Moser G.

Donadon M, Torzilli, G

Intraoperative ultrasound of the liver.

American Journal of Roentgenology 2012;198(4):W398 Raw IF: 2.775 Normalized IF: 2 Donadon M, Cimino M, Procopio F, Morenghi E, Montorsi M, Torzilli G.

Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma.

Updates in surgery 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Giuliante F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G, Portolani N, Torzilli G, Donadon M, Aldrighetti L, Pulitanò C, Guglielmi A, Ruzzenente A, Capussotti L, Ferrero A, Calise F, Scuderi V, Federico B, Nuzzo G.

Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients.

Journal of the American College of Surgeons 2012;215(2):244-54.

Raw IF: 4.549 Normalized IF: 6 Laghi L, Beghelli S, Spinelli A, Bianchi P, Basso G, Di Caro G, Brecht A, Celesti G, Turri G, Bersani S, Schumacher G, Rocken C, Grantzdorffer I, Roncalli M, Zerbi A, Neuhaus P, Bassi C, Montorsi M, Scarpa A, Malesci A*.

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

104

Plos One 2012;7(9):e46002.

Raw IF: 4.092

Clinical Radiology 2013;68(1):59-63.

Raw IF: 1.952 Normalized IF: 4

Normalized IF: 6

Integrated models of care in managing inflammatory bowel disease: a discussion.

Inflammatory Bowel Diseases 2012;18(8):1582-7.

Raw IF: 4.855 Normalized IF: 3 Montorsi M*, Zerbi A, Bassi C, Capussotti L, Coppola R, Sacchi M; the Italian Tachosil Study Group.

Efficacy of an absorbable fibrin sealant patch (TachoSil) after distal pancreatectomy: a multicenter, randomized, controlled trial.

Annals of Surgery. 2012;256(5):853-60.

Raw IF: 7.492 Normalized IF: 8 Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, Bresadola F, Calise F, Dalla Valle R, D’Amico DF, Gennari L, Giulini SM, Guglielmi A, Jovine E, Pellicci R, Pernthaler H, Pinna AD, Puleo S, Torzilli G, Capussotti L; Italian Chapter of the International Hepato-Pancreato-Biliary Association, Cillo U, Ercolani G, Ferrucci M, Mastrangelo L, Portolani N, Pulitanò C, Ribero D, Ruzzenente A, Scuderi V, Federico B.

Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.

Archives of Surgery 2012;147(1):26-34.

Raw IF: 4.422 Normalized IF: 6 Pressiani T, Boni C, Rimassa L*, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR,

Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Spinelli A*, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn’s Disease: a case-matched analysis.

Annals of Oncology 2013;24(2):406-11.

Raw IF: 6.425 Normalized IF: 6

Journal of Gastrointestinal Surgery 2013;17(1):126-32.

Raw IF: 2.826 Normalized IF: 6

Procopio F*, Torzilli G.

Torzilli G*, Procopio F, Donadon M, Del Fabbro D, Cimino M, Garcia-Etienne CA, Montorsi M.

Forty-nine colorectal cancer liver metastases in onestage hepatectomy with cumulative Pringle time lasting 348 min.

Updates in Surgery 2012;64(3):241-3.

Raw IF: 0

Upper transversal hepatectomy.

Annals of Surgical Oncology;2012:19(11):3566.

Raw IF: 4.166 Normalized IF: 6

Normalized IF: 0.1

Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E.

Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.

Torzilli G*, Cimino M, Del Fabbro D, Procopio F, Donadon M, Botea F, Garcia-Etienne C, Montorsi M.

Anatomical resection of segment 8 by means of ultrasound-guided vessel compression.

Annals of Surgical Oncology 2013;20(2):474.

Raw IF: 4.166 Normalized IF: 6

Annals of Surgical Oncology 2012;19:2256-63.

Raw IF: 4.166 Normalized IF: 3

Uzunoglu FG, Stehr A, Fink JA, Vettorazzi E, Koenig A, Gawad KA, Vashist YK, Kutup A, Mann O, Gavazzi F, Zerbi A, Bassi C, Dervenis C, Montorsi M, Bockhorn M, Izbicki JR.

Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, Aldrighetti L, Calise F, Gerunda GE, Tomatis M, Amisano M, Berloco P, Torzilli G, Capussotti L; for the Italian Intrahepatic Cholangiocarcinoma Study Group.

Annals of Surgery 2012;256(5):675-80.

Raw IF: 7.492 Normalized IF: 8

Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multiinstitutional analysis of 434 patients.

Archives of Surgery 2012. Epub ahead of print.

Raw IF: 4.422 Normalized IF: 6 Spinelli A*, Sacchi M, Bazzi P, Leone N, Danese S, Montorsi M.

Ultrasonic dissection versus conventional dissection techniques in pancreatic surgery: a randomized multicentre study.

Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, Ludovisi S, Michelone G, Alessiani M, Rosati R, Montorsi M, Mondelli MU.

Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection.

Hepatology2012;56(3):841-9.

Raw IF: 11.665 Normalized IF: 4

Laparoscopic surgery for recurrent Crohn’s disease.

Gastroenterology Research and Practice 2012. Epub ahead of print.

Raw IF: 0.978 Normalized IF: 1 Spinelli A*, De Cassan C, Sacchi M, Bazzi P, Danese S, Malesci A, Balzarini L, Montorsi M.

Gynaecology Serati M, Ghezzi F, Cattoni E, Braga A, Siesto G, Torella M, Cromi A, Vitobello D, Salvatore S.

Imaging modalities for perianal Crohn’s disease.

Tension-free vaginal tape for the treatment of urodynamic stress incontinence: efficacy and adverse effects at 10-year follow-up.

Current Drug Targets 2012;13(10):1287-93.

Raw IF: 3.553 Normalized IF: 6

European Urology2012;61(5):939-46.

Raw IF: 8.493 Normalized IF: 4

105

Papers published 2012

Serati M, Siesto G, Carollo S, Formenti G, Riva C, Cromi A, Ghezzi F.

Risk factors for cervical intraepithelial neoplasia recurrence after conization: a 10-year study.

European Journal of Obstetrics, Gynecology, and Reproductive Biology 2012;165(1):86-90.

Raw IF: 1.974 Normalized IF: 4 Vitobello D, Siesto G*, Bulletti C, Accardi A, IedĂ N.

Robotic radical parametrectomy with pelvic lymphadenectomy: our experience and review of the literature.

European Journal of Surgical Oncology 2012;38(6):548-54.

Raw IF: 2.499 Normalized IF: 4 Vitobello D, Fattizzi N, Santoro G, Rosati R, Baldazzi G, Bulletti C, Palmara V.

Robotic surgery and standard laparoscopy: a surgical hybrid technique for use in colorectal endometriosis.

The Journal of Obstetrics and Gynaecology Research 2013;39(1):217-2.

Raw IF: 0.942 Normalized IF: 1

Vitobello D, Siesto G*, Pirovano C, Ieda N.

Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.

European Journal of Surgical Oncology 2013;39(1):87-93.

Raw IF: 2.499 Normalized IF: 6

Gynaecology and Reproductive Medicine

Levi Setti PE*, Desgro M, Vaiarelli A, Patrizio P.

Oocyte Cryopreservation: Who, how and what to Expect.

Journal of Fertilization: In Vitro 2012;2:1000e118.

Raw IF: 0 Normalized IF: 0.1 Levi Setti PE*, Albani E, Matteo M, Morenghi E, Zannoni E, Baggiani AM, Arfuso V, Patrizio P.

Five years (2004-2009) of a restrictive law-regulating ART in Italy significantly reduced delivery rate: analysis of 10 706 cycles.

Human Reproduction 2013;28(2):343-9.

Raw IF: 4.475 Normalized IF: 6 Ragni G, Levi Setti PE, Fadini R, Brigante C, Scarduelli C, Alagna F, Arfuso V, Mignini-Renzini M, Candiani M, Paffoni A, Somigliana E.

Clomiphene citrate versus high doses of gonadotropins for in vitro fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial.

Reproductive Biology and Endocrinology 2012;10(1):114.

Raw IF: 2.045 Normalized IF: 2

Haemodynamics, Invasive Cardiology and Coronary Care Barbati E, Specchia C, Villella M, Rossi ML, Barlera S, Bottazzi B, Crociati L, dâ&#x20AC;&#x2122;Arienzo C, Fanelli R, Garlanda C, Gori F, Mango R, Mantovani A, Merla G, Nicolis EB, Pietri S, Presbitero P, Sudo Y, Villella A, Franzosi MG.

Influence of Pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels.

Plos One 2012;7(12):e53030.

Raw IF: 4.092

Normalized IF: 6

Belli G*, Presbitero P. Levi Setti PE, Patrizio P.

Oocyte cryopreservation. Recent progress, future expectations.

Contemporary Obstetrics/Gynecology 2012;5:52-8.

Raw IF: 0 Normalized IF: 0.1

Minerva Cardioangiologica 2012;60(2):195-201.

Raw IF: 0 Normalized IF: 0.1

The Italian Experience of A Restrictive IVF Law: A Review.

Biondi-Zoccai G, Romagnoli E, Castagno D, Sheiban I, De Servi S, Tamburino C, Colombo A, Burzotta F, Presbitero P, Bolognese L, Paloscia L, Rubino P, Sardella G, Briguori C, Niccoli L, Franco G, Di Girolamo D, Piatti L, Greco C, Petronio AS, Loi B, Benassi A, Patti A, Gaspardone A, Frati G, Sangiorgi G.

Journal of Fertilization:In Vitro2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1

Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for

Levi Setti PE, Patrizio P.

106

Multivessel disease in primary percutaneous coronary intervention.

the ACEF (age, creatinine, ejection fraction) score.

EuroIntervention 2012;8(3):359-67.

Raw IF: 3.285 Normalized IF: 4 Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G; SMILE-4 Working Party.

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, doubleblind, parallel-group, multicenter, European study (SMILE-4).

Clinical Cardiology2012;35(7):416-23.

Raw IF: 2.151

Bramucci E, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Ferrari R, Valgimigli M.

Sex-specific benefits of sirolimus-eluting stent on longterm outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial.

American Heart Journal 2012;163(1):104-111.

Raw IF: 4.651 Normalized IF: 6 Ferrante G, Presbitero P, Whitbourn R, Barlis P.

Normalized IF: 0.8

Buchanan GL, Chieffo A, Mehilli J, Mikhail GW, Mauri F, Presbitero P, Grinfeld L, Petronio AS, Skelding KA, Hoye A, Mehran R, Morice MC.

The occupational effects of interventional cardiology: results from the WIN for Safety survey.

EuroIntervention 2012;8(6):658-63.

Raw IF: 3.285 Normalized IF: 4 Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, Varbella F, Mauri F, Valgimigli M, Arampatzis C, Sabate M, Erglis A, Reimers B, Airoldi F, Laine M, Palop RL, Mikhail G, Maccarthy P, Romeo F, Colombo A.

A prospective, randomized trial of intravascularultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial.

American Heart Journal 2013;165(1):65-72.

Raw IF: 4.651 Normalized IF: 6 Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V; FREEDOM Trial Investigators (Collaborators: Presbitero P, Ornaghi D, Micieli G, Genovese S, Citterio E, Belli G, Pagnotta P).

Strategies for multivessel revascularization in patients with diabetes.

The New England Journal of Medicine 2012;367(25):2375-84.

Raw IF: 53.298 Normalized IF: 3 Ferrante G*, Presbitero P, Corrada E, Campo G, Bolognese L, Vassanelli C, Colangelo S, De Cesare N, E Rodriguez A,

Current applications of optical coherence tomography for coronary intervention.

International Journal of Cardiology 2012. Epub ahead of print.

Raw IF: 7.078 Normalized IF: 8 Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Menozzi A.

A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxeleluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) Study.

Journal of the American College of Cardiology 2012;60(24):2473-80.

Raw IF: 14.156 Normalized IF: 10 Pagnotta P, Briguori C, Ferrante G, Visconti G, Focaccio A, Belli G, Presbitero P.

Tornus catheter and rotational atherectomy in resistant chronic total occlusions.

International Journal of Cardiology 2012. Epub ahead of print.

Raw IF: 7.078 Normalized IF: 8 Panico C, Pagnotta P, Mennuni M, Corrada E, Barbaro C, Rossi M, Lisignoli L, Zavalloni V, Parenti D, Belli G, Gasparini G, Presbitero P.

Predictors of mortality in patients undergoing percutaneous aortic valve implantation.

Minerva Cardioangiologica 2012;60(6):561-71.

Raw IF: 0 Normalized IF: 0.1 Rossi ML*, Bocchi R, Barbaro C, Pagnotta P, Mennuni M, Zavalloni D, Gasparini G, Presbitero P.

Successful treatment by transcatheter aortic valve

107

Papers published 2012

implantation of severe aortic regurgitation in a patient with ascending aorta prosthesis.

Heart, Lung & Circulation 2012. Epub ahead of print.

Raw IF: 1.196 Normalized IF: 2 Roversi S, Biondi-Zoccai G, Romagnoli E, Sheiban I, De Servi S, Tamburino C, Colombo A, Burzotta F, Presbitero P, Bolognese L, Paloscia L, Rubino P, Sardella G, Briguori C, Niccoli L, Franco G, Di Girolamo D, Piatti L, Greco C, Petronio S, Loi B, Lioy E, Benassi A, Patti A, Gaspardone A, Capodanno D, Modena MG, Sangiorgi G.

Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients.

International Journal of Cardiology 2012. Epub ahead of print.

Raw IF: 7.078 Normalized IF: 8 Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

(Collaborators: Rossi ML).

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

New England Journal of Medicine 2012;367(22):2089-99.

Raw IF: 53.298 Normalized IF: 3 Zavalloni D, Presbitero P, Lodigiani C, Mango R, Cogliati T, Quaglia I, Corrada E, Mendolicchio GL, Gasparini GL, Rossi ML, Ferrazzi P, Belli G, Pagnotta P, Rota LL*.

Prevalence of inherited thrombophilia in patients with documented stent thrombosis.

Circulation Journal2012;76(8):1874-9.

Raw IF: 3.766 Normalized IF: 6

Hip and Knee Prosthetic Surgery Dagnino A, Grappiolo G, Benazzo FM, Learmonth ID, Portinaro N, Spotorno L.

Medium-term outcome in patients treated with total hip arthroplasty using a modular femoral stem.

Hip International 2012;22(3):274-9.

Raw IF: 0.763

Normalized IF: 2

Massè A, Aprato A, Grappiolo G, Turchetto L, Campacci A, Ganz R.

108

Ricci D, Grappiolo G, Franco M, Della Rocca F.

Case report: osteoid osteoma of the acetabulum treated with arthroscopy-assisted radiofrequency ablation.

Clinical Orthopaedics and Related Research 2013.Epub ahead of print.

Raw IF: 2.533 Normalized IF: 6

Internal Medicine Achenza MI, Meda F, Brunetta E, Selmi C*.

Serum autoantibodies for the diagnosis and management of autoimmune liver diseases.

Expert Review of Gastroenterology & Hepatology 2012;6(6):717-29.

Raw IF: 0 Normalized IF: 0.1 Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, Franke A, Bossa F, Amos CI, Gregersen PK, Siminovitch KA, Cusi D, de Bakker PI, Podda M, Gershwin ME, Seldin MF; Italian PBC Genetics Study Group.

Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis.

Genes and immunity 2012;13(6):461-8.

Raw IF: 3.872 Normalized IF: 6 Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, Deandrade M, Amos CI; The Italian PBC Genetics Study Group, Lazaridis KN, Seldin MF, Siminovitch KA.

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants.

Human Molecular Genetics 2012;21(23):5209-21.

Raw IF: 7.636 Normalized IF: 8 Porta A, Castiglioni P, Rienzo MD, Bari V, Bassani T, Marchi A, Takahashi AC, Tobaldini E, Montano N, Catai AM, Barbic F, Furlan R, Cividjian A, Quintin L.

Surgical hip dislocation for anatomic reorientation of slipped capital femoral epiphysis: preliminary results.

Short-term complexity indexes of heart period and systolic arterial pressure variabilities provide complementary information.

Hip International 2012;22(2):137-44.

Raw IF: 0.763

Journal of Applied Physiology 2012;113(12):1810-20.

Raw IF: 3.753 Normalized IF: 3

Normalized IF: 1

Varchetta S, Brunetta E, Roberto A, Mikulak J, Hudspeth KL, Mondelli MU, Mavilio D*.

Engagement of Siglec-7 receptor induces a proinflammatory response selectively in monocytes.

Plos One 2012. Epub ahead of print.

Raw IF: 4.092

biological history from adenomatous hyperplasia to bronchioalveolar carcinoma to adenocarcinoma: a case report.

Experimental and Therapeutic Medicine 2012;4:1032-4.

Raw IF: 0.206 Normalized IF: 1

Normalized IF: 6 De Luca C, Guglielminetti M, Ferrario A, Calabr M, Casari E*.

Knee Orthopaedics and Sport Traumatology

Candidemia: species involved, virulence factors and antimycotic susceptibility.

The New Microbiologica 2012;35(4):459-68.

Raw IF: 1 Normalized IF: 1

De Girolamo L, Quaglia A, Bait C, Cervellin M, Prospero E, Volpi P*.

Modified autologous matrix-induced chondrogenesis (AMIC) for the treatment of a large osteochondral defect in a varus knee: a case report.

Knee Surgery, Sports traumatology, Arthroscopy 2012;20(11):2287-90.

Raw IF: 2.209 Normalized IF: 6

Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S*.

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.

Inflammatory Bowel Diseases 2012;18(6):1042-47.

Raw IF: 4.855 Normalized IF: 6

Gille J, Behrens P, Volpi P, de Girolamo L, Reiss E, Zoch W, Anders S.

Outcome of Autologous Matrix Induced Chondrogenesis (AMIC) in cartilage knee surgery: data of the AMIC Registry.

Medical Oncology and Haematology

Archives of Orthopaedic and Trauma Surgery 2013;133(1):87-93.

Raw IF: 1.369 Normalized IF: 2

Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC.

Volpi P, Taioli E.

Quality of life in patients with advanced non-smallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

The health profile of professional soccer players: future opportunities for injury prevention.

Journal of Strength and Conditioning Research 2012;26(12):3473-9.

Raw IF: 1.831 Normalized IF: 4

Lancet Oncology 2012;13(3):292-9.

Raw IF: 22.589 Normalized IF: 15 Blaise D, Castagna L.

Laboratory tests Alpini C, Lotzniker M, Valaperta S, Bottone M.G, Malatesta M, Montanelli A, Merlini G.

Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques.

Autoimmunity Highlights2012;3(2):79-85.

Raw IF: 0 Normalized IF: 0.1 Bettio D*, Cariboni U, Venci A, Valente ML, Spaggiari P, Alloisio M.

Cytogenetic findings in lung cancer that illuminate its

Do different conditioning regimens really make a difference?

Hematology. American Society of Hematology Educational Program for the 2012. 2012;237-45.

Raw IF: 0 Normalized IF: 0.1 Bracarda S, Porta C, Boni C, Santoro A, Mucciarini C, Pazzola A, Cortesi E, Gasparro D, Labianca R, Di Costanzo F, Falcone A, Cinquini M, Caserta C, Paglino C, De Angelis V.

Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).

European Urology2013;63(2):254-61.

Raw IF: 8.493 Normalized IF: 8

109

Papers published 2012

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Journal of Hepatology 2012;57(4):821-9.

Raw IF: 9.264 Normalized IF: 8

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma.

Bone Marrow Transplantation 2013;48(2):249-52.

Raw IF: 3.746 Normalized IF: 6

Carbone A, Du MQ, Santoro A, Gloghini A.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Early lesions in lymphomas of germinal centre B-cell derivation: evidence and hypotheses.

Identifying and targeting ROS1 gene fusions in NonSmall Cell Lung Cancer.

Journal of Clinical Pathology 2012;65(10):955-8 Raw IF: 2.306 Normalized IF: 2

Clinical Cancer Research 2012;18(17):4570-9.

Raw IF: 7.742 Normalized IF: 8

Castagna L, Blaise D.

Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, Ivanov V, Schiano JM, Santoro A, Chabannon C, Balzarotti M, Blaise D, Bouabdallah R.

[Advances in haploidentical transplantation in hematological malignancies].

Bulletin du Cancer 2012;99(12):1141-51.

Raw IF: 0.672

Normalized IF: 1

Castagna L, Martino M.

Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?

Bone Marrow Transplantation 2013;48(2):305.

Raw IF: 3.746 Normalized IF: 2 Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Italian Myeloma Network.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Blood2012;120(1):9-19.

Raw IF: 9.898 Normalized IF: 8 Ceresoli GL, Zucali PA.

110

Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, Granata A, Bouabdallah R, Coso D, Chabannon C, Balzarotti M, Santoro A, Blaise D.

Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy.

Haematologica 2012;97(7):1073-9.

Raw IF: 6.424 Normalized IF: 6 Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J.

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.

Annals of Oncology 2012;23(8):2204-5.

Raw IF: 6.425 Normalized IF: 3 Mancosu P*, Navarria P, Castagna L, Roggio A, Pellegrini C, Reggiori G, Fogliata A, Lobefalo F, Castiglioni S, Alongi F, Cozzi L, Santoro A, Scorsetti M.

Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique.

Journal of Applied Clinical Medical Physics 2012;13(1):3653.

Raw IF: 1.291 Normalized IF: 2 Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G, Offidani M, Scortechini I, Moscato T, Fedele R, Milone G, Castagna L, Olivieri A.

Anti-angiogenic therapies for malignant pleural mesothelioma.

Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program.

Expert Opinion on Investigational Drugs 2012;21(6):833-44.

Raw IF: 5.274 Normalized IF: 6

Expert Opinion on Biological Therapy2012;12(11):1449-62.

Raw IF: 3.505 Normalized IF: 3

Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C, Liberati AM, Zamagni C, Musso M, Aglietta M, Schiavo R, Castagna L, Rosti G, Bruno B, Pedrazzoli P.

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.

Bone Marrow Transplantation 2012. Epub ahead of print.

Raw IF: 3.746 Normalized IF: 6 Martino M, Bottini A, Rosti G, Generali D, Secondino S, Barni S, Maisano R, Lanza F, Castagna L, Pedrazzoli P.

Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.

Expert Opinion on Biological Therapy2012;12(11):1505-5.

Raw IF: 3.505 Normalized IF: 3 Masci G*, Losurdo A, Gandini C, Garassino I, di Tommaso L, Torrisi R, Zuradelli M, Santoro A.

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit.

Ecancermedicalscience 2012;6:275.

Raw IF: 0

Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A.

Phase III, randomized, double-blind, placebo-controlled trial of Gemcitabine/Cisplatin alone or with Sorafenib for first-line treatment of advanced, Non-Squamous Non-Small Cell Lung Cancer.

Journal of Clinical Oncology 2012;30(25):3084-92.

Raw IF: 18.372 Normalized IF: 15 Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Journal of Hepatology 2012;57(7):101-7.

Raw IF: 9.264 Normalized IF: 8 Personeni N*, Rimassa L, Santoro A.

Biomarkers in hepatocellular carcinoma – letter.

Clinical Cancer Research2012;18(17):4861 Raw IF: 7.742 Normalized IF: 4

Normalized IF: 0.1

Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R.

Randomized phase II study of Danusertib (formerly PHA739358) in patients with metastatic Castration Resistant Prostate Cancer (CRPC) after docetaxel failure.

British Journal of Urology International 2013;111(1):44-52.

Raw IF: 2.844 Normalized IF: 6 Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, Laghi L, Roncalli M*.

Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.

Cancer 2013;119(2):266-76.

Raw IF: 4.771 Normalized IF: 6 Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga P, Di Bona E, Todisco E, Musto P, Spadea A, D’Arco A, Pileri S, Leone G, Amadori S, Facchetti F.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Haematologica 2013;98(2):239-46.

Raw IF: 6.424 Normalized IF: 6

Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A.

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-ofconcept study.

Breast Cancer Research and Treatment 2012;134(1):283-9.

Raw IF: 4.431 Normalized IF: 3 Petrini P, French CA, Rajan A, Cameron MJ, Jaffe ES, Zucali PA, Xie J, Wang Y, Giaccone G.

NUT rearrangement is uncommon in human thymic epithelial tumors.

Journal of Thoracic Oncology 2012;7(4):744-50.

Raw IF: 3.661 Normalized IF: 3 Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM, Wang Y, Giaccone G.

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Cell death & disease 2012;19(3):e351.

Raw IF: 5.333 Normalized IF: 6

111

Papers published 2012

Pressiani T, Boni C, Rimassa L*, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Annals of Oncology 2013;24(2):406-11.

Raw IF: 6.425 Normalized IF: 6 Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, Benedetti F, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, Carobbio A, Sacchi N, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo, GITMO.

Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high risk patients.

Leukemia 2012;26(8):1779-85.

Raw IF: 9.561 Normalized IF: 4 Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E.

Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.

Annals of Surgical Oncology 2012;19:2256-63.

Raw IF: 4.166 Normalized IF: 3 Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study.

Annals of Hematology 2012;91(6):931-9.

Raw IF: 2.615 Normalized IF: 4 Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D’Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E.

112

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s

lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

Annals of Hematology 2012;91(7):1013-22.

Raw IF: 2.615 Normalized IF: 4 Santoro A*, Comandone A, Basso U, Soto Parra H, De Sanctis R, Stroppa E, Marcon I, Giordano L, Lutman FR, Boglione A, Bertuzzi A.

Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.

Annals of Oncology 2012. Epub ahead of print.

Raw IF: 6.425 Normalized IF: 6 Santoro A, Rimassa L*, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C.

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebocontrolled phase 2 study.

Lancet Oncology 2013;14(1):55-63.

Raw IF: 22.589 Normalized IF: 15 Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J.

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.

British Journal of Cancer 2013;108(1):21-4.

Raw IF: 5.042 Normalized IF: 6 Scarfò L, Zibellini S, Tedeschi A, Maura F, Neri A, Bertazzoni P, Sarina B, Nalli G, Motta M, Rossini F, Cortelezzi A, Montillo M, Orlandi E, Ghia P.

Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?

Leukemia 2012;26(7):1703-7.

Raw IF: 9.561 Normalized IF: 4 Sclafani F*, Incarbone M, Rimassa L, Personeni N, Giordano L, Alloisio M, Santoro A.

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.

Journal of Thoracic and Cardiovascular Surgery 2013;145(1):97103.

Raw IF: 3.406 Normalized IF: 6

Scorsetti M, Alongi F*, Clerici E, Navarria P, Simonelli M, Rognone E, Santoro A.

Tancioni F*, Navarria P, Pessina F, Attuati L, Mancosu P, Alloisio M, Scorsetti M, Santoro A, Baena RR.

Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.

Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.

Tumori 2012;98(3):67e-71e.

Raw IF: 0.606

European Spine Journal 2012;S1:s146-8.

Raw IF: 1.965 Normalized IF: 2

Normalized IF: 1

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne CA, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C*.

Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Tronconi MC, Sclafani F, Rimassa L, Carnaghi C, Personeni N, Santoro A.

Reply to Y. Pointreau et al.

Journal of Clinical Oncology 2012;30(3):335.

Raw IF: 18.372 Normalized IF: 7.5 Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R.

Radiat Oncol 2012; 28(7):145.

Raw IF: 2.321 Normalized IF: 4

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

Simonelli M*, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Haematologica 2012;97(3):416-22.

Raw IF: 6.424 Normalized IF: 3

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Niamo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.

European Journal of Cancer 2012. Epub ahead of print.

Raw IF: 5.536 Normalized IF: 6 Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U.

Modulated chemotherapy according to modified comprehensive geriatric Assessment in 100 consecutive elderly patients with diffuse Large B-Cell Lymphoma.

Oncologist 2012;17(6):838-46.

Raw IF: 3.91 Normalized IF: 6

Phase I and pharmacodynamic study of high-dose NGRhTNF in patients with refractory solid tumours. British Journal of Cancer2013;108(1):58-63.

Raw IF: 5.042

Normalized IF: 6

Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G.

Reproducibility of the WHO classification of thymomas: practical implications.

Lung Cancer2013;79(3):236-41 Raw IF: 3.434 Normalized IF: 6

Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG.

Phase II study of imatinib in advanced chordoma.

Journal of Clinical Oncology 2012;30(9):914-20.

Raw IF: 18.372 Normalized IF: 7.5

113

Papers published 2012

Nephrology and Dialysis Graziani G*, Cucchiari D, Aroldi A, Angelini C, Gaetani P, Selmi C.

Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.

Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(5):510-2.

Raw IF: 4.764 Normalized IF: 6 Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C*.

Renal function in patients with β-thalassaemia major: a long-term follow-up study.

Nephrology, Dialysis, Transplantation2012;27(9):3547-51.

Raw IF: 3.396 Normalized IF: 4 Ponticelli C.

Tonsillectomy and IgA nephritis.

Magnani G, Fallani F, Coccolo F, Russo A, Ponticelli C, Rapezzi C, Grigioni F, Branzi A.

Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study.

The Journal of Heart and Lung Transplantation 2012;31(6):565-70.

Raw IF: 4.332 Normalized IF: 3

Neurologic Rehabilitation Bellelli G, Bernardini B, Pievani M, Frisoni GB, Guaita A, Trabucchi M.

A score to predict the development of adverse clinical events after transition from acute hospital wards to post-acute care settings.

Rejuvenation Research 2012;15(6):553-63.

Raw IF: 3.826 Normalized IF: 6

Nephrology, Dialysis, Transplantation2012;27(7):2610-3.

Raw IF: 3.396 Normalized IF: 4

Neurology Ponticelli C*, Graziani G.

Proteinuria after kidney transplantation.

Lunn MP, Nobile-Orazio E.

Transplant International2012;25(9):909-17.

Raw IF: 2.921 Normalized IF: 6

Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Ponticelli C, Graziani G.

Cochrane Database of Systematic Reviews 2012;5:CD002827.

Raw IF: 5.912 Normalized IF: 6

Education and counseling of renal transplant recipients.

Journal of Nephrology 2012;25(6):879-89.

Raw IF: 1.654 Normalized IF: 2

Mazzeo A, Stancanelli C, Russo M, Granata F, Gentile L, Di Leo R, Vita G, Nobile-Orazio E, Toscano A.

Ponticelli C, Glassock RJ.

Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A.

De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?

Transplant international2012;25(12):1205-10.

Raw IF: 2.921 Normalized IF: 6 Ponticelli C*.

What is the role of rituximab in idiopathic membranous nephropathy?

114

Muscle & Nerve 2012;45(3):451-2.

Raw IF: 2.367 Normalized IF: 2 Nobile-Orazio E*, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M; IMC Trial Group.

Expert Review of Clinical Immunology 2013;9(1):13-6.

Raw IF: 2.072 Normalized IF: 2

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Potena L, Prestinenzi P, Bianchi IG, Masetti M, Romani P,

Lancet Neurology 2012;11(6):493-502.

Raw IF: 23.462 Normalized IF: 15

Padua L, Briani C, Truini A, Aprile I, Bouhassirà D, Cruccu G, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A, Mondelli M, Ciaramitaro P, Cavaletti G, Cocito D, Fazio R, Santoro L, Galeotti F, Carpo M, Plasmati R, Benedetti L, Schenone A.

Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain.

Neurological Sciences 2012. Epub ahead of print.

Raw IF: 1.315 Normalized IF: 2

Gaetani P, Revay M, Sciacca S, Pessina F, Aimar E, Levi D, Morenghi E.

Traumatic brain injury in the elderly: considerations in a series of 103 patients older than 70.

Journal of Neurosurgical Sciences 2012;56(3):231-7.

Raw IF: 0.4 Normalized IF: 1

Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM.

Ortensi B, Osti D, Pellegatta S, Pisati F, Brescia P, Fornasari L, Levi D, Gaetani P, Colombo P, Ferri A, Nicolis S, Finocchiaro G, Pelicci G.

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy.

Rai is a new regulator of neural progenitor migration and glioblastoma invasion.

Cochrane Database of Systematic Reviews 2012;4:CD003217.

Raw IF: 5.912 Normalized IF: 6

Stem Cells 2012;30(5):817-32.

Raw IF: 7.781 Normalized IF: 8

Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS; PeriNomS Study Group.

Papagno C, Casarotti A, Comi A, Gallucci M, Riva M, Bello L.

Modifying the Medical Research Council grading system through Rasch analyses.

Brain2012;135(pt5):1639-49.

Raw IF: 9.457 Normalized IF: 1.8

Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG).

Journal of Neurooncology 2012;108(2):269-75.

Raw IF: 3.214 Normalized IF: 4 Rudà R, Bello L, Duffau H, Soffietti R.

Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Neuro Oncology 2012;S4:55-64.

Raw IF: 5.723 Normalized IF: 6

Neurosurgery Costa F*, Cardia A, Ortolina A, Fabio G, Zerbi A, Fornari M.

Spinal navigation: standard preoperative versus intraoperative computed tomography data set acquisition for computer-guidance system: radiological and clinical study in 100 consecutive patients.

Spine2011;36(24):2094-8.

Raw IF: 2.078

Normalized IF: 4

De Lorenzo D, De Momi E, Conti L, Votta E, Riva M, Fava E, Bello L, Ferrigno G.

Intraoperative forces and moments analysis on patient head clamp during awake brain surgery.

Medical & Biological Engineering & Computing 2012. Epub ahead of print.

Raw IF: 1.878 Normalized IF: 2

Tancioni F*, Navarria P, Pessina F, Attuati L, Mancosu P, Alloisio M, Scorsetti M, Santoro A, Baena RR.

Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.

European Spine Journal 2012;S1:s146-8.

Raw IF: 1.965 Normalized IF: 2 Van de Kelft E, Costa F, Van der Planken D, Schils F.

A prospective multicenter registry on the accuracy of pedicle screw placement in the thoracic, lumbar, and sacral levels with the use of the O-arm imaging system and StealthStation Navigation.

Spine2012;37(25):E1580-7.

Raw IF: 2.078

Normalized IF: 4

115

Papers published 2012

Nuclear Medicine Antunovic L, Franklin-Bezerra B, Rodari M, Pepe G, Chiti A.

(99m)Tc-DTPA uptake in clear-cell renal carcinoma metastases.

Revista Española de Medicina Nuclear e Imagen Molecular 2012;31(3):169-70.

Raw IF: 0 Normalized IF: 0.1 Antunovic L*, Cimitan M, Borsatti E, Baresic T, Sorio R, Giorda G, Steffan A, Balestreri L, Tatta R, Pepe G, Rubello D, Cecchin D, Canzonieri V.

Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.

Clinical Nuclear Medicine 2012;37(7):e184-8.

Raw IF: 3.674 Normalized IF: 6 Chiti A.

Shaping our future.

European Journal of Nuclear Medicine and Molecular Imaging2012;39(9):1371-72.

Raw IF: 4.991 Normalized IF: 6 Delbeke D, Chiti A, Christian P, Darcourt J, Donohoe K, Flotats A, Krause BJ, Royal HD.

SNMMI/EANM guideline for guideline development 6.0.

Journal of Nuclear Medicine Technology 2012;40(4):283-90.

Raw IF: 0 Normalized IF: 0.1 Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, Ivanov V, Schiano JM, Santoro A, Chabannon C, Balzarotti M, Blaise D, Bouabdallah R.

Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy.

Haematologica 2012;97(7):1073-9.

Raw IF: 6.424 Normalized IF: 6 Lopci E*, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, Cistaro A, Chiti A, Villavecchia G, Fanti S

18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. 116

Clinical Nuclear Medicine 2012;37(4):e73-8.

Raw IF: 3.674 Normalized IF: 3

Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, Fanti S.

FDG PET/CT predictive role in follicular lymphoma.

European Journal of Nuclear Medicine and Molecular Imaging 2012;39(5):864-71.

Raw IF: 4.991 Normalized IF: 3 Lopci E, D’Ambrosio D, Nanni C, Chiti A, Pession A, Marengo M, Fanti S.

Feasibility of carbidopa premedication in pediatric patients: a pilot study.

Cancer Biotherapy & Radiopharmaceuticals 2012;27(10):729-33.

Raw IF: 1.787 Normalized IF: 1 Lopci E, Fanti S.

Molecular imaging in oncology.

Recent Results in Cancer Research 2013;187:371-400.

Raw IF: 0 Normalized IF: 0.1 Pepe G, Moncayo R, Bombardieri E, Chiti A*.

Somatostatin receptor SPECT. European Journal of Nuclear Medicine and Molecular Imaging2012;39(s1):41-51.

Raw IF: 4.991 Normalized IF: 6 Pepe G, Chiti A.

Reply to comment on Pepe et al.: Somatostatin receptor SPECT. European Journal of Nuclear Medicine and Molecular Imaging2013;40(2):302.

Raw IF: 4.991 Normalized IF: 0 Rodari M, Lopci E, Pepe G, Antunovic L, Chiti A.

[11C]-choline PET/CT in imaging locally advanced prostate cancer.

Nuclear Medicine Review. Central & Eastern Europe 2011;14(2):118-9.

Raw IF: 0 Normalized IF: 0.1 Savolainen S, Konijnenberg M, Bardiès M, Lassmann M, Strigari L, Chiesa C, Chiti A, Reijonin V, Flux G.

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.

European Journal of Nuclear Medicine and Molecular Imaging2012;39(3):548-9.

Raw IF: 4.991 Normalized IF: 3

Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR, Chiti A, Al-Nahhas A, Pacak K, Rubello D.

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

European Journal of Nuclear Medicine and Molecular Imaging2012;39(12):1977-95.

Raw IF: 4.991 Normalized IF: 3

Romano MR*, Vallejo-Garcia JL, Camesasca FI, Vinciguerra P, Costagliola C

Vitreo-papillary adhesion as a prognostic factor in pseudo- and lamellar macular holes.

Eye 2012;26(6):810-5.

Raw IF: 1.851 Normalized IF: 4 Romano MR*, Vallejo-Garcia JL, Parmeggiani F, Vito R, Vinciguerra P.

Testori A, Meroni S, Moscovici OC, Magnoni P, Malerba P, Chiti A, Rahal D, Travaglini R, Cariboni U, Alloisio M, Orefice S.

Interaction between perfluorcarbon liquid and heavy silicone oil: risk factor for “sticky oil” formation.

Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Current Eye Research 2012;37(7):563-6.

Raw IF: 1.28 Normalized IF: 2

Medical Science Monitor2012;18(9):CR543-9.

Raw IF: 0 Normalized IF: 0.1

Romano MR, Zenoni S, Arpa P, Mariotti C.

Mixture of ether and silicone oil for the treatment of inferior complicated retinal detachment.

European Journal of Ophthalmology 2013;43(3):230-5.

Raw IF: 0.956 Normalized IF: 2

Ophthalmology Porta A, Castiglioni P, Rienzo MD, Bari V, Bassani T, Marchi A, Takahashi AC, Tobaldini E, Montano N, Catai AM, Barbic F, Furlan R, Cividjian A, Quintin L.

Short-term complexity indexes of heart period and systolic arterial pressure variabilities provide complementary information.

Rosetta P, Vinciguerra R, Romano MR, Vinciguerra P*.

Corneal collagen cross-linking window absorption.

Cornea 2013;32(4):550-4.

Raw IF: 1.733 Normalized IF: 4 Vallejo-Garcia JL, Asencio-Duran M, Pastora-Salvador N, Vinciguerra P, Romano MR.

Journal of Applied Physiology 2012;113(12):1810-20.

Raw IF: 3.753 Normalized IF: 3

Role of inflammation in endophthalmitis.

Romano MR*, Vallejo-Garcia JL, Randazzo A, Vinciguerra P.

Mediators of Inflammation 2012;2012:196094.

Raw IF: 3.263 Normalized IF: 4

Pneumatic tools for vitreoretinal surgery.

Clinical Pphthalmology2012;6:385-7.

Raw IF: 0

Normalized IF: 0.1

Romano M., Pastora Salvador N., Vallejo Garcia J.

Comment on: Heavy silicone oil removal without a suction pump: a surgical technique.

Retina. The Journal of Retinal and Vitreous Diseases 2012;32(4):863.

Raw IF: 2.812 Normalized IF: 3 Romano MR, Vinciguerra R, Randazzo A, Vinciguerra P.

Management of cyclodialysis cleft associated to hypotonic maculopathy.

Graefe’s archive for clinical and experimental ophthalmology 2012. Epub ahead of print.

Raw IF: 2.17 Normalized IF: 2

Vinciguerra P, Albé E*, Frueh BE, Trazza S, Epstein D.

Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus.

American Journal of Ophthalmology 2012;154(3):520-6.

Raw IF: 4.223 Normalized IF: 6

Orthopaedic Rehabilitation Castagna A, Delle Rose G, Borroni M*, De Cillis B, Conti M, Garofalo R, Ferguson D, Portinaro N.

Arthroscopic stabilization of the shoulder in adolescent athletes participating in overhead or contact sports.

Arthroscopy : the Journal of Arthroscopic & Related Surgery 2012;28(3):309-15.

Raw IF: 3.024 Normalized IF: 6

117

Papers published 2012

Delle Rose G*, Borroni M, Silvestro A, Garofalo R, Conti M, De Nittis P, Castagna A.

Sansone V, D’ Agostino MC, Bonora C, Sizzano F, De Girolamo L, Romeo P.

The long head of biceps as a source of pain in active population: tenotomy or tenodesis? A comparison of 2 case series with isolated lesions.

Early angiogenic response to shock waves in a threedimensional model of human microvascular endothelial cell culture (HMEC-1).

Musculoskeletal Surgery2012;96(s1):47-52.

Raw IF: 0 Normalized IF: 0.1

Journal of Biological Regulators and Homeostatic Agents.

2012;26(1):29-37.

Raw IF: 5.183 Normalized IF: 6

Dierickx C, Ceccarelli E, Conti M, Vanlommel J, Castagna A.

Regarding “Aberrant origin of the long head of the biceps: a case series”.

Journal of Shoulder and Elbow Surgery 2012;21(12):e20-2.

Raw IF: 2.747 Normalized IF: 3 Lucini D*, Palombo C, Malacarne M, Pagani M.

Relationship between carotid artery mechanics and the spontaneous baroreflex: a noninvasive investigation in normal humans.

Journal of Hypertension 2012;30(9):1809-16.

Raw IF: 4.021 Normalized IF: 6

Otorhinolaryngology Poletti AM*, Dubey SP, Barbò R, Pericotti S, Fiamengo B, Colombo G, Scorsetti M, Lorusso R, Mazzoni A.

Sporadic endolymphatic sac tumor: its clinical, radiological, and histological features, management, and follow-up.

Head and Neck 2012. Epub ahead of print.

Raw IF: 2.403 Normalized IF: 6

Lucini D*, Zuccotti GV, Scaramuzza A, Malacarne M, Gervasi F, Pagani M.

Exercise might improve cardiovascular autonomic regulation in adolescents with type 1 diabetes.

Acta Diabetologica 2012.Epub ahead of print.

Raw IF: 2.784 Normalized IF: 4 Lucini D*, de Giacomi G, Tosi F, Malacarne M, Respizzi S, Pagani M.

Altered cardiovascular autonomic regulation in overweight children engaged in regular physical activity.

Heart2012. Epub ahead of print.

Raw IF: 4.223 Normalized IF: 6 Noale M, Maggi S, Gonnelli S, Limongi F, Zanoni S, Zambon S, Rozzini R, Crepaldi G; ESOPO Study Working Group.

(Collaborators: Respizzi S.).

Quantitative ultrasound criteria for risk stratification in clinical practice: a comparative assessment.

Ultrasound in Medicine & Biology 2012;38(7):1138-44.

Raw IF: 2.293 Normalized IF: 1.2

118

pathology Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S.

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma.

Liver International2012;32(5):772-82.

Raw IF: 3.824 Normalized IF: 6 Bettio D*, Cariboni U, Venci A, Valente M.L, Spaggiari P, Alloisio M.

Cytogenetic findings in lung cancer that illuminate its biological history from adenomatous hyperplasia to bronchioalveolar carcinoma to adenocarcinoma: a case report.

Experimental and Therapeutical Medicine 2012;4:1032-4.

Raw IF: 0.206 Normalized IF: 1

Pagani M, Lucini D, Porta A.

Cappuzzo F, Cho YG, Sacconi A, Alì G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M.

Sympathovagal balance from heart rate variability: time for a second round?

p95HER2 truncated form in resected Non-small Cell Lung Cancer.

Experimental Physiology2012;97(10):1141-2.

Raw IF: 3.211 Normalized IF: 2

Journal of Thoracic Oncology 2012;7(3):520-7.

Raw IF: 3.661 Normalized IF: 3

Cimino M, Mussi C, Colombo P, Lutman F, Quagliuolo V*.

Leiomyosarcoma arising from the inferior mesenteric vein draining in the splenomesenteric angle with a tumour thrombus at the splenomesenteric confluence: a case report and review of the literature.

Updates in Surgery 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Identifying and targeting ROS1 gene fusions in NonSmall Cell Lung Cancer.

Laghi L, Beghelli S, Spinelli A, Bianchi P, Basso G, Di Caro G, Brecht A, Celesti G, Turri G, Bersani S, Schumacher G, Rocken C, Grantzdorffer I, Roncalli M, Zerbi A, Neuhaus P, Bassi C, Montorsi M, Scarpa A, Malesci A*.

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

Plos One 2012;7(9):e46002.

Raw IF: 4.092

Normalized IF: 6

Masci G*, Losurdo A, Gandini C, Garassino I, di Tommaso L, Torrisi R, Zuradelli M, Santoro A.

Clinical Cancer Research 2012;18(17):4570-9.

Raw IF: 7.742 Normalized IF: 8

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit.

Di Tommaso L*, Roncalli M.

Ecancermedicalscience 2012;6:275.

Raw IF: 0

The “farmer” pathologist: a midsummer night’s dream.

Human Pathology;2012:43(4):615-6.

Raw IF: 2.876 Normalized IF: 3 Di Tommaso L, Chiesa G, Arena V, Guanella G, Galli C, Roncalli M*.

Cardiac hibernoma: a case report.

Histopathology 2012;61(5):985-7.

Raw IF: 3.082

Normalized IF: 2

Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, Marra F, Mantero S, Roncalli M, Invernizzi P, Pinzani M.

Role of the Stromal-derived factor-1 (SDF-1) - CXCR4 axis in the Interaction between hepatic stellate cells and cholangiocarcinoma.

Journal of Hepatology 2012;57(4):813-20.

Raw IF: 9.264 Normalized IF: 8 Iavarone M, Manini MA, Sangiovanni A, Fraquelli M, Forzenigo LV, Di Tommaso L, Aghemo A, Roncalli M, Ronchi G, Colombo M.

Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis.

Digestive and Liver Disease 2013;45(1):43-9.

Raw IF: 3.054 Normalized IF: 2

Normalized IF: 0.1

Meroni S, Moscovici OC, Rahal D, Malerba P, Balzarini L, Tinterri C.

Synchronous bilateral primary breast lymphoma.

The Breast Journal2012;18(4):378-9.

Raw IF: 1.643 Normalized IF: 4 Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, Laghi L, Roncalli M*.

Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.

Cancer 2013;119(2):266-76.

Raw IF: 4.771 Normalized IF: 6 Ortensi B, Osti D, Pellegatta S, Pisati F, Brescia P, Fornasari L, Levi D, Gaetani P, Colombo P, Ferri A, Nicolis S, Finocchiaro G, Pelicci G.

Rai is a new regulator of neural progenitor migration and glioblastoma invasion.

Stem Cells 2012;30(5):817-32.

Raw IF: 7.781 Normalized IF: 8

Klinger M, Caviggioli F, Klinger F, Villani F, Arra E, Di Tommaso L.

Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM, Wang Y, Giaccone G.

Tuberous breast: morphological study and overview of a borderline entity.

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

The Canadian Journal of Plastic Surgery 2011;12(2):42-4.

Raw IF: 0.179 Normalized IF: 1

Cell death & disease 2012;19(3):e351.

Raw IF: 5.333 Normalized IF: 6

119

Papers published 2012

Poletti AM*, Dubey SP, Barbò R, Pericotti S, Fiamengo B, Colombo G, Scorsetti M, Lorusso R, Mazzoni A.

Taverna G*, Benecchi L, Grizzi F, Seveso M, Giusti G, Piccinelli A, Benetti A, Colombo P, Minuti F, Graziotti P.

Sporadic endolymphatic sac tumor: its clinical, radiological, and histological features, management, and follow-up.

Can a Gleason 6 or less microfocus of prostate cancer in one biopsy and prostate-specific antigen level <10â&#x20AC;&#x2030;ng/ mL be Defined as the archetype of low-risk prostate disease?

Head and Neck 2012. Epub ahead of print.

Raw IF: 2.403 Normalized IF: 6 Raffa GM*, Malvindi PG, Settepani F, Melotti F, Monti L, Spaggiari P, Basciu A, Cappai A, Citterio E, Tarelli G.

Hamartoma of mature cardiac myocytes in adults and young: case report and literature review.

International journal of cardiology 2013;163(2):e28-30.

Raw IF: 7.078 Normalized IF: 4 Repici A*, Pagano N, Hassan C, Cavenati S, Rando G, Spaggiari P, Sharma P, Zullo A.

Endoscopic submucosal dissection of gastric neoplastic lesions in patients with liver cirrhosis: a systematic review.

Journal of Gastrointestinal and Liver Diseases 2012;21(3):303-7.

Raw IF: 1.811 Normalized IF: 2

Journal of Oncology 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1 Testori A, Meroni S, Moscovici OC, Magnoni P, Malerba P, Chiti A, Rahal D, Travaglini R, Cariboni U, Alloisio M, Orefice S.

Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Medical Science Monitor2012;18(9):CR543-9.

Raw IF: 0 Normalized IF: 0.1 Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G.

Reproducibility of the WHO classification of thymomas: practical implications.

Lung Cancer2013;79(3):236-41 Raw IF: 3.434 Normalized IF: 6

Repici A*, Hassan C, Pagano N, Rando G, Romeo F, Spaggiari P, Roncalli M, Ferrara E, Malesci A.

High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm.

Gastrointestinal Endoscopy 2013;77(1):96-101.

Raw IF: 4.923 Normalized IF: 6 Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, Ahn EY, Kim GI, Choi JS, Kim YB, Park YN.

A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and EMT. Hepatology 2012;55(6):1776-86.

Raw IF: 11.665 Normalized IF: 4 Simonelli M*, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

120

European Journal of Cancer 2012. Epub ahead of print.

Raw IF: 5.536 Normalized IF: 6

Plastic Surgery Caviggioli F, Forcellini D, Vinci V, Cornegliani G, Klinger F, Klinger M*.

Employment of needles: a different technique for fat placement.

Plastic and Reconstructive Surgery 2012;130(2):373e-4e.

Raw IF: 3.382 Normalized IF: 6 Caviggioli F, Vinci V, Maione L, Lisa A, Klinger M.

Autologous fat grafting in secondary breast reconstruction.

Annals of Plastic Surgery2013;70(1):119.

Raw IF: 1.318

Normalized IF: 0

Gaetani P, Klinger M, Levi D, Bussone G, Giannasi S, Caviggioli F, Marazzi M, Broggi G.

Treatment of chronic headache of cervical origin with lipostructure: an observational study.

Headache 2012. Epub ahead of print.

Raw IF: 2.524 Normalized IF: 4

Klinger FM, Caviggioli F, Forcellini D, Vinci V, Maione L, Pajardi G, Klinger M.

Breast fistula repair after autologous fat graft: a case report.

Case Reports in Medicine 2011;2011:547387.

Raw IF: 0 Normalized IF: 0.1 Klinger M, Caviggioli F, Klinger F, Villani F, Arra E, Di Tommaso L.

Tuberous breast: morphological study and overview of a borderline entity.

The Canadian Journal of Plastic Surgery 2011;12(2):42-4.

Raw IF: 0.179 Normalized IF: 1 Orlando S, Cornalba G, Brambilla G, Pedicini V, Poretti D, Bordoni MG, Vercellio G.

Alongi F*, Fogliata A, Clerici E, Navarria P, Tozzi A, Comito T, Ascolese AM, Clivio A, Lobefalo F, Reggiori G, Cozzi L, Mancosu P, Tomatis S, Scorsetti M.

Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients.

Radiation Oncology 2012;7(1):204.

Raw IF: 2.321 Normalized IF: 4 Arcangeli S, Scorsetti M, Alongi F.

Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review.

Critical Reviews in Oncology/Hematology 2012;84(1):101-8.

Raw IF: 4.411 Normalized IF: 6

Diagnostic-therapeutic paths and socio-economical remarks in a group of 35 patients affected by arteriovenous malformations.

Ceresoli GL, Ricardi U, Vavassori V, Scorsetti M.

Italian Journal of Vascular and Endovascular Surgery 2012;19(1):41-9.

Raw IF: 0.028 Normalized IF: 1

Radiotherapy and Oncology 2012;105(2):271.

Raw IF: 5.58 Normalized IF: 3

Radiotherapy and Radiosurgery Alongi F, Scorsetti M.

Reirradiation: hopes and concerns of the radiation oncologist. Reply.

Tumori 2012;98(1):172-3 Raw IF: 0.606

Normalized IF: 0.5

Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M.

Adjuvant radiotherapy for malignant pleural mesothelioma: challenges and pitfalls.

Fogliata A, Scorsetti M, Navarria P, Catalano M, Clivio A, Cozzi L, Lobefalo F, Nicolini G, Palumbo V, Pellegrini C, Reggiori G, Roggio A, Vanetti E, Alongi F, Pentimalli S, Mancosu P.

Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy.

Acta Oncologica 2012. Epub ahead of print.

Raw IF: 3.33 Normalized IF: 4 Mancosu P*, Navarria P, Castagna L, Roggio A, Pellegrini C, Reggiori G, Fogliata A, Lobefalo F, Castiglioni S, Alongi F, Cozzi L, Santoro A, Scorsetti M.

Review and uses of stereotactic body radiation therapy for oligometastases.

Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique.

Oncologist 2012;17(8):1100-7.

Raw IF: 3.91 Normalized IF: 6

Journal of Applied Clinical Medical Physics 2012;13(1):3653.

Raw IF: 1.291 Normalized IF: 2

Alongi F*, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F, Reggiori G, Clivio A, Cozzi L, Scorsetti M.

Mancosu P*, Castiglioni S, Reggiori G, Catalano M, Alongi F, Pellegrini C, Arcangeli S, Tozzi A, Lobefalo F, Fogliata A, Navarria P, Cozzi L, Scorsetti M.

Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer: report of feasibility and acute toxicity.

Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations.

Strahlentherapie und Onkologie 2012;188(11):990-6.

Raw IF: 3.561 Normalized IF: 6

Radiation Oncology 2012;7(1):16.

Raw IF: 2.321 Normalized IF: 2

121

Papers published 2012

Poletti AM*, Dubey SP, Barbò R, Pericotti S, Fiamengo B, Colombo G, Scorsetti M, Lorusso R, Mazzoni A.

A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C*.

Sporadic endolymphatic sac tumor: its clinical, radiological, and histological features, management, and follow-up.

Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Head and Neck 2012. Epub ahead of print.

Raw IF: 2.403 Normalized IF: 6 Reggiori G, Mancosu P, Castiglioni S, Alongi F, Pellegrini C, Lobefalo F, Catalano M, Fogliata A, Arcangeli S, Navarria P, Cozzi L, Scorsetti M.

Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis.

Medical Physics 2012;39(2):1112.

Raw IF: 2.83 Normalized IF: 4

Radiat Oncol 2012; 28(7):145.

Raw IF: 2.321 Normalized IF: 4 Tancioni F*, Navarria P, Pessina F, Attuati L, Mancosu P, Alloisio M, Scorsetti M, Santoro A, Baena RR.

Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.

European Spine Journal 2012;S1:s146-8.

Raw IF: 1.965 Normalized IF: 2

Scorsetti M, Alongi F*, Navarria P, Cortinovis D, Bidoli P.

Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis.

Tumori 2012;98(2):31E-4E. Raw IF: 0.606

Normalized IF: 1

Scorsetti M, Alongi F*, Filippi AR, Pentimalli S, Navarria P, Clerici E, Castiglioni S, Tozzi A, Reggiori G, Mancosu P, Ricardi U.

Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients.

Acta Oncologica 2012;51(5):618-23.

Raw IF: 3.33 Normalized IF: 4

Rheumatology De Socio GV, Fabbriciani G, Massarotti M, Messina S, Cecchini E, Marasini B.

Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required.

Mediterranean Journal of Hematology and Infectious Diseases 2012;4(1):e2012-025.

Raw IF: 0 Normalized IF: 0.1 Marasini B, Massarotti M*.

Scorsetti M, Alongi F*, Clerici E, Navarria P, Simonelli M, Rognone E, Santoro A.

Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.

Tumori 2012;98(3):67e-71e.

Raw IF: 0.606

122

Normalized IF: 1

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne CA, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona

Statins and cardiovascular risk in rheumatic diseases.

International Journal of Immunopathology and Pharmacology 2012;25(1):25-30.

Raw IF: 2.991 Normalized IF: 4 Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, MĂźller-Ladner U; EUSTAR Co-authors.

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Annals of the Rheumatic Diseases 2012;71(8):1355-60.

Raw IF: 8.727 Normalized IF: 1.6

Shoulder and Elbow Surgery

Thoracic Surgery

Castagna A, Delle Rose G, Borroni M*, De Cillis B, Conti M, Garofalo R, Ferguson D, Portinaro N.

Bettio D*, Cariboni U, Venci A, Valente ML, Spaggiari P, Alloisio M.

Arthroscopic stabilization of the shoulder in adolescent athletes participating in overhead or contact sports.

Cytogenetic findings in lung cancer that illuminate its biological history from adenomatous hyperplasia to bronchioalveolar carcinoma to adenocarcinoma: a case report.

Arthroscopy : the Journal of Arthroscopic & Related Surgery 2012;28(3):309-15.

Raw IF: 3.024 Normalized IF: 6

Experimental and Therapeutic Medicine 2012;4:1032-4.

Raw IF: 0.206 Normalized IF: 1

Castagna A.

Editorial. The fifth monographic issue of Musculoskeletal Surgery edited by the Italian Society of Shoulder and Elbow Surgery exhibits a further progress in contents and in quality.

Musculoskeletal Surgery2012;96(s1):1-2.

Raw IF: 0 Normalized IF: 0.1 De Biase CF, Delcogliano M, Borroni M, Castagna A.

Reverse total shoulder arthroplasty: radiological and clinical result using an eccentric glenosphere.

Musculoskeletal Surgery2012;96(S1):S27-34.

Raw IF: 0 Normalized IF: 0.1 Delle Rose G*, Borroni M, Silvestro A, Garofalo R, Conti M, De Nittis P, Castagna A.

The long head of biceps as a source of pain in active population: tenotomy or tenodesis? A comparison of 2 case series with isolated lesions.

Musculoskeletal Surgery2012;96(s1):47-52.

Raw IF: 0 Normalized IF: 0.1 Dierickx C, Ceccarelli E, Conti M, Vanlommel J, Castagna A. Regarding â&#x20AC;&#x153;Aberrant origin of the long head of the biceps: a case seriesâ&#x20AC;?.

Journal of Shoulder and Elbow Surgery 2012;21(12):e20-2.

Raw IF: 2.747 Normalized IF: 3 Postacchini R, Castagna A, Borroni M, Cinotti G, Postacchini F, Gumina S.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.

Identifying and targeting ROS1 gene fusions in NonSmall Cell Lung Cancer.

Clinical Cancer Research 2012;18(17):4570-9.

Raw IF: 7.742 Normalized IF: 8 Frullanti E, Colombo F, Falvella FS, Galvan A, Noci S, De Cecco L, Incarbone M, Alloisio M, Santambrogio L, Nosotti M, Tosi D, Pastorino U, Dragani TA.

Association of lung adenocarcinoma clinical stage with gene expression pattern in noninvolved lung tissue.

International Journal of Cancer2012;131(5):E643-8 Raw IF: 5.444 Normalized IF: 3 Sclafani F*, Incarbone M, Rimassa L, Personeni N, Giordano L, Alloisio M, Santoro A.

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.

Journal of Thoracic and Cardiovascular Surgery 2013;145(1):97-103.

Raw IF: 3.406 Normalized IF: 6 Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne CA, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C*.

Total shoulder arthroplasty for the treatment of failed hemiarthroplasty in patients with fracture of the proximal humerus.

Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Journal of Shoulder and Elbow Surgery 2012; 21(11):1542-9.

Raw IF: 2.747 Normalized IF: 6

Radiat Oncol 2012; 28(7):145.

Raw IF: 2.321 Normalized IF: 4

123

Papers published 2012

Tancioni F*, Navarria P, Pessina F, Attuati L, Mancosu P, Alloisio M, Scorsetti M, Santoro A, Baena RR.

Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.

European Spine Journal 2012;S1:s146-8.

Raw IF: 1.965 Normalized IF: 2 Testori A, Meroni S, Moscovici OC, Magnoni P, Malerba P, Chiti A, Rahal D, Travaglini R, Cariboni U, Alloisio M, Orefice S.

Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

Medical Science Monitor2012;18(9):CR543-9.

Raw IF: 0 Normalized IF: 0.1 Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G.

Reproducibility of the WHO classification of thymomas: practical implications.

Lung Cancer2013;79(3):236-41 Raw IF: 3.434 Normalized IF: 6

Thrombosis Centre Pezzini A, Grassi M, Lodigiani C, Patella R, Gandolfo C, Zini A, Musolino R, Calabrò RS, Bovi P, Adami A, DeLodovici ML, Del Zotto E, Rota LL, Rasura M, Del Sette M, Spalloni A, Giossi A, Volonghi I, Casoni F, Cerrato P, Costa P, Magoni M, Toriello A, Paciaroni M, Dalla Volta G, Iacoviello L, Padovani A; Italian Project on Stroke in Young Adults Investigators.

Interaction between proatherosclerotic factors and right-to-left shunt on the risk of cryptogenic stroke: the Italian Project on Stroke in Young Adults.

Heart2012;98(6):485-9.

Raw IF: 4.223 Normalized IF: 6

124

Urology

Zavalloni D, Presbitero P, Lodigiani C, Mango R, Cogliati T, Quaglia I, Corrada E, Mendolicchio GL, Gasparini GL, Rossi ML, Ferrazzi P, Belli G, Pagnotta P, Rota LL*.

de la Rosette JJ, Opondo D, Daels FP, Giusti G, Serrano A, Kandasami SV, Wolf JS Jr, Grabe M, Gravas S; CROES PCNL Study Group.

Prevalence of inherited thrombophilia in patients with documented stent thrombosis.

Categorisation of complications and validation of the Clavien Score for percutaneous nephrolithotomy.

Circulation Journal2012;76(8):1874-9.

Raw IF: 3.766 Normalized IF: 6

European Urology2012;62(2):246-55.

Raw IF: 8.493 Normalized IF: 8

Naselli A, Hurle R, Puppo P.

The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer.

Expert Review of Anticancer Therapy2012;12(12):1523-8.

Raw IF: 2.652 Normalized IF: 4 Taverna G*, Benecchi L, Grizzi F, Seveso M, Giusti G, Piccinelli A, Benetti A, Colombo P, Minuti F, Graziotti P.

Can a Gleason 6 or less microfocus of prostate cancer in one biopsy and prostate-specific antigen level <10â&#x20AC;&#x2030;ng/mL be Defined as the archetype of low-risk prostate disease?

Journal of Oncology 2012. Epub ahead of print.

Raw IF: 0 Normalized IF: 0.1

Vascular and Interventional Radiology Mauri G, Poretti D, Pedicini V, Lanza E, Brambilla G.

Endovascular treatment of an anastomotic iliac pseudoaneurysm after surgical aortic repair using a Cardiatis multilayer stent.

Vascular 2012;20(5):290-3.

Raw IF: 0.891

Normalized IF: 1

Mauri G, Sconfienza LM, Fiore B, Brambilla G, Pedicini V, Poretti D, Lutman RF, Montorsi M, Sardanelli F.

Post-surgical enteric fistula treatment with imageguided percutaneous injection of cyanoacrylic glue.

Clinical Radiology 2013;68(1):59-63.

Raw IF: 1.952 Normalized IF: 4 Orlando S, Cornalba G, Brambilla G, Pedicini V, Poretti D, Bordoni MG, Vercellio G.

Diagnostic-therapeutic paths and socio-economical remarks in a group of 35 patients affected by arteriovenous malformations.

Italian Journal of Vascular and Endovascular Surgery 2012;19(1):41-9.

Raw IF: 0.028 Normalized IF: 1 Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Journal of Hepatology 2012;57(7):101-7.

Raw IF: 9.264 Normalized IF: 8

125

Scientific Report Š Humanitas May 2013 Scientific Direction: Alberto Mantovani Communication Manager: Walter Bruno Editorial Coordination: Humanitas: Monica Florianello in collaboration with: Michele Tedeschi (Clinical Trials Office) Silvia Marra (Library) Danilo Petroni (Grant Office) Elena Pisano and Silvia Gibertoni (Human Resources Office) Zadig, Milano: Giulia Candiani in collaboration with: Maria Rosa Valetto and Laura Ferroglio Graphic design: Luisa Goglio, Brescia Photographs: Marco Capovilla, Milano Paolo Carlini, Milano Renzo Chiesa, Milano Humanitas Press Office

Printed in May 2013

by Tipografia F.lli Verderio, Milano

via Manzoni 56 20089 Rozzano (Milano, Italy) Phone +39 02 8224 2445 Fax +39 02 8224 5101 www.humanitas.it